

Genes references

```
!!AA_SEQUENCE 1.0
ID AAY01708 standard; peptide; 22 AA.
XX AC AAY01708;
XX DT 24-JUN-1999 (first entry)
XX DE Peptide for making peptide-lipid complex by co-lyophilization approach.
XX KW Peptide-lipid complex; co-lyophilization approach; liposome;
XX compound storage; vaccine; dyslipoproteinemia; hypercholesterolemia;
XX hypertriglyceridemia; low HDL; apolipoprotein A-I deficiency;
XX cardiovascular disease; atherosclerosis; septic shock;
XX infectious disease.
XX OS Synthetic.
XX PN WO9917740-A1.
XX PD 15-APR-1999.
XX PF 28-SEP-1998; 98WO-US020330.
XX PR 02-OCT-1997; 97US-00942597.
XX PA (DASS//) DASSEUX J.
XX PI Dasseux J;
XX PI WPI; 1999-277181/23.
XX DR Preparation of a lyophilized peptide/lipid product - by co-lyophilization
XX of peptides and solubilizing in lipid.
XX PS Example 1; Page 18; 42pp; English.
XX CC The present sequence represents a peptide used to make peptide-lipid
XX complexes by the co-lyophilization approach of the invention. Preparation
XX of a lyophilized peptide/lipid product comprises co-lyophilization of one
XX or more peptides which are able to adopt an amphipathic conformation or
XX their analogues, and one or more lipids in a solvent system to form a
XX peptide/lipid product which can be rehydrated to form peptide/lipid
XX complexes, solubilizing at least one amphipathic peptide or its analog in
XX a first solution, solubilizing at least one lipid in a second solution
XX which is miscible with the first solution, combining the solutions and
XX lyophilizing to form a product which can be rehydrated to form
XX peptide/lipid complexes. The method is used for generating stable
XX peptide/lipid vesicles and complexes such as micellar, spherical and
XX discoidal complexes in bulk preparations and in smaller units e.g.
XX dosages. Liposomes are known to be used for delivery vehicles for drugs,
XX cosmetics and bioactive compounds. The method may also be used for
XX storage of compounds which may otherwise be unstable or insoluble in the
XX absence of lipids or for formulation of products for treatment or
XX prevention of human diseases such as co-presentation of antigens in
XX vaccines, treatment or prevention of dyslipoproteinemias, e.g.
XX hypercholesterolemia, hypertriglyceridemia, low HDL and apolipoprotein A-
XX I deficiency, cardiovascular disease such as atherosclerosis, septic
XX shock or infectious diseases. The method can also be used in the
XX preparation of complexes which can be used as carriers for drugs, as
XX vectors (to deliver drugs, DNA and genes) e.g. to the liver or to extra
XX hepatic cells or as scavengers to trap toxins such as pesticides and LPS
XX Sequence 22 AA;
XX
XX AAY01708 Length: 22 May 22, 2007 14:41 Type: P Check: 8862
XX
XX 1 PVLDFRELL NELLEALKQK LK
XX
XX !!AA_SEQUENCE 1.0
XX ID AAY18691 standard; peptide; 22 AA.
XX AC AAY18691;
XX
```

```
DT 09-JUL-1999 (first entry)
XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #12.
XX
XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
XX lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
XX cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
XX high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
XX septic shock.
XX OS Synthetic.
XX OS Homo sapiens.
XX PN WO9916408-A2.
XX PD 08-APR-1999.
XX PF 28-SEP-1998; 98WO-US020328.
XX PR 29-SEP-1997; 97US-00940093.
XX PA (DASS//) DASSEUX J.
XX PA (SEK//) SEKUL R.
XX PA (BUTT//) BUTTNER K.
XX PA (CORN//) CORNUT I.
XX PA (METZ//) METZ G.
XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX PI WPI; 1999-277031/23.
XX DR Peptide agonists of apolipoprotein A-I.
XX PT Example; Page 104; 152pp; English.
XX PS
XX CC The present invention describes an agonist (A) of apolipoprotein A-I
XX (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
XX amphipathic alpha-helix in presence of lipids. (A), and their lipid
XX complexes, are used to treat or prevent diseases associated with
XX dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
XX atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
XX deficiency; hypertriglyceridemia and metabolic syndrome, also for
XX treating septic shock. When labeled, (A) can also be used diagnostically
XX to measure serum levels of HDL, in particular the HDL subpopulation that
XX is involved in retrograde cholesterol transport, also to image HDL at
XX e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
XX AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
XX exhibiting core peptides, which are apoA-I agonists
XX Sequence 22 AA;
XX
XX AAY18691 Length: 22 May 22, 2007 14:41 Type: P Check: 8777
XX
XX 1 PVLDFRELL NELLEAGKQK LK
XX
XX !!AA_SEQUENCE 1.0
XX ID AAY18808 standard; peptide; 22 AA.
XX AC AAY18808;
XX DT 09-JUL-1999 (first entry)
XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #129.
XX
XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
XX lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
XX cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
XX high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
XX septic shock.
XX OS Synthetic.
XX OS Homo sapiens.
XX
```

PN WO9916408-A2.
XX 08-APR-1999.
XX 28-SEP-1998; 98WO-US020328.
XX 29-SEP-1997; 97US-00940093.
XX (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX WPI; 1999-277031/23.
XX Peptide agonists of apolipoprotein A-I.
XX Example; Page 111; 152pp; English.
XX The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 14-22 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity CC exhibiting core peptides, which are apoA-I agonists
XX Sequence 22 AA;
SQ AAY18680 Length: 22 May 22, 2007 14:41 Type: P Check: 8868 ..
1 PVLEFNDLL RELLEALQKQ LK
!!AA SEQUENCE 1.0
ID AAY18696 standard; peptide; 22 AA.
XX AAY18696;
XX 09-JUL-1999 (first entry)
XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #17.
XX Apoipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX Synthetic.
OS Homo sapiens.
XX WO9916408-A2.
XX 08-APR-1999.
XX 28-SEP-1998; 98WO-US020328.
XX 29-SEP-1997; 97US-00940093.
XX (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX WPI; 1999-277031/23.
XX Peptide agonists of apolipoprotein A-I.
XX Example; Page 108; 152pp; English.
XX The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 14-22 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with
XX CC

XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX WPI; 1999-277031/23.
XX Peptide agonists of apolipoprotein A-I.
XX Example; Page 104; 152pp; English.
XX The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 14-22 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity CC exhibiting core peptides, which are apoA-I agonists
XX Sequence 22 AA;
SQ AAY18696 Length: 22 May 22, 2007 14:41 Type: P Check: 8850 ..
1 PVLELPEKLL QELLEALKQK LK
!!AA SEQUENCE 1.0
ID AAY18766 standard; peptide; 22 AA.
XX AAY18766;
XX 09-JUL-1999 (first entry)
XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #87.
XX Apoipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX Synthetic.
OS Homo sapiens.
XX WO9916408-A2.
XX 08-APR-1999.
XX 28-SEP-1998; 98WO-US020328.
XX 29-SEP-1997; 97US-00940093.
XX (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX WPI; 1999-277031/23.
XX Peptide agonists of apolipoprotein A-I.
XX Example; Page 108; 152pp; English.
XX The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 14-22 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with

CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ

AAY18766 Length: 22 May 22, 2007 14:41 Type: P Check: 8866 ..

1 PLELLKELL QELLEALKQK LK

!!AA SEQUENCE 1.0
 ID _AAY18815 standard; peptide; 22 AA.
 XX
 AC AAY18815;
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #136.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916408-A2.
 XX
 DT 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020328.
 XX
 PR 29-SEP-1997; 97US-00940093.
 XX
 PA (DASS//) DASSEUX J.
 PA (SEKU//) SEKUL R.
 PA (BUTT//) BUTTNER K.
 PA (CORN//) CORNUT I.
 PA (METZ//) METZ G.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 WPI; 1999-277031/23.
 DR
 XX
 PT Peptide agonists of apolipoprotein A-I.
 XX
 PS Example; Page 111; 152pp; English.
 XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ

AAY18815 Length: 22 May 22, 2007 14:41 Type: P Check: 8800 ..

1 PLELLKELL QELLEALKQK LK

!!AA SEQUENCE 1.0
 ID _AAY18815 standard; peptide; 22 AA.
 XX
 AC AAY18815;
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #136.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916408-A2.
 XX
 DT 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020328.
 XX
 PR 29-SEP-1997; 97US-00940093.
 XX
 PA (DASS//) DASSEUX J.
 PA (SEKU//) SEKUL R.
 PA (BUTT//) BUTTNER K.
 PA (CORN//) CORNUT I.
 PA (METZ//) METZ G.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 WPI; 1999-277031/23.
 DR
 XX
 PT Peptide agonists of apolipoprotein A-I.
 XX
 PS Example; Page 111; 152pp; English.
 XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ

1 PALELFKDLL QELLEALKQK LK

!!AA SEQUENCE 1.0
 ID _AAY18683 standard; peptide; 22 AA.
 XX
 AC AAY18683;
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #4.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916408-A2.
 XX
 DT 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020328.
 XX
 PR 29-SEP-1997; 97US-00940093.
 XX
 PA (DASS//) DASSEUX J.
 PA (SEKU//) SEKUL R.
 PA (BUTT//) BUTTNER K.
 PA (CORN//) CORNUT I.
 PA (METZ//) METZ G.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 WPI; 1999-277031/23.
 DR
 XX
 PT Peptide agonists of apolipoprotein A-I.
 XX
 PS Example; Page 104; 152pp; English.
 XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ

AAY18683 Length: 22 May 22, 2007 14:41 Type: P Check: 8862 ..

1 PVLDLFRELL NELLEALKQK LK

!!AA SEQUENCE 1.0
 ID _AAY18719 standard; peptide; 22 AA.
 XX
 AC AAY18719;
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #40.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;

KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 OS Synthetic.
 OS Homo sapiens.
 XX WO9916408-A2.
 XX 08-APR-1999.
 XX 28-SEP-1998; 98WO-US020328.
 XX 29-SEP-1997; 97US-00940093.
 XX (DASS/) DASSEUX J.
 XX (SEKU/) SEKUL R.
 XX (BUTT/) BUTTNER K.
 XX (CORN/) CORNUT I.
 XX (METZ/) METZ G.
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277031/23.
 XX Peptide agonists of apolipoprotein A-I.
 XX Example; Page 106; 152pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 XX SQ

AAV18719 Length: 22 May 22, 2007 14:41 Type: P Check: 8872 ..
 1 PVLDFNELL RELLEALQKK LK
 !!AA SEQUENCE 1.0
 ID AAY18817 standard; peptide; 22 AA.
 AC AAY18817;
 XX 09-JUL-1999 (first entry)
 DT
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #138.
 XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 OS Synthetic.
 OS Homo sapiens.
 XX WO9916408-A2.
 XX 08-APR-1999.
 XX 28-SEP-1998; 98WO-US020328.

XX 29-SEP-1997; 97US-00940093.
 XX (DASS/) DASSEUX J.
 XX (SEKU/) SEKUL R.
 XX (BUTT/) BUTTNER K.
 XX (CORN/) CORNUT I.
 XX (METZ/) METZ G.
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277031/23.
 XX Peptide agonists of apolipoprotein A-I.
 XX Example; Page 111; 152pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 XX SQ

AAV18817 Length: 22 May 22, 2007 14:41 Type: P Check: 9149 ..
 1 PVLDFNELL NEGLEWLKQK LK
 !!AA SEQUENCE 1.0
 ID AAY18820 standard; peptide; 22 AA.
 XX AAY18820;
 XX 09-JUL-1999 (first entry)
 DT
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #141.
 XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 OS Synthetic.
 OS Homo sapiens.
 XX WO9916408-A2.
 XX 08-APR-1999.
 XX 28-SEP-1998; 98WO-US020328.
 XX 29-SEP-1997; 97US-00940093.
 XX (DASS/) DASSEUX J.
 XX (SEKU/) SEKUL R.
 XX (BUTT/) BUTTNER K.
 XX (CORN/) CORNUT I.
 XX (METZ/) METZ G.
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277031/23.

PT Peptide agonists of apolipoprotein A-I.
 XX Example; Page 111; 152pp; English.
 XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ
 AAY18820 Length: 22 May 22, 2007 14:41 Type: P Check: 8767 ..
 1 PVLDLFPRELL NEGLEALKQK LK
 !!AA_SEQUENCE 1.0
 ID AAY18682 standard; peptide; 22 AA.
 XX
 AC AAY18682;
 XX
 DT 09-JUL-1999 (first entry)
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #3.
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916408-A2.
 XX
 DT 08-APR-1999.
 PF 28-SEP-1998; 98WO-US020328.
 XX
 PR 29-SEP-1997; 97US-00940093.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277031/23.
 XX
 PT Peptide agonists of apolipoprotein A-I.
 PS Example; Page 104; 152pp; English.
 XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that

CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ
 AAY18682 Length: 22 May 22, 2007 14:41 Type: P Check: 9214 ..
 1 PVLDLFPRELL NELLEWLKQK LK
 !!AA_SEQUENCE 1.0
 ID AAY18686 standard; peptide; 22 AA.
 XX
 AC AAY18686;
 XX
 DT 09-JUL-1999 (first entry)
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #7.
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916408-A2.
 XX
 DT 08-APR-1999.
 PF 28-SEP-1998; 98WO-US020328.
 XX
 PR 29-SEP-1997; 97US-00940093.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277031/23.
 XX
 PT Peptide agonists of apolipoprotein A-I.
 PS Example; Page 104; 152pp; English.
 XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ
 AAY18686 Length: 22 May 22, 2007 14:41 Type: P Check: 8813 ..
 1 PVLDLFPRELL NELLEALKQK LK
 !!AA_SEQUENCE 1.0
 ID AAY18702 standard; peptide; 22 AA.

XX AAY18702;
 XX 09-JUL-1999 (first entry)
 XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #23.
 DE
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 XX Synthetic.
 OS Homo sapiens.
 XX WO9916408-A2.
 XX 08-APR-1999.
 XX 28-SEP-1998; 98WO-US020328.
 XX 29-SEP-1997; 97US-00940093.
 XX (DASS/) DASSEUX J.
 XX (SEKU/) SEKUL R.
 XX (BUTT/) BUTTNER K.
 XX (CORN/) CORNUT I.
 XX (METZ/) METZ G.
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277031/23.
 XX Peptide agonists of apolipoprotein A-I.
 XX Example; Page 105; 152pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 XX AAY18702 Length: 22 May 22, 2007 14:41 Type: P Check: 8830 ..
 !!AA SEQUENCE 1.0
 ID _AAY18777 standard; peptide; 22 AA.
 XX AAY18777;
 XX 09-JUL-1999 (first entry)
 XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #98.
 DE
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 XX Synthetic.
 OS Homo sapiens.
 XX WO9916408-A2.
 XX 08-APR-1999.
 XX 28-SEP-1998; 98WO-US020328.
 XX 29-SEP-1997; 97US-00940093.
 XX (DASS/) DASSEUX J.
 XX (SEKU/) SEKUL R.
 XX (BUTT/) BUTTNER K.
 XX (CORN/) CORNUT I.
 XX (METZ/) METZ G.
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277031/23.
 XX Peptide agonists of apolipoprotein A-I.
 XX Example; Page 105; 152pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 XX AAY18777 Length: 22 May 22, 2007 14:41 Type: P Check: 8771 ..
 !!AA SEQUENCE 1.0
 ID _AAY18699 standard; peptide; 22 AA.
 XX AAY18699;
 XX 09-JUL-1999 (first entry)
 XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #20.
 DE
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 XX Synthetic.
 OS Homo sapiens.
 XX WO9916408-A2.
 XX 08-APR-1999.
 XX 28-SEP-1998; 98WO-US020328.
 XX 29-SEP-1997; 97US-00940093.
 XX (DASS/) DASSEUX J.
 XX (SEKU/) SEKUL R.

OS Synthetic.
 OS Homo sapiens.
 XX WO9916408-A2.
 XX 08-APR-1999.
 XX 28-SEP-1998; 98WO-US020328.
 XX 29-SEP-1997; 97US-00940093.
 XX (DASS/) DASSEUX J.
 XX (SEKU/) SEKUL R.
 XX (BUTT/) BUTTNER K.
 XX (CORN/) CORNUT I.
 XX (METZ/) METZ G.
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277031/23.
 XX Peptide agonists of apolipoprotein A-I.
 XX Example; Page 109; 152pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 XX AAY18777 Length: 22 May 22, 2007 14:41 Type: P Check: 8771 ..
 !!AA SEQUENCE 1.0
 ID _AAY18699 standard; peptide; 22 AA.
 XX AAY18699;
 XX 09-JUL-1999 (first entry)
 XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #20.
 DE
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 XX Synthetic.
 OS Homo sapiens.
 XX WO9916408-A2.
 XX 08-APR-1999.
 XX 28-SEP-1998; 98WO-US020328.
 XX 29-SEP-1997; 97US-00940093.
 XX (DASS/) DASSEUX J.
 XX (SEKU/) SEKUL R.

PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
XX
PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX
XX WPI; 1999-277031/23.
DR
XX
XX Peptide agonists of apolipoprotein A-I.
PT
XX
PS Example; Page 105; 152pp; English.
XX
XX The present invention describes an agonist (A) of apolipoprotein A-I
CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
CC complexes, are used to treat or prevent diseases associated with
CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
CC treating septic shock. When labeled, (A) can also be used diagnostically
CC to measure serum levels of HDL, in particular the HDL subpopulation that
CC is involved in retrograde cholesterol transport, also to image HDL at
CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
CC exhibiting core peptides, which are apoA-I agonists
XX
XX Sequence 22 AA;
SQ

AAY18699 Length: 22 May 22, 2007 14:41 Type: P Check: 8817 ..

1 PVLDFREGL NELLEALKQK LK
!!AA SEQUENCE 1.0
ID AAY18708 standard; peptide; 22 AA.
XX
AC AAY18708;
XX
DT 09-JUL-1999 (first entry)
XX
DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #29.
XX
KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX
OS Synthetic.
OS Homo sapiens.
XX
XX WO9916408-A2.
XX
XX 08-APR-1999.
XX
XX 28-SEP-1998; 98WO-US020328.
XX
XX 29-SEP-1997; 97US-00940093.
XX
XX (DASS/) DASSEUX J.
XX (SEKU/) SEKUL R.
XX (BUTT/) BUTTNER K.
XX (CORN/) CORNUT I.
XX (METZ/) METZ G.
XX
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
PI
XX WPI; 1999-277031/23.
XX
XX Peptide agonists of apolipoprotein A-I.
PT
XX
XX Example; Page 105; 152pp; English.
XX
XX The present invention describes an agonist (A) of apolipoprotein A-I
CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
CC complexes, are used to treat or prevent diseases associated with
CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
CC treating septic shock. When labeled, (A) can also be used diagnostically
CC to measure serum levels of HDL, in particular the HDL subpopulation that
CC is involved in retrograde cholesterol transport, also to image HDL at
CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
CC exhibiting core peptides, which are apoA-I agonists
XX
XX Sequence 22 AA;
SQ

AAY18708 Length: 22 May 22, 2007 14:41 Type: P Check: 8847 ..

1 AVLDLFRELL NELLEALKQK LK
!!AA SEQUENCE 1.0
ID AAY18709 standard; peptide; 22 AA.
XX
AC AAY18709;
XX
DT 09-JUL-1999 (first entry)
XX
DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #30.
XX
KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX
OS Synthetic.
OS Homo sapiens.
XX
XX WO9916408-A2.
XX
XX 08-APR-1999.
XX
XX 28-SEP-1998; 98WO-US020328.
XX
XX 29-SEP-1997; 97US-00940093.
XX
XX (DASS/) DASSEUX J.
XX (SEKU/) SEKUL R.
XX (BUTT/) BUTTNER K.
XX (CORN/) CORNUT I.
XX (METZ/) METZ G.
XX
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
PI
XX WPI; 1999-277031/23.
XX
XX Peptide agonists of apolipoprotein A-I.
PT
XX
XX Example; Page 105; 152pp; English.
XX
XX The present invention describes an agonist (A) of apolipoprotein A-I
CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
CC complexes, are used to treat or prevent diseases associated with
CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
CC treating septic shock. When labeled, (A) can also be used diagnostically
CC to measure serum levels of HDL, in particular the HDL subpopulation that
CC is involved in retrograde cholesterol transport, also to image HDL at
CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
CC exhibiting core peptides, which are apoA-I agonists
XX

SQ Sequence 22 AA;
 AAY18709 Length: 22 May 22, 2007 14:41 Type: P Check: 8862 ..
 1 PVLDFRELL NELLEALKQK LK
 !!AA_SEQUENCE 1.0
 ID _AAY18715 standard; peptide; 22 AA.
 AC AAY18715;
 XX
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #36.
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 OS Synthetic.
 OS Homo sapiens.
 XX
 XX
 PN WO9916408-A2.
 XX
 XX 08-APR-1999.
 XX
 XX 28-SEP-1998; 98WO-US020328.
 XX
 XX 29-SEP-1997; 97US-00940093.
 XX
 XX (DASS/) DASSEUX J.
 XX (SEKU/) SEKUL R.
 XX (BUTT/) BUTTNER K.
 XX (CORN/) CORNUT I.
 XX (METZ/) METZ G.
 XX
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277031/23.
 XX
 XX Peptide agonists of apolipoprotein A-I.
 XX
 XX Example; Page 105; 152pp; English.
 XX
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 XX (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 XX amphipathic alpha-helix in presence of lipids. (A), and their lipid
 XX complexes, are used to treat or prevent diseases associated with
 XX dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 XX atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 XX deficiency; hypertriglyceridemia and metabolic syndrome, also for
 XX treating septic shock. When labeled, (A) can also be used diagnostically
 XX to measure serum levels of HDL, in particular the HDL subpopulation that
 XX is involved in retrograde cholesterol transport, also to image HDL at
 XX e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 XX AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 XX exhibiting core peptides, which are apoA-I agonists
 XX
 XX Sequence 22 AA;
 AAY18715 Length: 22 May 22, 2007 14:41 Type: P Check: 8866 ..
 1 PLELLKELL QELLEALKQK LK
 !!AA_SEQUENCE 1.0
 ID _AAY18807 standard; peptide; 22 AA.
 AC AAY18807;
 XX
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #125.
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 OS Synthetic.
 OS Homo sapiens.
 XX
 XX
 PN WO9916408-A2.
 XX
 XX 08-APR-1999.
 XX
 XX 28-SEP-1998; 98WO-US020328.
 XX
 XX 29-SEP-1997; 97US-00940093.
 XX
 XX (DASS/) DASSEUX J.
 XX (SEKU/) SEKUL R.
 XX (BUTT/) BUTTNER K.
 XX (CORN/) CORNUT I.
 XX (METZ/) METZ G.
 XX
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277031/23.
 XX
 XX Peptide agonists of apolipoprotein A-I.
 XX
 XX Example; Page 105; 152pp; English.
 XX
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 XX (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 XX amphipathic alpha-helix in presence of lipids. (A), and their lipid
 XX complexes, are used to treat or prevent diseases associated with
 XX dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 XX atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 XX deficiency; hypertriglyceridemia and metabolic syndrome, also for
 XX treating septic shock. When labeled, (A) can also be used diagnostically
 XX to measure serum levels of HDL, in particular the HDL subpopulation that
 XX is involved in retrograde cholesterol transport, also to image HDL at
 XX e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 XX AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 XX exhibiting core peptides, which are apoA-I agonists
 XX
 XX Sequence 22 AA;
 AAY18715 Length: 22 May 22, 2007 14:41 Type: P Check: 8866 ..
 1 PLELLKELL QELLEALKQK LK
 !!AA_SEQUENCE 1.0
 ID _AAY18807 standard; peptide; 22 AA.
 AC AAY18807;
 XX
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #125.
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 OS Synthetic.
 OS Homo sapiens.
 XX
 XX
 PN WO9916408-A2.
 XX
 XX 08-APR-1999.
 XX
 XX 28-SEP-1998; 98WO-US020328.
 XX
 XX 29-SEP-1997; 97US-00940093.
 XX
 XX (DASS/) DASSEUX J.
 XX (SEKU/) SEKUL R.
 XX (BUTT/) BUTTNER K.
 XX (CORN/) CORNUT I.
 XX (METZ/) METZ G.
 XX
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277031/23.
 XX
 XX Peptide agonists of apolipoprotein A-I.
 XX
 XX Example; Page 105; 152pp; English.
 XX
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 XX (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 XX amphipathic alpha-helix in presence of lipids. (A), and their lipid
 XX complexes, are used to treat or prevent diseases associated with
 XX dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 XX atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 XX deficiency; hypertriglyceridemia and metabolic syndrome, also for
 XX treating septic shock. When labeled, (A) can also be used diagnostically
 XX to measure serum levels of HDL, in particular the HDL subpopulation that
 XX is involved in retrograde cholesterol transport, also to image HDL at
 XX e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 XX AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 XX exhibiting core peptides, which are apoA-I agonists
 XX
 XX Sequence 22 AA;
 AAY18715 Length: 22 May 22, 2007 14:41 Type: P Check: 8866 ..
 1 PLELLKELL QELLEALKQK LK
 !!AA_SEQUENCE 1.0
 ID _AAY18807 standard; peptide; 22 AA.
 AC AAY18807;
 XX
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #125.
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 OS Synthetic.
 OS Homo sapiens.
 XX
 XX
 PN WO9916408-A2.
 XX
 XX 08-APR-1999.
 XX
 XX 28-SEP-1998; 98WO-US020328.
 XX
 XX 29-SEP-1997; 97US-00940093.
 XX
 XX (DASS/) DASSEUX J.
 XX (SEKU/) SEKUL R.
 XX (BUTT/) BUTTNER K.
 XX (CORN/) CORNUT I.
 XX (METZ/) METZ G.
 XX
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277031/23.
 XX
 XX Peptide agonists of apolipoprotein A-I.
 XX
 XX Example; Page 105; 152pp; English.
 XX
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 XX (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 XX amphipathic alpha-helix in presence of lipids. (A), and their lipid
 XX complexes, are used to treat or prevent diseases associated with
 XX dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 XX atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 XX deficiency; hypertriglyceridemia and metabolic syndrome, also for
 XX treating septic shock. When labeled, (A) can also be used diagnostically
 XX to measure serum levels of HDL, in particular the HDL subpopulation that
 XX is involved in retrograde cholesterol transport, also to image HDL at
 XX e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 XX AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 XX exhibiting core peptides, which are apoA-I agonists
 XX
 XX Sequence 22 AA;
 AAY18715 Length: 22 May 22, 2007 14:41 Type: P Check: 8866 ..
 1 PLELLKELL QELLEALKQK LK
 !!AA_SEQUENCE 1.0
 ID _AAY18807 standard; peptide; 22 AA.
 AC AAY18807;
 XX
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #125.
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 OS Synthetic.
 OS Homo sapiens.
 XX
 XX
 PN WO9916408-A2.
 XX
 XX 08-APR-1999.
 XX
 XX 28-SEP-1998; 98WO-US020328.
 XX
 XX 29-SEP-1997; 97US-00940093.
 XX
 XX (DASS/) DASSEUX J.
 XX (SEKU/) SEKUL R.
 XX (BUTT/) BUTTNER K.
 XX (CORN/) CORNUT I.
 XX (METZ/) METZ G.

PD 08-APR-1999.
XX PF 28-SEP-1998; 98WO-US020328.
XX PR 29-SEP-1997; 97US-00940093.
XX (DASSE//) DASSEUX J.
PA (SEKU//) SEKUL R.
PA (BUTT//) BUTTNER K.
PA (CORN//) CORNUT I.
PA (METZ//) METZ G.
PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX WPI; 1999-277031/23.
XX DR Peptide agonists of apolipoprotein A-I.
XX PT Example; Page 110; 152pp; English.
XX PS The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 14-22 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity exhibiting core peptides, which are apoA-I agonists
XX Sequence 22 AA;
XX AAY18906 Length: 22 May 22, 2007 14:41 Type: P Check: 9038 ..
XX 1 NVLDLFPRELL NELLEALKQK LK
!!AA_SEQUENCE 1.0
ID AAY18806 standard; peptide; 22 AA.
XX AC AAY18806;
XX DT 09-JUL-1999 (first entry)
XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #127.
XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human; lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome; septic shock.
XX OS Synthetic.
XX OS Homo sapiens.
XX PN WO9916408-A2.
XX PD 08-APR-1999.
XX PF 28-SEP-1998; 98WO-US020328.
XX PR 29-SEP-1997; 97US-00940093.
XX (DASSE//) DASSEUX J.
PA (SEKU//) SEKUL R.
PA (BUTT//) BUTTNER K.
PA (CORN//) CORNUT I.
PA (METZ//) METZ G.
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX WPI; 1999-277031/23.
XX DR Peptide agonists of apolipoprotein A-I.
XX PT Example; Page 104; 152pp; English.
XX PS The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 14-22 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity exhibiting core peptides, which are apoA-I agonists
XX Sequence 22 AA;
XX AAY18804 Length: 22 May 22, 2007 14:41 Type: P Check: 8860 ..
XX 1 NVLDLFPRELL NELLEALKQK LK
!!AA_SEQUENCE 1.0
ID AAY18806 standard; peptide; 22 AA.
XX AC AAY18806;
XX DT 09-JUL-1999 (first entry)
XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #127.
XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human; lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome; septic shock.
XX OS Synthetic.
XX OS Homo sapiens.
XX PN WO9916408-A2.
XX PD 08-APR-1999.
XX PF 28-SEP-1998; 98WO-US020328.
XX PR 29-SEP-1997; 97US-00940093.
XX (DASSE//) DASSEUX J.
PA (SEKU//) SEKUL R.
PA (BUTT//) BUTTNER K.
PA (CORN//) CORNUT I.
PA (METZ//) METZ G.
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
PI WPI; 1999-277031/23.

CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX
 SQ Sequence 22 AA;
 AAY18694 Length: 22 May 22, 2007 14:41 Type: P Check: 8972 ..
 1 PVLDFRELL NELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY18705 standard; peptide; 22 AA.
 XX
 AC AAY18705;
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #26.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916408-A2.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020328.
 XX
 PR 29-SEP-1997; 97US-00940093.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 DR WPI; 1999-277031/23.
 XX
 PT Peptide agonists of apolipoprotein A-I.
 XX
 PS Example; Page 105; 152pp; English.
 XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX
 SQ Sequence 22 AA;
 AAY18705 Length: 22 May 22, 2007 14:41 Type: P Check: 9038 ..
 1 PVLDFRELL NELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY18809 standard; peptide; 22 AA.
 XX
 AC AAY18809;
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #130.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;

!!AA SEQUENCE 1.0
 ID AAY18707 standard; peptide; 22 AA.
 XX
 AC AAY18707;
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #28.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916408-A2.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020328.
 XX
 PR 29-SEP-1997; 97US-00940093.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 DR WPI; 1999-277031/23.
 XX
 PT Peptide agonists of apolipoprotein A-I.
 XX
 PS Example; Page 105; 152pp; English.
 XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX
 SQ Sequence 22 AA;
 AAY18707 Length: 22 May 22, 2007 14:41 Type: P Check: 9016 ..
 1 PVLDFRELL NELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY18809 standard; peptide; 22 AA.
 XX
 AC AAY18809;
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #130.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;

XX DT 09-JUL-1999 (first entry)
XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #143.
XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX OS Synthetic.
OS Homo sapiens.
XX PN WO9916408-A2.
XX PD 08-APR-1999.
XX PF 28-SEP-1998; 98WO-US020328.
XX PR 29-SEP-1997; 97US-00940093.
XX PA (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX WPI; 1999-277031/23.
XX DR Peptide agonists of apolipoprotein A-I.
XX PT Example; Page 111; 152pp; English.
XX CC The present invention describes an agonist (A) of apolipoprotein A-I
CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
CC complexes, are used to treat or prevent diseases associated with
CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
CC treating septic shock. When labeled, (A) can also be used diagnostically
CC to measure serum levels of HDL, in particular the HDL subpopulation that
CC is involved in retrograde cholesterol transport, also to image HDL at
CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
CC exhibiting core peptides, which are apoA-I agonists
XX SQ Sequence 22 AA;
AAY18822 Length: 22 May 22, 2007 14:41 Type: P Check: 8797 ..
1 PVLDLFRELL NEGLEALKQK LK
!!AA_SEQUENCE 1.0
ID AAY18681 standard; peptide; 23 AA.
XX AC AAY18681;
XX DT 09-JUL-1999 (first entry)
XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #2.
XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX OS Synthetic.
OS Homo sapiens.

XX PN WO9916408-A2.
XX PD 08-APR-1999.
XX PF 28-SEP-1998; 98WO-US020328.
XX PR 29-SEP-1997; 97US-00940093.
XX PA (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX WPI; 1999-277031/23.
XX DR Peptide agonists of apolipoprotein A-I.
XX PT Example; Page 104; 152pp; English.
XX CC The present invention describes an agonist (A) of apolipoprotein A-I
CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
CC complexes, are used to treat or prevent diseases associated with
CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
CC treating septic shock. When labeled, (A) can also be used diagnostically
CC to measure serum levels of HDL, in particular the HDL subpopulation that
CC is involved in retrograde cholesterol transport, also to image HDL at
CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
CC exhibiting core peptides, which are apoA-I agonists
XX SQ Sequence 23 AA;
AAY18681 Length: 23 May 22, 2007 14:41 Type: P Check: 578 ..
1 GVLDLFRELL NELLEALKQK LKK
!!AA_SEQUENCE 1.0
ID AAY18718 standard; peptide; 22 AA.
XX AC AAY18718;
XX DT 09-JUL-1999 (first entry)
XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #39.
XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX OS Synthetic.
OS Homo sapiens.
XX PN WO9916408-A2.
XX PD 08-APR-1999.
XX PF 28-SEP-1998; 98WO-US020328.
XX PR 29-SEP-1997; 97US-00940093.
XX PA (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.

PA (METZ/) METZ G.
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277031/23.
 DR Peptide agonists of apolipoprotein A-I.
 XX Example; Page 106; 152pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ AAY18718 Length: 22 May 22, 2007 14:41 Type: P Check: 8739 ..
 1 PVLDFREL EELLKALKKK LK
 !!AA SEQUENCE 1.0
 ID AAY18688 standard; peptide; 22 AA.
 XX AAY18688;
 XX 09-JUL-1999 (first entry)
 DT Lecithin:cholesterol acyltransferase activation exhibiting peptide #9.
 XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 XX lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX Synthetic.
 OS Homo sapiens.
 XX WO9916408-A2.
 PN 08-APR-1999.
 PD 28-SEP-1998; 98WO-US020328.
 XX 29-SEP-1997; 97US-00940093.
 PF (DASS/) DASSEUX J.
 XX (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277031/23.
 DR Peptide agonists of apolipoprotein A-I.
 XX Example; Page 104; 152pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid

CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ AAY18688 Length: 22 May 22, 2007 14:41 Type: P Check: 8812 ..
 1 PVLDFREL NELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY18759 standard; peptide; 22 AA.
 XX AAY18759;
 XX 09-JUL-1999 (first entry)
 DT Lecithin:cholesterol acyltransferase activation exhibiting peptide #80.
 XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX Synthetic.
 OS Homo sapiens.
 XX WO9916408-A2.
 PN 08-APR-1999.
 PD 28-SEP-1998; 98WO-US020328.
 XX 29-SEP-1997; 97US-00940093.
 PF (DASS/) DASSEUX J.
 XX (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277031/23.
 DR Peptide agonists of apolipoprotein A-I.
 XX Example; Page 108; 152pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ

AAV18759 Length: 22 May 22, 2007 14:41 Type: P Check: 8869 ..

1 PVLDLPERLL NELLEALQKK LK

!!AA SEQUENCE 1.0

ID _AAV18812 standard; peptide; 22 AA.

AC AAV18812;

XX 09-JUL-1999 (first entry)

DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #133.

XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.

XX Synthetic.

OS Homo sapiens.

XX WO9916408-A2.

PN 08-APR-1999.

PD 28-SEP-1998; 98WO-US020328.

XX 29-SEP-1997; 97US-00940093.

XX (DASS/) DASSEUX J.

PA (SEKU/) SEKUL R.

PA (BUTT/) BUTTNER K.

PA (CORN/) CORNUT I.

PA (METZ/) METZ G.

XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;

PI WPI; 1999-277031/23.

XX Peptide agonists of apolipoprotein A-I.

XX Example; Page 111; 152pp; English.

XX The present invention describes an agonist (A) of apolipoprotein A-I
CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
CC complexes, are used to treat or prevent diseases associated with
CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
CC treating septic shock. When labeled, (A) can also be used diagnostically
CC to measure serum levels of HDL, in particular the HDL subpopulation that
CC is involved in retrograde cholesterol transport, also to image HDL at
CC e.g. atherosclerotic streaks, and to raise antibodies. AAV18680 to
CC AAV18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
CC exhibiting core peptides, which are apoA-I agonists

XX Sequence 22 AA;

AAV18812 Length: 22 May 22, 2007 14:41 Type: P Check: 8888 ..

1 PVLDLPERLL EDLLQALNKK LK

!!AA SEQUENCE 1.0

ID _AAV18687 standard; peptide; 22 AA.

AC AAV18687;

XX 09-JUL-1999 (first entry)

DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #8.

XX

KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.

XX Synthetic.

OS Homo sapiens.

XX WO9916408-A2.

XX 08-APR-1999.

XX 28-SEP-1998; 98WO-US020328.

XX 29-SEP-1997; 97US-00940093.

XX (DASS/) DASSEUX J.

PA (SEKU/) SEKUL R.

PA (BUTT/) BUTTNER K.

PA (CORN/) CORNUT I.

PA (METZ/) METZ G.

XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;

PI WPI; 1999-277031/23.

XX Peptide agonists of apolipoprotein A-I.

XX Example; Page 104; 152pp; English.

XX The present invention describes an agonist (A) of apolipoprotein A-I
CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
CC complexes, are used to treat or prevent diseases associated with
CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
CC treating septic shock. When labeled, (A) can also be used diagnostically
CC to measure serum levels of HDL, in particular the HDL subpopulation that
CC is involved in retrograde cholesterol transport, also to image HDL at
CC e.g. atherosclerotic streaks, and to raise antibodies. AAV18680 to
CC AAV18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
CC exhibiting core peptides, which are apoA-I agonists

XX Sequence 22 AA;

AAV18687 Length: 22 May 22, 2007 14:41 Type: P Check: 8797 ..

1 PVLDLPERLL NEGLEALKQK LK

!!AA SEQUENCE 1.0

ID _AAV18692 standard; peptide; 22 AA.

XX AAV18692;

XX 09-JUL-1999 (first entry)

DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #13.

XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.

XX Synthetic.

OS Homo sapiens.

XX WO9916408-A2.

XX 08-APR-1999.

XX

PF 28-SEP-1998; 98WO-US020328.
 XX
 PR 29-SEP-1997; 97US-00940093.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX
 DR WPI; 1999-277031/23.
 XX
 PT Peptide agonists of apolipoprotein A-I.
 XX
 PS Example; Page 104; 152pp; English.
 XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX
 SQ Sequence 22 AA;
 XX
 AAY18692 Length: 22 May 22, 2007 14:41 Type: P Check: 8788 ..
 1 GVLDLRELL NEGLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY18695 standard; peptide; 22 AA.
 AC AAY18695;
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #16.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916408-A2.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020328.
 XX
 PR 29-SEP-1997; 97US-00940093.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX
 DR WPI; 1999-277031/23.
 XX
 PT Peptide agonists of apolipoprotein A-I.
 XX
 PS Example; Page 104; 152pp; English.
 XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX
 SQ Sequence 22 AA;
 XX
 AAY18692 Length: 22 May 22, 2007 14:41 Type: P Check: 8788 ..
 1 GVLDLRELL NEGLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY18695 standard; peptide; 22 AA.
 AC AAY18695;
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #16.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916408-A2.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020328.
 XX
 PR 29-SEP-1997; 97US-00940093.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX
 DR WPI; 1999-277031/23.
 XX

XX Peptide agonists of apolipoprotein A-I.
 XX
 PT Example; Page 104; 152pp; English.
 XX
 PS The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX
 SQ Sequence 22 AA;
 XX
 AAY18695 Length: 22 May 22, 2007 14:41 Type: P Check: 8898 ..
 1 PVLDLRELL NELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY18701 standard; peptide; 22 AA.
 XX
 AC AAY18701;
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #22.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916408-A2.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020328.
 XX
 PR 29-SEP-1997; 97US-00940093.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX
 DR WPI; 1999-277031/23.
 XX
 PT Peptide agonists of apolipoprotein A-I.
 XX
 PS Example; Page 105; 152pp; English.
 XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically

CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX
 SQ Sequence 22 AA;

AAY18701 Length: 22 May 22, 2007 14:41 Type: P Check: 8958 ..

1 PVLDFRELL NELLEGLKQK LK

!!AA_SEQUENCE 1.0

ID AAY18802 standard; peptide; 22 AA.

XX

AC AAY18802;

XX

DT 09-JUL-1999 (first entry)

XX

DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #123.

XX

KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;

KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;

KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;

KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;

KW septic shock.

XX

OS Synthetic.

OS Homo sapiens.

XX

PN WO9916408-A2.

XX

PD 08-APR-1999.

XX

PF 28-SEP-1998; 98WO-US020328.

XX

PR 29-SEP-1997; 97US-00940093.

XX

PA (DASS/) DASSEUX J.

PA (SEKU/) SEKUL R.

PA (BUTT/) BUTTNER K.

PA (CORN/) CORNUT I.

PA (METZ/) METZ G.

XX

PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;

XX

DR WPI; 1999-277031/23.

XX

PT Peptide agonists of apolipoprotein A-I.

XX

PS Example; Page 110; 152pp; English.

XX

CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists

XX Sequence 22 AA;

AAY18802 Length: 22 May 22, 2007 14:41 Type: P Check: 8863 ..

1 QVLDLFRELL NELLEALKQK LK

!!AA_SEQUENCE 1.0

ID AAY18814 standard; peptide; 22 AA.

XX

AC AAY18814;

XX

DT 09-JUL-1999 (first entry)

XX

DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #135.

XX

KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;

KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;

KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;

KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;

KW septic shock.

XX

OS Synthetic.

OS Homo sapiens.

XX

PN WO9916408-A2.

XX

PD 08-APR-1999.

XX

PF 28-SEP-1998; 98WO-US020328.

XX

PR 29-SEP-1997; 97US-00940093.

XX

PA (DASS/) DASSEUX J.

PA (SEKU/) SEKUL R.

PA (BUTT/) BUTTNER K.

PA (CORN/) CORNUT I.

PA (METZ/) METZ G.

XX

PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;

XX

DR WPI; 1999-277031/23.

XX

PT Peptide agonists of apolipoprotein A-I.

XX

PS Example; Page 111; 152pp; English.

XX

CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists

XX Sequence 22 AA;

AAY18814 Length: 22 May 22, 2007 14:41 Type: P Check: 8850 ..

1 DVLDLFRELL NELLEALKQK LK

!!AA_SEQUENCE 1.0

ID AAY18821 standard; peptide; 22 AA.

XX

AC AAY18821;

XX

DT 09-JUL-1999 (first entry)

XX

DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #142.

XX

KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;

KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;

KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;

KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;

KW septic shock.

XX Synthetic.
OS Homo sapiens.
XX
XX WO9916408-A2.
XX
XX 08-APR-1999.
XX
XX 28-SEP-1998; 98WO-US020328.
XX
XX 29-SEP-1997; 97US-00940093.
XX
XX (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
XX
PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX WPI; 1999-277031/23.
XX
XX Peptide agonists of apolipoprotein A-I.
XX
XX Example; Page 111; 152pp; English.
XX
XX The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 14-22 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity CC exhibiting core peptides, which are apoA-I agonists
XX
XX Sequence 22 AA;
SQ
AAY18621 Length: 22 May 22, 2007 14:41 Type: P Check: 8801 ..
1 PVLELFPRELL NEGLEALKQK LK
!!AA SEQUENCE 1.0
ID _AAY18811 standard; peptide; 22 AA.
XX
AC AAY18811;
XX
DT 09-JUL-1999 (first entry)
XX
DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #132.
XX
KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9916408-A2.
XX
XX 08-APR-1999.
XX
XX 28-SEP-1998; 98WO-US020328.
XX
XX 29-SEP-1997; 97US-00940093.
XX
XX (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
XX
PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX WPI; 1999-277031/23.
XX
XX Peptide agonists of apolipoprotein A-I.
XX
XX Example; Page 111; 152pp; English.
XX
XX The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 14-22 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity CC exhibiting core peptides, which are apoA-I agonists
XX
XX Sequence 22 AA;
SQ

PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
XX
PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX WPI; 1999-277031/23.
XX
XX Peptide agonists of apolipoprotein A-I.
XX
XX Example; Page 111; 152pp; English.
XX
XX The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 14-22 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity CC exhibiting core peptides, which are apoA-I agonists
XX
XX Sequence 22 AA;
SQ
AAY18811 Length: 22 May 22, 2007 14:41 Type: P Check: 8865 ..
1 PVLDLFPRELL ENLEALQK LK
!!AA SEQUENCE 1.0
ID _AAY18813 standard; peptide; 22 AA.
XX
AC AAY18813;
XX
DT 09-JUL-1999 (first entry)
XX
DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #134.
XX
KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9916408-A2.
XX
XX 08-APR-1999.
XX
XX 28-SEP-1998; 98WO-US020328.
XX
XX 29-SEP-1997; 97US-00940093.
XX
XX (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
XX
PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX WPI; 1999-277031/23.
XX
XX Peptide agonists of apolipoprotein A-I.
XX
XX Example; Page 111; 152pp; English.
XX

CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ
 AAY18813 Length: 22 May 22, 2007 14:41 Type: P Check: 8912 ..
 1 PVLELPERLL EDLLKALNQK LK
 !!AA SEQUENCE 1.0
 ID AAY18818 standard; peptide; 22 AA.
 XX AAY18818;
 AC AAY18818;
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #139.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 XX Synthetic.
 OS Homo sapiens.
 OS
 XX
 PN W09916408-A2.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020328.
 XX
 PR 29-SEP-1997; 97US-00940093.
 XX
 XX (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 PI
 XX WPI; 1999-277031/23.
 DR
 XX
 PT Peptide agonists of apolipoprotein A-I.
 XX
 XX Example; Page 111; 152pp; English.
 XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists

XX Sequence 22 AA;
 SQ
 AAY18818 Length: 22 May 22, 2007 14:41 Type: P Check: 8907 ..
 1 PVLDLFRELW NEGLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY18697 standard; peptide; 22 AA.
 XX AAY18697;
 AC AAY18697;
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #18.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 XX Synthetic.
 OS Homo sapiens.
 OS
 XX
 PN W09916408-A2.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020328.
 XX
 PR 29-SEP-1997; 97US-00940093.
 XX
 XX (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 PI
 XX WPI; 1999-277031/23.
 DR
 XX
 PT Peptide agonists of apolipoprotein A-I.
 XX
 XX Example; Page 105; 152pp; English.
 XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ
 AAY18697 Length: 22 May 22, 2007 14:41 Type: P Check: 8853 ..
 1 GVLDLFRLL NELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY18765 standard; peptide; 22 AA.
 XX AAY18765;
 AC AAY18765;
 XX
 DT 09-JUL-1999 (first entry)
 XX

XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #86.
 XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 XX KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX OS Synthetic.
 OS OS Homo sapiens.
 XX PN WO9916408-A2.
 XX PD 08-APR-1999.
 XX PF 28-SEP-1998; 98WO-US020328.
 XX PR 29-SEP-1997; 97US-00940093.
 XX PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277031/23.
 XX PT Peptide agonists of apolipoprotein A-I.
 XX PS Example; Page 108; 152pp; English.
 XX CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX SQ Sequence 22 AA;
 XX AAY18765 Length: 22 May 22, 2007 14:41 Type: P Check: 8898 ..
 1 PVLELPERLL DELLNALQKK LK
 !!AA SEQUENCE 1.0
 ID AAY18703 standard; peptide; 22 AA.
 XX AC AAY18703;
 XX DT 09-JUL-1999 (first entry)
 XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #24.
 XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX OS Synthetic.
 OS OS Homo sapiens.
 XX PN WO9916408-A2.

XX PD 08-APR-1999.
 XX PF 28-SEP-1998; 98WO-US020328.
 XX PR 29-SEP-1997; 97US-00940093.
 XX PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277031/23.
 XX PT Peptide agonists of apolipoprotein A-I.
 XX PS Example; Page 105; 152pp; English.
 XX CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX SQ Sequence 22 AA;
 XX AAY18703 Length: 22 May 22, 2007 14:41 Type: P Check: 8856 ..
 1 PVLDLFRLL NELLEALQKK LK
 !!AA SEQUENCE 1.0
 ID AAY18805 standard; peptide; 22 AA.
 XX AC AAY18805;
 XX DT 09-JUL-1999 (first entry)
 XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #126.
 XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX OS Synthetic.
 OS OS Homo sapiens.
 XX PN WO9916408-A2.
 XX PD 08-APR-1999.
 XX PF 28-SEP-1998; 98WO-US020328.
 XX PR 29-SEP-1997; 97US-00940093.
 XX PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277031/23.
 XX PT Peptide agonists of apolipoprotein A-I.
 XX PS Example; Page 105; 152pp; English.
 XX CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX SQ Sequence 22 AA;

PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 DR WPI; 1999-277031/23.
 XX
 XX
 PT Peptide agonists of apolipoprotein A-I.
 XX
 XX Example; Page 111; 152pp; English.
 XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 14-22 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18680 to
 CC AAY18933 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ
 AAY18905 Length: 22 May 22, 2007 14:41 Type: P Check: 8792 ..
 1 PVLDLFRELL NELGEALKQK LK
 !!AA_SEQUENCE 1.0
 ID AAY18948 standard; peptide; 22 AA.
 XX
 AC AAY18948;
 XX
 XX 09-JUL-1999 (first entry)
 DT
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #15.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916458-A1.
 XX
 XX 08-APR-1999.
 PD
 XX
 XX 28-SEP-1998; 98WO-US020326.
 PF
 XX
 PR 29-SEP-1997; 97US-00940096.
 XX
 XX (DASS/) DASSEUX J.
 XX (SEKU/) SEKUL R.
 XX (BUTT/) BUTTNER K.
 XX (CORN/) CORNUT I.
 XX (METZ/) METZ G.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277034/23.
 XX
 XX Peptide agonists of apolipoprotein A-I.
 XX
 XX Example; Page 108; 254pp; English.
 XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ
 AAY18953 Length: 22 May 22, 2007 14:41 Type: P Check: 8817 ..
 1 PVLDLFRELL NELLEALKQK LK
 !!AA_SEQUENCE 1.0
 ID AAY18953 standard; peptide; 22 AA.
 XX
 AC AAY18953;
 XX
 XX 09-JUL-1999 (first entry)
 DT
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #20.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916458-A1.
 XX
 XX 08-APR-1999.
 PD
 XX
 XX 28-SEP-1998; 98WO-US020326.
 PF
 XX
 PR 29-SEP-1997; 97US-00940096.
 XX
 XX (DASS/) DASSEUX J.
 XX (SEKU/) SEKUL R.
 XX (BUTT/) BUTTNER K.
 XX (CORN/) CORNUT I.
 XX (METZ/) METZ G.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277034/23.
 XX
 XX Peptide agonists of apolipoprotein A-I.
 XX
 XX Example; Page 107; 254pp; English.
 XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,

```

1 PVLDFREGL NELLEALKQK LK
!!AA SEQUENCE 1.0
ID _RAY19020 standard; peptide; 22 AA.
XX AC AAY19020;
XX
XX
DT 09-JUL-1999 (first entry)
XX
DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #87.
XX
XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX
XX Synthetic.
OS
OS Homo sapiens.
XX
XX WO9916458-A1.
PN
XX
XX 08-APR-1999.
PD
XX
XX 28-SEP-1998; 98WO-US020326.
PF
XX
XX 29-SEP-1997; 97US-00940096.
PR
XX
XX (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
XX
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
PI WPI; 1999-277034/23.
XX
XX Peptide agonists of apolipoprotein A-I.
DR
XX Example; Page 111; 254pp; English.
XX
XX The present invention describes an agonist (A) of apolipoprotein A-I
CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
CC complexes, are used to treat or prevent diseases associated with
CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
CC treating septic shock. When labeled, (A) can also be used diagnostically
CC to measure serum levels of HDL, in particular the HDL subpopulation that
CC is involved in retrograde cholesterol transport, also to image HDL at
CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
CC exhibiting core peptides, which are apoA-I agonists
XX
XX Sequence 22 AA;
SQ
AAY19031 Length: 22 May 22, 2007 14:41 Type: P Check: 8771 ..
1 PVLDFRELL NEELEALKQK LK
!!AA SEQUENCE 1.0
ID _AAY18941 standard; peptide; 22 AA.
XX
XX AC AAY18941;
XX
XX 09-JUL-1999 (first entry)
DT
XX
XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #8.
DE
XX
XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX
XX Synthetic.
OS
OS Homo sapiens.
XX
XX WO9916458-A1.
PN
XX
XX 08-APR-1999.
PD
XX
XX 28-SEP-1998; 98WO-US020326.
PF
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;

```


CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
CC exhibiting core peptides, which are apoA-I agonists
XX
SQ Sequence 22 AA;

AAY18956 Length: 22 May 22, 2007 14:41 Type: P Check: 8830 ..
1 PLLELFKELL QELLEALKQK LK
!!AA SEQUENCE 1.0
ID AAY18962 standard; peptide; 22 AA.
XX
XX AAY18962;
AC
XX
DT 09-JUL-1999 (first entry)
XX
XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #29.
DE
XX
XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX
OS Synthetic.
OS Homo sapiens.
XX
XX WO9916458-A1.
PN
XX
XX 08-APR-1999.
PD
XX
XX 28-SEP-1998; 98WO-US020326.
PF
XX
XX 29-SEP-1997; 97US-00940096.
PR
XX
XX (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
XX
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
PI WPI; 1999-277034/23.
XX
XX 28-SEP-1998; 98WO-US020326.
PF
XX
XX 29-SEP-1997; 97US-00940096.
PR
XX
XX (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
XX
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
PI WPI; 1999-277034/23.
XX
XX Peptide agonists of apolipoprotein A-I.
PT
XX
XX Example; Page 108; 254pp; English.
PS
XX
XX The present invention describes an agonist (A) of apolipoprotein A-I
CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
CC complexes, are used to treat or prevent diseases associated with
CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
CC treating septic shock. When labeled, (A) can also be used diagnostically
CC to measure serum levels of HDL, in particular the HDL subpopulation that
CC is involved in retrograde cholesterol transport, also to image HDL at
CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
CC exhibiting core peptides, which are apoA-I agonists
XX
XX Sequence 22 AA;
SQ

AAY18962 Length: 22 May 22, 2007 14:41 Type: P Check: 8847 ..
1 AVLDLPRELL NELLEALKQK LK
!!AA SEQUENCE 1.0
ID AAY18989 standard; peptide; 22 AA.
XX
XX
DT 09-JUL-1999 (first entry)
XX
XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #133.
DE
XX
XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX
OS Synthetic.
OS Homo sapiens.
XX
XX WO9916458-A1.
PN
XX
XX 08-APR-1999.
PD
XX
XX 28-SEP-1998; 98WO-US020326.
PF
XX
XX 29-SEP-1997; 97US-00940096.
PR
XX
XX (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
XX
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
PI WPI; 1999-277034/23.
XX
XX 28-SEP-1998; 98WO-US020326.
PF
XX
XX 29-SEP-1997; 97US-00940096.
PR
XX
XX (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
XX
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
PI WPI; 1999-277034/23.
XX
XX Peptide agonists of apolipoprotein A-I.
PT
XX
XX Example; Page 108; 254pp; English.
PS
XX
XX The present invention describes an agonist (A) of apolipoprotein A-I
CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
CC complexes, are used to treat or prevent diseases associated with
CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
CC treating septic shock. When labeled, (A) can also be used diagnostically
CC to measure serum levels of HDL, in particular the HDL subpopulation that
CC is involved in retrograde cholesterol transport, also to image HDL at
CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
CC exhibiting core peptides, which are apoA-I agonists
XX
XX Sequence 22 AA;
SQ

AC AAY18989;
XX
DT 09-JUL-1999 (first entry)
XX
XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #56.
DE
XX
XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX
OS Synthetic.
OS Homo sapiens.
XX
XX WO9916458-A1.
PN
XX
XX 08-APR-1999.
PD
XX
XX 28-SEP-1998; 98WO-US020326.
PF
XX
XX 29-SEP-1997; 97US-00940096.
PR
XX
XX (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
XX
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
PI WPI; 1999-277034/23.
XX
XX Peptide agonists of apolipoprotein A-I.
PT
XX
XX Example; Page 110; 254pp; English.
PS
XX
XX The present invention describes an agonist (A) of apolipoprotein A-I
CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
CC complexes, are used to treat or prevent diseases associated with
CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
CC treating septic shock. When labeled, (A) can also be used diagnostically
CC to measure serum levels of HDL, in particular the HDL subpopulation that
CC is involved in retrograde cholesterol transport, also to image HDL at
CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
CC exhibiting core peptides, which are apoA-I agonists
XX
XX Sequence 22 AA;
SQ

AAY18989 Length: 22 May 22, 2007 14:41 Type: P Check: 8841 ..
1 PVLDLPRELL NELLEALKQK KX
!!AA SEQUENCE 1.0
ID AAY19066 standard; peptide; 22 AA.
XX
XX AAY19066;
AC
XX
DT 09-JUL-1999 (first entry)
XX
XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #133.
DE
XX
XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX
OS Synthetic.
OS Homo sapiens.
XX
XX WO9916458-A1.
PN
XX
XX 08-APR-1999.
PD
XX
XX 28-SEP-1998; 98WO-US020326.
PF
XX
XX 29-SEP-1997; 97US-00940096.
PR
XX
XX (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
XX
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
PI WPI; 1999-277034/23.
XX
XX Peptide agonists of apolipoprotein A-I.
PT
XX
XX Example; Page 110; 254pp; English.
PS
XX
XX The present invention describes an agonist (A) of apolipoprotein A-I
CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
CC complexes, are used to treat or prevent diseases associated with
CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
CC treating septic shock. When labeled, (A) can also be used diagnostically
CC to measure serum levels of HDL, in particular the HDL subpopulation that
CC is involved in retrograde cholesterol transport, also to image HDL at
CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
CC exhibiting core peptides, which are apoA-I agonists
XX
XX Sequence 22 AA;
SQ


```

OS Homo sapiens.
XX W09916458-A1.
XX
XX PD 08-APR-1999.
XX
XX PF 28-SEP-1998; 98WO-US020326.
XX
XX PR 29-SEP-1997; 97US-00940096.
XX
XX PA (DASS//) DASSEUX J.
XX PA (SEKU//) SEKUL R.
XX PA (BUTT//) BUTTNER K.
XX PA (CORN//) CORNUT I.
XX PA (METZ//) METZ G.
XX
XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX
XX DR WPI; 1999-277034/23.
XX
XX PT Peptide agonists of apolipoprotein A-I.
XX
XX PS Example; Page 114; 254pp; English.
XX
XX CC The present invention describes an agonist (A) of apolipoprotein A-I
XX CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
XX CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
XX CC complexes, are used to treat or prevent diseases associated with
XX CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
XX CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
XX CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
XX CC treating septic shock. When labeled, (A) can also be used diagnostically
XX CC to measure serum levels of HDL, in particular the HDL subpopulation that
XX CC is involved in retrograde cholesterol transport, also to image HDL at
XX CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
XX CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
XX CC exhibiting core peptides, which are apoA-I agonists
XX
XX SQ Sequence 22 AA;
XX
AAY19066 Length: 22 May 22, 2007 14:41 Type: P Check: 8888 ..
XX
XX 1 PVLELFFERILL EDLLQALNKK LK
XX
!!AA SEQUENCE 1.0
ID -AAY18942 standard; peptide; 22 AA.
XX
XX AC AAY18942;
XX
XX DT 09-JUL-1999 (first entry)
XX
XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #9.
XX
XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
XX KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
XX KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
XX KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
XX KW septic shock.
XX
XX OS Synthetic.
XX OS Homo sapiens.
XX
XX PN W09916458-A1.
XX
XX PD 08-APR-1999.
XX
XX PF 28-SEP-1998; 98WO-US020326.
XX
XX PR 29-SEP-1997; 97US-00940096.
XX
XX XX (DASS//) DASSEUX J.
XX PA (SEKU//) SEKUL R.
XX PA (BUTT//) BUTTNER K.
XX PA (CORN//) CORNUT I.
XX PA (METZ//) METZ G.
XX
XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX
XX DR WPI; 1999-277034/23.
XX
XX PT Peptide agonists of apolipoprotein A-I.
XX
XX PS Example; Page 108; 254pp; English.
XX
XX CC The present invention describes an agonist (A) of apolipoprotein A-I
XX CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
XX CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
XX CC complexes, are used to treat or prevent diseases associated with
XX CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
XX CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
XX CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
XX CC treating septic shock. When labeled, (A) can also be used diagnostically
XX CC to measure serum levels of HDL, in particular the HDL subpopulation that
XX CC is involved in retrograde cholesterol transport, also to image HDL at
XX CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
XX CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
XX CC exhibiting core peptides, which are apoA-I agonists
XX
XX SQ Sequence 22 AA;
XX
AAY18942 Length: 22 May 22, 2007 14:41 Type: P Check: 8812 ..
XX
XX 1 PVLDLFFRELG NELLEALKQK LK
XX
!!AA SEQUENCE 1.0
ID -AAY18955 standard; peptide; 22 AA.
XX
XX AC AAY18955;
XX
XX DT 09-JUL-1999 (first entry)
XX
XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #22.
XX
XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
XX KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
XX KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
XX KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
XX KW septic shock.
XX
XX OS Synthetic.
XX OS Homo sapiens.
XX
XX PN W09916458-A1.
XX
XX PD 08-APR-1999.
XX
XX PF 28-SEP-1998; 98WO-US020326.
XX
XX PR 29-SEP-1997; 97US-00940096.
XX
XX XX (DASS//) DASSEUX J.
XX PA (SEKU//) SEKUL R.
XX PA (BUTT//) BUTTNER K.
XX PA (CORN//) CORNUT I.
XX PA (METZ//) METZ G.
XX
XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX
XX DR WPI; 1999-277034/23.
XX
XX PT Peptide agonists of apolipoprotein A-I.
XX
XX PS Example; Page 108; 254pp; English.
XX
XX CC The present invention describes an agonist (A) of apolipoprotein A-I
XX CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an

```

CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX
 SQ Sequence 22 AA;

AAY18955 Length: 22 May 22, 2007 14:41 Type: P Check: 8958 ..

1 PVLDLFRELL NELLEGLKQK LK

!!AA SEQUENCE 1.0
 ID AAY19059 standard; peptide; 22 AA.
 AC AAY19059;
 XX
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #126.

XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916458-A1.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020326.
 XX
 PR 29-SEP-1997; 97US-00940096.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 PI WPI; 1999-277034/23.
 XX
 DR Peptide agonists of apolipoprotein A-I.
 PT
 PS Example; Page 114; 254pp; English.
 XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX
 SQ Sequence 22 AA;

AAY19062 Length: 22 May 22, 2007 14:41 Type: P Check: 8968 ..

1 PVLELFNDLL RELLEALQKK LK

!!AA SEQUENCE 1.0
 ID AAY18936 standard; peptide; 22 AA.
 AC AAY18936;
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #3.

AAY19059 Length: 22 May 22, 2007 14:41 Type: P Check: 8792 ..

1 PVLDLFRELL NELGEALQKK LK

!!AA SEQUENCE 1.0
 ID AAY19062 standard; peptide; 22 AA.
 AC AAY19062;
 XX
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #129.

XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916458-A1.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020326.
 XX
 PR 29-SEP-1997; 97US-00940096.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 PI WPI; 1999-277034/23.
 XX
 DR Peptide agonists of apolipoprotein A-I.
 PT
 PS Example; Page 114; 254pp; English.
 XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX
 SQ Sequence 22 AA;

AAY19062 Length: 22 May 22, 2007 14:41 Type: P Check: 8868 ..

1 PVLELFNDLL RELLEALQKK LK

!!AA SEQUENCE 1.0
 ID AAY18936 standard; peptide; 22 AA.
 AC AAY18936;
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #3.

XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX Synthetic.
 OS Homo sapiens.
 XX WO9916458-A1.
 PN 08-APR-1999.
 PD 28-SEP-1998; 98WO-US020326.
 PF 29-SEP-1997; 97US-00940096.
 PR (DASS/) DASSEUX J.
 XX (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 PI WPI; 1999-277034/23.
 XX Peptide agonists of apolipoprotein A-I.
 DR Example; Page 107; 254pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ AAY18936 Length: 22 May 22, 2007 14:41 Type: P Check: 9214 ..
 1 PVLDLFRELL NELLEWLKQK LK
 !!IAA_SEQUENCE 1.0
 ID AAY18940 standard; peptide; 22 AA.
 XX AC AAY18940;
 XX 09-JUL-1999 (first entry)
 DT Lecithin:cholesterol acyltransferase activation exhibiting peptide #7.
 DE Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX Synthetic.
 OS Homo sapiens.
 XX WO9916458-A1.
 PN 08-APR-1999.
 PD 28-SEP-1998; 98WO-US020326.
 PF 29-SEP-1997; 97US-00940096.
 PR (DASS/) DASSEUX J.
 XX (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 PI WPI; 1999-277034/23.
 XX Peptide agonists of apolipoprotein A-I.
 DR Example; Page 107; 254pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ AAY18940 Length: 22 May 22, 2007 14:41 Type: P Check: 8813 ..
 1 PVLDLFRELL NELLEALKQK LK
 !!IAA_SEQUENCE 1.0
 ID AAY18961 standard; peptide; 22 AA.
 XX AC AAY18961;
 XX 09-JUL-1999 (first entry)
 DT Lecithin:cholesterol acyltransferase activation exhibiting peptide #28.
 DE Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX Synthetic.
 OS Homo sapiens.
 XX WO9916458-A1.
 PN 08-APR-1999.
 PD 28-SEP-1998; 98WO-US020326.
 PF 29-SEP-1997; 97US-00940096.
 PR (DASS/) DASSEUX J.
 XX (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 PI WPI; 1999-277034/23.
 XX Peptide agonists of apolipoprotein A-I.
 DR Example; Page 107; 254pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ AAY18940 Length: 22 May 22, 2007 14:41 Type: P Check: 8813 ..

DR WPI; 1999-277034/23.
 XX Peptide agonists of apolipoprotein A-I.
 XX Example; Page 108; 254pp; English.
 XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ
 AAY18961 Length: 22 May 22, 2007 14:41 Type: P Check: 9016 ..
 1 PVLDLFPRELL NELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY18969 standard; peptide; 22 AA.
 AC AAY18969;
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #36.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916458-A1.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020326.
 XX
 PR 29-SEP-1997; 97US-00940096.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX
 DR WPI; 1999-277034/23.
 XX
 PT Peptide agonists of apolipoprotein A-I.
 XX
 PS Example; Page 108; 254pp; English.
 XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A) and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ

CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ
 AAY18969 Length: 22 May 22, 2007 14:41 Type: P Check: 8866 ..
 1 PLELLKELL QELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY19068 standard; peptide; 22 AA.
 XX
 AC AAY19068;
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #135.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916458-A1.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020326.
 XX
 PR 29-SEP-1997; 97US-00940096.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX
 DR WPI; 1999-277034/23.
 XX
 PT Peptide agonists of apolipoprotein A-I.
 XX
 PS Example; Page 114; 254pp; English.
 XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ
 AAY19068 Length: 22 May 22, 2007 14:41 Type: P Check: 8850 ..
 1 DVLDLFPRELL NELLEALKQK LK

```

!!AA_SEQUENCE 1.0
ID _AAV19072 standard; peptide; 22 AA.
XX
XX AC AAV19072;
XX
XX DT 09-JUL-1999 (first entry)
XX
XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #139.
XX
XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
XX KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
XX KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
XX KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
XX KW septic shock.
XX
XX OS Synthetic.
XX OS Homo sapiens.
XX
XX FN WO9916458-A1.
XX
XX PD 08-APR-1999.
XX
XX PF 28-SEP-1998; 98WO-US020326.
XX
XX PR 29-SEP-1997; 97US-00940096.
XX
XX PA (DASS/) DASSEUX J.
XX PA (SEKU/) SEKUL R.
XX PA (BUTT/) BUTTNER K.
XX PA (CORN/) CORNUT I.
XX PA (METZ/) METZ G.
XX
XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX
XX WPI; 1999-277034/23.
XX
XX PF Peptide agonists of apolipoprotein A-I.
XX
XX PS Example; Page 114; 254pp; English.
XX
XX CC The present invention describes an agonist (A) of apolipoprotein A-I
XX CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
XX CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
XX CC complexes, are used to treat or prevent diseases associated with
XX CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
XX CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
XX CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
XX CC treating septic shock. When labeled, (A) can also be used diagnostically
XX CC to measure serum levels of HDL, in particular the HDL subpopulation that
XX CC is involved in retrograde cholesterol transport, also to image HDL at
XX CC e.g. atherosclerotic streaks, and to raise antibodies. AAV18934 to
XX CC AAV19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
XX CC exhibiting core peptides, which are apoA-I agonists
XX
XX SQ Sequence 22 AA;
XX
XX AAV19072 Length: 22 May 22, 2007 14:41 Type: P Check: 8907 ..
XX
XX 1 PVLDLFRELW NEGLEALKQK LK
XX
XX !!AA_SEQUENCE 1.0
XX ID _AAV18963 standard; peptide; 22 AA.
XX
XX AC AAV18963;
XX
XX XX 09-JUL-1999 (first entry)
XX
XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #30.
XX
XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
XX KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
XX KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
XX KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
XX

```

```

KW septic shock.
XX
XX OS Synthetic.
XX OS Homo sapiens.
XX
XX FN WO9916458-A1.
XX
XX PD 08-APR-1999.
XX
XX PF 28-SEP-1998; 98WO-US020326.
XX
XX PR 29-SEP-1997; 97US-00940096.
XX
XX PA (DASS/) DASSEUX J.
XX PA (SEKU/) SEKUL R.
XX PA (BUTT/) BUTTNER K.
XX PA (CORN/) CORNUT I.
XX PA (METZ/) METZ G.
XX
XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX
XX WPI; 1999-277034/23.
XX
XX PF Peptide agonists of apolipoprotein A-I.
XX
XX PS Example; Page 108; 254pp; English.
XX
XX CC The present invention describes an agonist (A) of apolipoprotein A-I
XX CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
XX CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
XX CC complexes, are used to treat or prevent diseases associated with
XX CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
XX CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
XX CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
XX CC treating septic shock. When labeled, (A) can also be used diagnostically
XX CC to measure serum levels of HDL, in particular the HDL subpopulation that
XX CC is involved in retrograde cholesterol transport, also to image HDL at
XX CC e.g. atherosclerotic streaks, and to raise antibodies. AAV18934 to
XX CC AAV19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
XX CC exhibiting core peptides, which are apoA-I agonists
XX
XX SQ Sequence 22 AA;
XX
XX AAV18963 Length: 22 May 22, 2007 14:41 Type: P Check: 8862 ..
XX
XX 1 PVLDLFRELL NELLEALKQK LK
XX
XX !!AA_SEQUENCE 1.0
XX ID _AAV18972 standard; peptide; 22 AA.
XX
XX AC AAV18972;
XX
XX DT 09-JUL-1999 (first entry)
XX
XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #39.
XX
XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
XX KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
XX KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
XX KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
XX KW septic shock.
XX
XX OS Synthetic.
XX OS Homo sapiens.
XX
XX FN WO9916458-A1.
XX
XX PD 08-APR-1999.
XX
XX PF 28-SEP-1998; 98WO-US020326.
XX
XX PR 29-SEP-1997; 97US-00940096.
XX

```

PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277034/23.
 DR Peptide agonists of apolipoprotein A-I.
 XX Example; Page 109; 254pp; English.
 XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ
 AAY18972 Length: 22 May 22, 2007 14:41 Type: P Check: 8739 ..
 1 PVLDLFRELL EBLKALKKK LK
 !!AA SEQUENCE 1.0
 ID AAY18957 standard; peptide; 22 AA.
 AC AAY18957;
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #24.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916458-A1.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020326.
 XX
 PR 29-SEP-1997; 97US-00940096.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277034/23.
 DR Peptide agonists of apolipoprotein A-I.
 XX Example; Page 108; 254pp; English.
 XX
 PS

XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ
 AAY18957 Length: 22 May 22, 2007 14:41 Type: P Check: 8856 ..
 1 PVLDLFRELL NELLEALQKK LK
 !!AA SEQUENCE 1.0
 ID AAY19076 standard; peptide; 22 AA.
 XX
 AC AAY19076;
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #143.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916458-A1.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020326.
 XX
 PR 29-SEP-1997; 97US-00940096.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277034/23.
 DR Peptide agonists of apolipoprotein A-I.
 XX Example; Page 114; 254pp; English.
 XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ

```

CC exhibiting core peptides, which are apoA-I agonists
SQ Sequence 22 AA;

AAV19076 Length: 22 May 22, 2007 14:41 Type: P Check: 8797 ..
1 PVLDLFRELL NEGLEALKQK LK

!!AA_SEQUENCE 1.0
ID _AAV19019 standard; peptide; 22 AA.
XX
AC AAV19019;
XX
DT 09-JUL-1999 (first entry)
XX
DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #86.
XX
KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9916458-A1.
XX
DT 09-JUL-1999 (first entry)
XX
DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #86.
XX
KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9916458-A1.
XX
PD 08-APR-1999.
XX
PF 28-SEP-1998; 98WO-US020326.
XX
PP 29-SEP-1997; 97US-00940096.
XX
PR (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
XX
PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX WPI; 1999-277034/23.
XX
DR Peptide agonists of apolipoprotein A-I.
XX
PT Example; Page 109; 254pp; English.
XX
PS The present invention describes an agonist (A) of apolipoprotein A-I
XX (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
XX amphipathic alpha-helix in presence of lipids. (A), and their lipid
XX complexes, are used to treat or prevent diseases associated with
XX dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
XX atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
XX deficiency; hypertriglyceridemia and metabolic syndrome, also for
XX treating septic shock. When labeled, (A) can also be used diagnostically
XX to measure serum levels of HDL, in particular the HDL subpopulation that
XX is involved in retrograde cholesterol transport, also to image HDL at
XX e.g. atherosclerotic streaks, and to raise antibodies. AAV18934 to
XX AAV19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
XX exhibiting core peptides, which are apoA-I agonists
XX Sequence 22 AA;

AAV19073 Length: 22 May 22, 2007 14:41 Type: P Check: 8872 ..
1 PVLDLFRELL RELLEALKQK LK

!!AA_SEQUENCE 1.0
ID _AAV18937 standard; peptide; 22 AA.
XX
AC AAV18937;
XX
DT 09-JUL-1999 (first entry)
XX
DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #4.
XX
KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX
OS Synthetic.
OS Homo sapiens.
XX

```

PN WO9916458-A1.
 XX 08-APR-1999.
 XX 28-SEP-1998; 98WO-US020326.
 XX 29-SEP-1997; 97US-00940096.
 XX (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277034/23.
 XX Peptide agonists of apolipoprotein A-I.
 XX Example; Page 107; 254pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 15-29 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ AAY18937 Length: 22 May 22, 2007 14:41 Type: P Check: 8862 ..
 1 PVLDFRELL NELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY18959 standard; peptide; 22 AA.
 AC AAY18959;
 XX 09-JUL-1999 (first entry)
 XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #26.
 DE Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX Synthetic.
 OS Homo sapiens.
 XX WO9916458-A1.
 PN 08-APR-1999.
 XX 28-SEP-1998; 98WO-US020326.
 XX 29-SEP-1997; 97US-00940096.
 XX (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277034/23.
 XX Peptide agonists of apolipoprotein A-I.
 XX Example; Page 107; 254pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 15-29 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ AAY18937 Length: 22 May 22, 2007 14:41 Type: P Check: 8862 ..
 1 PVLDFRELL NELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY18959 standard; peptide; 22 AA.
 AC AAY18959;
 XX 09-JUL-1999 (first entry)
 XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #26.
 DE Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX Synthetic.
 OS Homo sapiens.
 XX WO9916458-A1.
 PN 08-APR-1999.
 XX 28-SEP-1998; 98WO-US020326.
 XX 29-SEP-1997; 97US-00940096.
 XX (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.

XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277034/23.
 XX Peptide agonists of apolipoprotein A-I.
 XX Example; Page 108; 254pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 15-29 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ AAY18959 Length: 22 May 22, 2007 14:41 Type: P Check: 9038 ..
 1 PVLDFRELL NELLELLKQK LK
 !!AA SEQUENCE 1.0
 ID AAY19063 standard; peptide; 22 AA.
 AC AAY19063;
 XX 09-JUL-1999 (first entry)
 XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #130.
 DE Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX Synthetic.
 OS Homo sapiens.
 XX WO9916458-A1.
 PN 08-APR-1999.
 XX 28-SEP-1998; 98WO-US020326.
 XX 29-SEP-1997; 97US-00940096.
 XX (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277034/23.
 XX Peptide agonists of apolipoprotein A-I.
 XX Example; Page 114; 254pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 15-29 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with

CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ

AAY19063 Length: 22 May 22, 2007 14:41 Type: P Check: 8874 ..

1 PVLEFNDLL NELLEALKQK LK

!!AA SEQUENCE 1.0
 ID AAY18946 standard; peptide; 22 AA.
 AC AAY18946;
 XX
 DT 09-JUL-1999 (first entry)
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #13.
 XX

Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916458-A1.
 XX
 PD 08-APR-1999.
 XX

28-SEP-1998; 98WO-US020326.
 XX
 29-SEP-1997; 97US-00940096.
 XX
 (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 PI WPI; 1999-277034/23.
 DR
 XX
 XX Peptide agonists of apolipoprotein A-I.
 XX
 XX Example; Page 107; 254pp; English.
 XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ

AAY18946 Length: 22 May 22, 2007 14:41 Type: P Check: 8788 ..

1 PVLEFNDLL NELLEALKQK LK

!!AA SEQUENCE 1.0
 ID AAY18946 standard; peptide; 22 AA.
 AC AAY18946;
 XX
 DT 09-JUL-1999 (first entry)
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #138.
 XX

Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916458-A1.
 XX
 PD 08-APR-1999.
 XX

28-SEP-1998; 98WO-US020326.
 XX
 29-SEP-1997; 97US-00940096.
 XX
 (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 PI WPI; 1999-277034/23.
 DR
 XX
 XX Peptide agonists of apolipoprotein A-I.
 XX
 XX Example; Page 107; 254pp; English.
 XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ

1 GVLDLFPRELL NELLEALKQK LK

!!AA SEQUENCE 1.0
 ID AAY19056 standard; peptide; 22 AA.
 AC AAY19056;
 XX
 DT 09-JUL-1999 (first entry)
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #123.
 XX

Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916458-A1.
 XX
 PD 08-APR-1999.
 XX

28-SEP-1998; 98WO-US020326.
 XX
 29-SEP-1997; 97US-00940096.
 XX
 (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 PI WPI; 1999-277034/23.
 DR
 XX
 XX Peptide agonists of apolipoprotein A-I.
 XX
 XX Example; Page 113; 254pp; English.
 XX
 CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ

AAY19056 Length: 22 May 22, 2007 14:41 Type: P Check: 8863 ..

1 QVLDLFPRELL NELLEALKQK LK

!!AA SEQUENCE 1.0
 ID AAY19071 standard; peptide; 22 AA.
 AC AAY19071;
 XX
 DT 09-JUL-1999 (first entry)
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #138.
 XX

Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase activation exhibiting peptide #138.
 XX
 XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW

KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 OS Synthetic.
 OS Homo sapiens.
 XX WO9916458-A1.
 XX
 XX
 XX PD 08-APR-1999.
 XX
 XX PF 28-SEP-1998; 98WO-US020326.
 XX
 XX PR 29-SEP-1997; 97US-00940096.
 XX
 XX PA (DASS/) DASSEUX J.
 XX PA (SEKU/) SEKUL R.
 XX PA (BUTT/) BUTTNER K.
 XX PA (CORN/) CORNUT I.
 XX PA (METZ/) METZ G.
 XX
 XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277034/23.
 XX
 XX PT Peptide agonists of apolipoprotein A-I.
 XX PS Example; Page 114; 254pp; English.
 XX
 XX CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 XX
 XX SQ AAY19071 Length: 22 May 22, 2007 14:41 Type: P Check: 9149 ..
 1 PVLDFRELL NEGLEWLKQK LK
 !!AA SEQUENCE 1.0
 ID AAY18951 standard; peptide; 22 AA.
 AC AAY18951;
 XX
 XX DT 09-JUL-1999 (first entry)
 XX
 XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #18.
 XX
 XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 OS Synthetic.
 OS Homo sapiens.
 XX WO9916458-A1.
 XX
 XX PD 08-APR-1999.
 XX
 XX PF 28-SEP-1998; 98WO-US020326.
 XX
 XX PR 29-SEP-1997; 97US-00940096.
 XX
 XX PA (DASS/) DASSEUX J.
 XX PA (SEKU/) SEKUL R.
 XX PA (BUTT/) BUTTNER K.
 XX PA (CORN/) CORNUT I.
 XX PA (METZ/) METZ G.
 XX
 XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277034/23.
 XX
 XX PT Peptide agonists of apolipoprotein A-I.
 XX PS Example; Page 114; 254pp; English.
 XX
 XX CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 XX
 XX SQ AAY19071 Length: 22 May 22, 2007 14:41 Type: P Check: 9149 ..
 1 PVLDFRELL NEGLEWLKQK LK
 !!AA SEQUENCE 1.0
 ID AAY18951 standard; peptide; 22 AA.
 AC AAY18951;
 XX
 XX DT 09-JUL-1999 (first entry)
 XX
 XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #18.
 XX
 XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 OS Synthetic.
 OS Homo sapiens.
 XX WO9916458-A1.
 XX
 XX PD 08-APR-1999.
 XX
 XX PF 28-SEP-1998; 98WO-US020326.
 XX
 XX PR 29-SEP-1997; 97US-00940096.
 XX
 XX PA (DASS/) DASSEUX J.
 XX PA (SEKU/) SEKUL R.
 XX PA (BUTT/) BUTTNER K.
 XX PA (CORN/) CORNUT I.
 XX PA (METZ/) METZ G.
 XX
 XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277034/23.
 XX
 XX PT Peptide agonists of apolipoprotein A-I.
 XX PS Example; Page 108; 254pp; English.
 XX
 XX CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 XX
 XX SQ AAY18951 Length: 22 May 22, 2007 14:41 Type: P Check: 8853 ..
 1 GVLDLFRELL NELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY18950 standard; peptide; 22 AA.
 AC AAY18950;
 XX
 XX DT 09-JUL-1999 (first entry)
 XX
 XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #17.
 XX
 XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 OS Synthetic.
 OS Homo sapiens.
 XX WO9916458-A1.
 XX
 XX PD 08-APR-1999.
 XX
 XX PF 28-SEP-1998; 98WO-US020326.
 XX
 XX PR 29-SEP-1997; 97US-00940096.
 XX
 XX PA (DASS/) DASSEUX J.
 XX PA (SEKU/) SEKUL R.
 XX PA (BUTT/) BUTTNER K.
 XX PA (CORN/) CORNUT I.
 XX PA (METZ/) METZ G.
 XX
 XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
 XX WPI; 1999-277034/23.
 XX
 XX PT Peptide agonists of apolipoprotein A-I.
 XX PS Example; Page 108; 254pp; English.
 XX
 XX CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 XX
 XX SQ AAY18951 Length: 22 May 22, 2007 14:41 Type: P Check: 8853 ..
 1 GVLDLFRELL NELLEALKQK LK

PT Peptide agonists of apolipoprotein A-I.

XX Example; Page 107; 254pp; English.

XX The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 15-29 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity CC exhibiting core peptides, which are apoA-I agonists

XX Sequence 22 AA;

AAV18950 Length: 22 May 22, 2007 14:41 Type: P Check: 8850 ..

1 PVLELFKELL QELLEALKQK LK

!!AA SEQUENCE 1.0

ID AAY19060 standard; peptide; 22 AA.

XX AC AAY19060;

XX DT 09-JUL-1999 (first entry)

XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #127.
KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.

XX Synthetic.

XX Homo sapiens.

XX WO9916458-A1.

XX PD 08-APR-1999.

PF 28-SEP-1998; 98WO-US020326.

PR 29-SEP-1997; 97US-00940096.

XX (DASS/) DASSEUX J.

PA (SEKU/) SEKUL R.

PA (BUTT/) BUTTNER K.

PA (CORN/) CORNUT I.

PA (METZ/) METZ G.

PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;

XX WPI; 1999-277034/23.

PT Peptide agonists of apolipoprotein A-I.

XX Example; Page 114; 254pp; English.

XX The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 15-29 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that

CC is involved in retrograde cholesterol transport, also to image HDL at
CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
CC exhibiting core peptides, which are apoA-I agonists

XX Sequence 22 AA;

AAV19060 Length: 22 May 22, 2007 14:41 Type: P Check: 9038 ..

1 PVLDLFPRELL NELLELLKQK LK

!!AA SEQUENCE 1.0

ID AAY19061 standard; peptide; 22 AA.

XX AC AAY19061;

XX DT 09-JUL-1999 (first entry)

XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #128.

XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.

XX Synthetic.

XX Homo sapiens.

XX WO9916458-A1.

XX PD 08-APR-1999.

XX 28-SEP-1998; 98WO-US020326.

PR 29-SEP-1997; 97US-00940096.

XX (DASS/) DASSEUX J.

PA (SEKU/) SEKUL R.

PA (BUTT/) BUTTNER K.

PA (CORN/) CORNUT I.

PA (METZ/) METZ G.

PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;

XX WPI; 1999-277034/23.

PT Peptide agonists of apolipoprotein A-I.

XX Example; Page 114; 254pp; English.

XX The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 15-29 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity CC exhibiting core peptides, which are apoA-I agonists

XX Sequence 22 AA;

AAV19061 Length: 22 May 22, 2007 14:41 Type: P Check: 8942 ..

1 PVLDLFPRELL NELLEFLKQK LK

!!AA SEQUENCE 1.0

ID AAY18944 standard; peptide; 22 AA.

XX AAY18944;
AC 09-JUL-1999 (first entry)
DT Lecithin:cholesterol acyltransferase activation exhibiting peptide #11.
DE
XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX
XX Synthetic.
OS Homo sapiens.
XX WO9916458-A1.
XX 08-APR-1999.
XX 28-SEP-1998; 98WO-US020326.
XX 29-SEP-1997; 97US-00940096.
XX (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
PI WPI; 1999-277034/23.
XX Peptide agonists of apolipoprotein A-I.
XX Example; Page 107; 254pp; English.
XX The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 15-29 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity CC exhibiting core peptides, which are apoA-I agonists
XX Sequence 22 AA;
XX AAY18944 Length: 22 May 22, 2007 14:41 Type: P Check: 8846 ..
1 PVLDLFKELL QELLEALKQK LK
!!AA SEQUENCE 1.0
ID AAY18945 standard; peptide; 22 AA.
XX AAY18945;
AC 09-JUL-1999 (first entry)
DT Lecithin:cholesterol acyltransferase activation exhibiting peptide #12.
DE
XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX
XX Synthetic.
OS Homo sapiens.
XX WO9916458-A1.
XX 08-APR-1999.
XX 28-SEP-1998; 98WO-US020326.
XX 29-SEP-1997; 97US-00940096.
XX (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
PI WPI; 1999-277034/23.
XX Peptide agonists of apolipoprotein A-I.
XX Example; Page 107; 254pp; English.
XX The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 15-29 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity CC exhibiting core peptides, which are apoA-I agonists
XX Sequence 22 AA;
XX AAY18944 Length: 22 May 22, 2007 14:41 Type: P Check: 8846 ..
1 PVLDLFKELL QELLEALKQK LK
!!AA SEQUENCE 1.0
ID AAY18945 standard; peptide; 22 AA.
XX AAY18945;
AC 09-JUL-1999 (first entry)
DT Lecithin:cholesterol acyltransferase activation exhibiting peptide #11.
DE
XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX
XX Synthetic.
OS Homo sapiens.
XX WO9916458-A1.
XX 08-APR-1999.
XX 28-SEP-1998; 98WO-US020326.
XX 29-SEP-1997; 97US-00940096.
XX (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.

OS Synthetic.
OS Homo sapiens.
XX WO9916458-A1.
XX 08-APR-1999.
XX 28-SEP-1998; 98WO-US020326.
XX 29-SEP-1997; 97US-00940096.
XX (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
PI WPI; 1999-277034/23.
XX Peptide agonists of apolipoprotein A-I.
XX Example; Page 107; 254pp; English.
XX The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 15-29 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity CC exhibiting core peptides, which are apoA-I agonists
XX Sequence 22 AA;
XX AAY18945 Length: 22 May 22, 2007 14:41 Type: P Check: 8777 ..
1 PVLDLFKELL NELLEAGKQK LK
!!AA SEQUENCE 1.0
ID AAY19058 standard; peptide; 22 AA.
XX AAY19058;
AC 09-JUL-1999 (first entry)
DT Lecithin:cholesterol acyltransferase activation exhibiting peptide #125.
DE
XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX
XX Synthetic.
OS Homo sapiens.
XX WO9916458-A1.
XX 08-APR-1999.
XX 28-SEP-1998; 98WO-US020326.
XX 29-SEP-1997; 97US-00940096.
XX (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.

PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
XX (METZ/) METZ G.
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX WPI; 1999-277034/23.
XX Peptide agonists of apolipoprotein A-I.
PS Example; Page 113; 254pp; English.
XX The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 15-29 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to CC AAY187 represent lecithin:cholesterol acyltransferase (LCAT) activity CC exhibiting core peptides, which are apoA-I agonists
XX Sequence 22 AA;
SQ AAY19058 Length: 22 May 22, 2007 14:41 Type: P Check: 8860 ..
1 NVLDLFRELL NELLEALKQK LK
!!AA SEQUENCE 1.0
ID _AAY19064 standard; peptide; 22 AA.
XX AAY19064;
XX 09-JUL-1999 (first entry)
XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #131.
XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX Synthetic.
OS Homo sapiens.
XX WO9916458-A1.
XX 08-APR-1999.
XX 28-SEP-1998; 98WO-US020326.
XX 29-SEP-1997; 97US-00940096.
XX (DASS/) DASSEUX J.
XX (SEKU/) SEKUL R.
XX (BUTT/) BUTTNER K.
XX (CORN/) CORNUT I.
XX (METZ/) METZ G.
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX WPI; 1999-277034/23.
XX Peptide agonists of apolipoprotein A-I.
PS Example; Page 114; 254pp; English.
XX The present invention describes an agonist (A) of apolipoprotein A-I

CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to CC AAY187 represent lecithin:cholesterol acyltransferase (LCAT) activity CC exhibiting core peptides, which are apoA-I agonists
XX Sequence 22 AA;
SQ AAY19064 Length: 22 May 22, 2007 14:41 Type: P Check: 8928 ..
1 PVLELFKELL NELLDALRQK LK
!!AA SEQUENCE 1.0
ID _AAY19069 standard; peptide; 22 AA.
XX AAY19069;
XX 09-JUL-1999 (first entry)
XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #136.
XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX Synthetic.
OS Homo sapiens.
XX WO9916458-A1.
XX 08-APR-1999.
XX 28-SEP-1998; 98WO-US020326.
XX 29-SEP-1997; 97US-00940096.
XX (DASS/) DASSEUX J.
XX (SEKU/) SEKUL R.
XX (BUTT/) BUTTNER K.
XX (CORN/) CORNUT I.
XX (METZ/) METZ G.
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX WPI; 1999-277034/23.
XX Peptide agonists of apolipoprotein A-I.
PS Example; Page 114; 254pp; English.
XX The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 15-29 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to CC AAY187 represent lecithin:cholesterol acyltransferase (LCAT) activity CC exhibiting core peptides, which are apoA-I agonists
XX

```

SQ Sequence 22 AA;
AAV19069 Length: 22 May 22, 2007 14:41 Type: P Check: 8800 ..
1 PALELPKDLL QELLEALKQK LK
!!AA SEQUENCE 1.0
ID AAY19074 standard; peptide; 22 AA.
XX AC AAY19074;
XX DT 09-JUL-1999 (first entry)
XX XX
XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #141.
XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX OS Synthetic.
XX OS Homo sapiens.
XX PN W09916458-A1.
XX XX
XX DT 08-APR-1999.
XX XX
XX PF 28-SEP-1998; 98WO-US020326.
XX XX
XX PR 29-SEP-1997; 97US-00940096.
XX XX
XX PA (DASS/) DASSEUX J.
XX PA (SEKU/) SEKUL R.
XX PA (BUTT/) BUTTNER K.
XX PA (CORN/) CORNUT I.
XX PA (METZ/) METZ G.
XX XX
XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX WPI; 1999-277034/23.
XX XX
XX PT Peptide agonists of apolipoprotein A-I.
XX PS Example; Page 107; 254pp; English.
XX CC The present invention describes an agonist (A) of apolipoprotein A-I
CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
CC complexes, are used to treat or prevent diseases associated with
CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
CC treating septic shock. When labeled, (A) can also be used diagnostically
CC to measure serum levels of HDL, in particular the HDL subpopulation that
CC is involved in retrograde cholesterol transport, also to image HDL at
CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
CC exhibiting core peptides, which are apoA-I agonists
XX SQ Sequence 23 AA;
AAV18935 Length: 23 May 22, 2007 14:41 Type: P Check: 578 ..
1 GVLDLFFRELL NELLEALKQK LKK
!!AA SEQUENCE 1.0
ID AAY18949 standard; peptide; 22 AA.
XX AC AAY18949;
XX XX
XX DT 09-JUL-1999 (first entry)
XX XX
XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #16.
XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX OS Synthetic.
XX OS Homo sapiens.
XX PN W09916458-A1.
XX XX

```

```

PD 08-APR-1999.
XX
XX PF 28-SEP-1998; 98WO-US020326.
XX
XX PR 29-SEP-1997; 97US-00940096.
XX
XX (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
XX
PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX
XX DR WPI; 1999-277034/23.
XX
XX PT Peptide agonists of apolipoprotein A-I.
XX
XX PS Example; Page 107; 254pp; English.
XX
XX CC The present invention describes an agonist (A) of apolipoprotein A-I
CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
CC complexes, are used to treat or prevent diseases associated with
CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
CC treating septic shock. When labeled, (A) can also be used diagnostically
CC to measure serum levels of HDL, in particular the HDL subpopulation that
CC is involved in retrograde cholesterol transport, also to image HDL at
CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
CC exhibiting core peptides, which are apoA-I agonists
XX
XX SQ Sequence 22 AA;
XX
XX AAY18949 Length: 22 May 22, 2007 14:41 Type: P Check: 8898 ..
XX
XX 1 PVLDLRLRELL NELLEALKQK LK
XX
XX !!AA SEQUENCE 1.0
XX ID AAY19013 standard; peptide; 22 AA.
XX AC AAY19013;
XX
XX DT 09-JUL-1999 (first entry)
XX
XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #80.
XX
XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
XX lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
XX cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
XX high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
XX septic shock.
XX
XX OS Synthetic.
XX OS Homo sapiens.
XX
XX PN WO9916458-A1.
XX
XX PD 08-APR-1999.
XX
XX PF 28-SEP-1998; 98WO-US020326.
XX
XX PR 29-SEP-1997; 97US-00940096.
XX
XX (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
XX
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX
XX DR WPI; 1999-277034/23.
XX
XX PT Peptide agonists of apolipoprotein A-I.
XX
XX PS Example; Page 107; 254pp; English.
XX
XX CC The present invention describes an agonist (A) of apolipoprotein A-I
XX (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
XX amphipathic alpha-helix in presence of lipids. (A), and their lipid
XX complexes, are used to treat or prevent diseases associated with
XX dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
XX atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
XX deficiency; hypertriglyceridemia and metabolic syndrome, also for
XX treating septic shock. When labeled, (A) can also be used diagnostically
XX to measure serum levels of HDL, in particular the HDL subpopulation that
XX is involved in retrograde cholesterol transport, also to image HDL at
XX e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
XX AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
XX exhibiting core peptides, which are apoA-I agonists
XX
XX SQ Sequence 22 AA;
XX
XX AAY18949 Length: 22 May 22, 2007 14:41 Type: P Check: 8898 ..
XX
XX 1 PVLDLRLRELL NELLEALKQK LK
XX
XX !!AA SEQUENCE 1.0
XX ID AAY19013 standard; peptide; 22 AA.
XX AC AAY19013;
XX
XX DT 09-JUL-1999 (first entry)
XX
XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #80.
XX
XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
XX lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
XX cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
XX high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
XX septic shock.
XX
XX OS Synthetic.
XX OS Homo sapiens.
XX
XX PN WO9916458-A1.
XX
XX PD 08-APR-1999.
XX
XX PF 28-SEP-1998; 98WO-US020326.
XX
XX PR 29-SEP-1997; 97US-00940096.
XX
XX (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
XX
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;
XX
XX DR WPI; 1999-277034/23.
XX
XX PT Peptide agonists of apolipoprotein A-I.
XX
XX PS Example; Page 112; 254pp; English.
XX
XX CC The present invention describes an agonist (A) of apolipoprotein A-I
XX (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
XX amphipathic alpha-helix in presence of lipids. (A), and their lipid
XX complexes, are used to treat or prevent diseases associated with
XX dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
XX atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I

```

CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists

XX Sequence 22 AA;

AAV19033 Length: 22 May 22, 2007 14:41 Type: P Check: 8862 ..

1 PVLDLFRELL NELLEALKQK LK

!!AA SEQUENCE 1.0

ID AAY19065 standard; peptide; 22 AA.

XX AC AAY19065;

XX DT 09-JUL-1999 (first entry)

XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #132.

XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.

XX OS Synthetic.

XX OS Homo sapiens.

XX PN WO9916458-A1.

XX PD 08-APR-1999.

XX PF 28-SEP-1998; 98WO-US020326.

XX PR 29-SEP-1997; 97US-00940096.

XX PS (DASS/) DASSEUX J.

PA (SEKU/) SEKUL R.

PA (BUTT/) BUTTNER K.

PA (CORN/) CORNUT I.

PA (METZ/) METZ G.

XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;

XX DR WPI; 1999-277034/23.

XX PT Peptide agonists of apolipoprotein A-I.

XX PS Example; Page 114; 254pp; English.

XX CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists

XX Sequence 22 AA;

AAV19065 Length: 22 May 22, 2007 14:41 Type: P Check: 8865 ..

1 PVLDLFRELL ENLEALKQK LK

!!AA SEQUENCE 1.0

ID AAY19075 standard; peptide; 22 AA.

XX AC AAY19075;

XX DT 09-JUL-1999 (first entry)

XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #142.

XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.

XX OS Synthetic.

XX OS Homo sapiens.

XX PN WO9916458-A1.

XX PD 08-APR-1999.

XX PF 28-SEP-1998; 98WO-US020326.

XX PR 29-SEP-1997; 97US-00940096.

XX PS (DASS/) DASSEUX J.

PA (SEKU/) SEKUL R.

PA (BUTT/) BUTTNER K.

PA (CORN/) CORNUT I.

PA (METZ/) METZ G.

XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G;

XX DR WPI; 1999-277034/23.

XX PT Peptide agonists of apolipoprotein A-I.

XX PS Example; Page 114; 254pp; English.

XX CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY18934 to
 CC AAY19187 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists

XX Sequence 22 AA;

AAV19075 Length: 22 May 22, 2007 14:41 Type: P Check: 8801 ..

1 PVLELFRELL NEGLEALKQK LK

!!AA SEQUENCE 1.0

ID AAY19213 standard; peptide; 22 AA.

XX AC AAY19213;

XX DT 14-JUL-1999 (first entry)

XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #26.

XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;

KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 XX septic shock.
 OS Synthetic.
 OS Homo sapiens.
 XX WO9916459-A1.
 PN 08-APR-1999.
 XX
 XX
 XX 28-SEP-1998; 98WO-US020327.
 XX
 PR 29-SEP-1997; 97US-00940095.
 XX
 XX (DASSEUX J.
 PA (SEKUL R.
 PA (BUTTNER K.
 PA (CORNUT I.
 PA (METZ G.
 PA (DUFOURCQ J.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-277035/23.
 DR Peptide agonists of apolipoprotein A-I.
 XX
 XX Claim 19; Page 156; 280pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 XX
 XX AAY19213 Length: 22 May 22, 2007 14:41 Type: P Check: 9038 ..
 XX
 XX 1 PVLDFRELL NELLELLKQK LK
 !!AA SEQUENCE 1.0
 ID AAY19328 standard; peptide; 22 AA.
 XX
 AC AAY19328;
 XX
 DT 14-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #141.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916459-A1.
 XX
 XX 08-APR-1999.
 XX
 XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916459-A1.
 XX
 XX 08-APR-1999.
 XX
 XX 28-SEP-1998; 98WO-US020327.
 XX

PR 29-SEP-1997; 97US-00940095.
 XX
 XX (DASSEUX J.
 PA (SEKUL R.
 PA (BUTTNER K.
 PA (CORNUT I.
 PA (METZ G.
 PA (DUFOURCQ J.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-277035/23.
 DR Peptide agonists of apolipoprotein A-I.
 XX
 XX Claim 19; Page 157; 280pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 XX
 XX AAY19328 Length: 22 May 22, 2007 14:41 Type: P Check: 8767 ..
 XX
 XX 1 PVLDFRELL NEGLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY19205 standard; peptide; 22 AA.
 XX
 AC AAY19205;
 XX
 DT 14-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #18.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916459-A1.
 XX
 XX 08-APR-1999.
 XX
 XX 28-SEP-1998; 98WO-US020327.
 XX
 PR 29-SEP-1997; 97US-00940095.
 XX
 XX (DASSEUX J.
 PA (SEKUL R.
 PA (BUTTNER K.
 PA (CORNUT I.
 PA (METZ G.
 PA (DUFOURCQ J.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-277035/23.
 DR

XX Peptide agonists of apolipoprotein A-I.
 XX Claim 19; Page 156; 280pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 15-29 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ
 AAY19205 Length: 22 May 22, 2007 14:41 Type: P Check: 8853 ..
 1 GVLDLFRELL NELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY19314 standard; peptide; 22 AA.
 XX
 AC AAY19314;
 XX
 DT 14-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #127.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916459-A1.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020327.
 XX
 PR 29-SEP-1997; 97US-00940095.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-277035/23.
 XX
 PR Peptide agonists of apolipoprotein A-I.
 XX
 PS Claim 19; Page 156; 280pp; English.
 XX
 XX The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 15-29 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for

CC treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ
 AAY19314 Length: 22 May 22, 2007 14:41 Type: P Check: 9038 ..
 1 PVLDLFRELL NELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY19194 standard; peptide; 22 AA.
 XX
 AC AAY19194;
 XX
 DT 14-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #7.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916459-A1.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020327.
 XX
 PR 29-SEP-1997; 97US-00940095.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-277035/23.
 XX
 PR Peptide agonists of apolipoprotein A-I.
 XX
 PS Claim 19; Page 156; 280pp; English.
 XX
 XX The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 15-29 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ
 AAY19194 Length: 22 May 22, 2007 14:41 Type: P Check: 8813 ..
 1 PVLDLFRELL NELLEALKQK LK


```

XX PR 29-SEP-1997; 97US-00940095.
XX PA (DASS/) DASSEUX J.
XX PA (SEKU/) SEKUL R.
XX PA (BUTT/) BUTTNER K.
XX PA (CORN/) CORNUT I.
XX PA (METZ/) METZ G.
XX PA (DUFO/) DUFOURCQ J.
XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
XX XX
XX DR WPI; 1999-277035/23.
XX PT Peptide agonists of apolipoprotein A-I.
XX PS Claim 19; Page 156; 280pp; English.
XX CC The present invention describes an agonist (A) of apolipoprotein A-I
XX CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
XX CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
XX CC complexes, are used to treat or prevent diseases associated with
XX CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
XX CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
XX CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
XX CC treating septic shock. When labeled, (A) can also be used diagnostically
XX CC to measure serum levels of HDL, in particular the HDL subpopulation that
XX CC is involved in retrograde cholesterol transport, also to image HDL at
XX CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
XX CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
XX CC exhibiting core peptides, which are apoA-I agonists
XX SQ Sequence 22 AA;

AAY19211 Length: 22 May 22, 2007 14:41 Type: P Check: 8856
1 PVLDFRELL NELLEALQKK LK

!!AA SEQUENCE 1.0
ID AAY19267 standard; peptide; 22 AA.
AC AAY19267;
XX
XX DT 14-JUL-1999 (first entry)
XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #80.
XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
XX KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
XX KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
XX KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
XX KW septic shock.
XX OS Synthetic.
XX OS Homo sapiens.
XX PN WO9916459-A1.
XX PD 08-APR-1999.
XX PF 28-SEP-1998; 98WO-US020327.
XX PR 29-SEP-1997; 97US-00940095.
XX PA (DASS/) DASSEUX J.
XX PA (SEKU/) SEKUL R.
XX PA (BUTT/) BUTTNER K.
XX PA (CORN/) CORNUT I.
XX PA (METZ/) METZ G.
XX PA (DUFO/) DUFOURCQ J.
XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
XX XX
XX DR WPI; 1999-277035/23.
XX PT Peptide agonists of apolipoprotein A-I.
XX PS Claim 19; Page 157; 280pp; English.
XX CC The present invention describes an agonist (A) of apolipoprotein A-I
XX CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
XX CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
XX CC complexes, are used to treat or prevent diseases associated with
XX CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
XX CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
XX CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
XX CC treating septic shock. When labeled, (A) can also be used diagnostically
XX CC to measure serum levels of HDL, in particular the HDL subpopulation that
XX CC is involved in retrograde cholesterol transport, also to image HDL at
XX CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
XX CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
XX CC exhibiting core peptides, which are apoA-I agonists
XX SQ Sequence 22 AA;

AAY19211 Length: 22 May 22, 2007 14:41 Type: P Check: 8856
1 PVLDFRELL NELLEALQKK LK

!!AA SEQUENCE 1.0
ID AAY19267 standard; peptide; 22 AA.
AC AAY19267;
XX
XX DT 14-JUL-1999 (first entry)
XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #80.
XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
XX KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
XX KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
XX KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
XX KW septic shock.
XX OS Synthetic.
XX OS Homo sapiens.
XX PN WO9916459-A1.
XX PD 08-APR-1999.
XX PF 28-SEP-1998; 98WO-US020327.
XX PR 29-SEP-1997; 97US-00940095.
XX PA (DASS/) DASSEUX J.
XX PA (SEKU/) SEKUL R.
XX PA (BUTT/) BUTTNER K.
XX PA (CORN/) CORNUT I.
XX PA (METZ/) METZ G.
XX PA (DUFO/) DUFOURCQ J.
XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
XX XX

```

```

DR WPI; 1999-277035/23.
XX
XX PT Peptide agonists of apolipoprotein A-I.
XX PS Example; Page 120; 280pp; English.
XX CC
XX CC The present invention describes an agonist (A) of apolipoprotein A-I
XX CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
XX CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
XX CC complexes, are used to treat or prevent diseases associated with
XX CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
XX CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
XX CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
XX CC treating septic shock. When labeled, (A) can also be used diagnostically
XX CC to measure serum levels of HDL, in particular the HDL subpopulation that
XX CC is involved in retrograde cholesterol transport, also to image HDL at
XX CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
XX CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
XX CC exhibiting core peptides, which are apoA-I agonists
XX SQ Sequence 22 AA;

AAY19267 Length: 22 May 22, 2007 14:41 Type: P Check: 8869
1 PVLDFRELL NELLEALQKK LK

!!AA SEQUENCE 1.0
ID AAY19323 standard; peptide; 22 AA.
XX
XX AC AAY19323;
XX
XX DT 14-JUL-1999 (first entry)
XX
XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #136.
XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
XX KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
XX KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
XX KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
XX KW septic shock.
XX OS Synthetic.
XX OS Homo sapiens.
XX PN WO9916459-A1.
XX PD 08-APR-1999.
XX PF 28-SEP-1998; 98WO-US020327.
XX PR 29-SEP-1997; 97US-00940095.
XX PA (DASS/) DASSEUX J.
XX PA (SEKU/) SEKUL R.
XX PA (BUTT/) BUTTNER K.
XX PA (CORN/) CORNUT I.
XX PA (METZ/) METZ G.
XX PA (DUFO/) DUFOURCQ J.
XX
XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
XX XX
XX DR WPI; 1999-277035/23.
XX PT Peptide agonists of apolipoprotein A-I.
XX PS Claim 19; Page 157; 280pp; English.
XX CC The present invention describes an agonist (A) of apolipoprotein A-I
XX CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
XX CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
XX CC complexes, are used to treat or prevent diseases associated with
XX CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
XX CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I

```

CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ
 AAY19323 Length: 22 May 22, 2007 14:41 Type: P Check: 8800 ..
 1 PALELPKOLL QELLEALKQK LK
 !!IAA SEQUENCE 1.0
 ID AAY19330 standard; peptide; 22 AA.
 XX AC AAY19330;
 XX DT 14-JUL-1999 (first entry)
 XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #143.
 XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX OS Synthetic.
 XX OS Homo sapiens.
 XX PN W09916459-A1.
 XX PD 08-APR-1999.
 XX PF 28-SEP-1998; 98WO-US020327.
 XX PR 29-SEP-1997; 97US-00940095.
 XX PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 WPI; 1999-277035/23.
 XX PT Peptide agonists of apolipoprotein A-I.
 XX PS Example; Page 123; 280pp; English.
 XX CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ
 AAY19330 Length: 22 May 22, 2007 14:41 Type: P Check: 8797 ..
 1 PALELPKOLL QELLEALKQK LK
 !!IAA SEQUENCE 1.0
 ID AAY19330 standard; peptide; 22 AA.
 XX AC AAY19330;
 XX DT 14-JUL-1999 (first entry)
 XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #143.
 XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX OS Synthetic.
 XX OS Homo sapiens.
 XX PN W09916459-A1.
 XX PD 08-APR-1999.
 XX PF 28-SEP-1998; 98WO-US020327.
 XX PR 29-SEP-1997; 97US-00940095.
 XX PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 WPI; 1999-277035/23.
 XX PT Peptide agonists of apolipoprotein A-I.
 XX PS Example; Page 123; 280pp; English.
 XX CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ

1 PVLDLFRELL NEGLEALKQK LK
 !!IAA SEQUENCE 1.0
 ID AAY19200 standard; peptide; 22 AA.
 XX AC AAY19200;
 XX DT 14-JUL-1999 (first entry)
 XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #13.
 XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX OS Synthetic.
 XX OS Homo sapiens.
 XX PN W09916459-A1.
 XX PD 08-APR-1999.
 XX PF 28-SEP-1998; 98WO-US020327.
 XX PR 29-SEP-1997; 97US-00940095.
 XX PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 WPI; 1999-277035/23.
 XX PT Peptide agonists of apolipoprotein A-I.
 XX PS Claim 19; Page 156; 280pp; English.
 XX CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ
 AAY19200 Length: 22 May 22, 2007 14:41 Type: P Check: 8788 ..
 1 GVLDLFRELL NEGLEALKQK LK
 !!IAA SEQUENCE 1.0
 ID AAY19204 standard; peptide; 22 AA.
 XX AC AAY19204;
 XX DT 14-JUL-1999 (first entry)
 XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #17.
 XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;

XX WPI; 1999-277035/23.
 DR Peptide agonists of apolipoprotein A-I.
 PT
 XX
 XX Claim 19; Page 156; 280pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 15-29 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ
 AAY19210 Length: 22 May 22, 2007 14:41 Type: P Check: 8830 ..
 1 PLLELFKEILL QELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY19216 standard; peptide; 22 AA.
 XX
 AC AAY19216;
 XX
 DT 14-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #29.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916459-A1.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020327.
 XX
 PR 29-SEP-1997; 97US-00940095.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-277035/23.
 XX
 PT Peptide agonists of apolipoprotein A-I.
 XX
 PS Claim 19; Page 156; 280pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 15-29 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ

CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ
 AAY19216 Length: 22 May 22, 2007 14:41 Type: P Check: 8847 ..
 1 AVLDLFRELL NELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY19320 standard; peptide; 22 AA.
 XX
 AC AAY19320;
 XX
 DT 14-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #133.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916459-A1.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020327.
 XX
 PR 29-SEP-1997; 97US-00940095.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-277035/23.
 XX
 PT Peptide agonists of apolipoprotein A-I.
 XX
 PS Claim 19; Page 157; 280pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 15-29 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ
 AAY19320 Length: 22 May 22, 2007 14:41 Type: P Check: 8888 ..

```

1 PVLELPERLL EDLLQALNKK LK
!!AA SEQUENCE 1.0
ID AAY19321 standard; peptide; 22 AA.
XX
AC AAY19321;
XX
DT 14-JUL-1999 (first entry)
XX
DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #134.
XX
DE Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9916459-A1.
XX
PD 08-APR-1999.
XX
PF 28-SEP-1998; 98WO-US020327.
XX
PR 29-SEP-1997; 97US-00940095.
XX
PA (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
PA (DUFO/) DUFOURCQ J.
XX
PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
XX WPI; 1999-277035/23.
XX
PT Peptide agonists of apolipoprotein A-I.
XX
PS Claim 19; Page 157; 280pp; English.
XX
CC The present invention describes an agonist (A) of apolipoprotein A-I
CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
CC complexes, are used to treat or prevent diseases associated with
CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
CC treating septic shock. When labeled, (A) can also be used diagnostically
CC to measure serum levels of HDL, in particular the HDL subpopulation that
CC is involved in retrograde cholesterol transport, also to image HDL at
CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
CC exhibiting core peptides, which are apoA-I agonists
XX
SQ Sequence 22 AA;
XX
AAY19325 Length: 22 May 22, 2007 14:41 Type: P Check: 9149 ..
1 PVLDLPERLL NEGLEWLKQK LK
!!AA SEQUENCE 1.0
ID AAY19223 standard; peptide; 22 AA.
XX
AC AAY19223;
XX
DT 14-JUL-1999 (first entry)
XX
DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #36.
XX
KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9916459-A1.
XX
PD 08-APR-1999.
XX
DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #138.
XX

```


XX 28-SEP-1998; 98WO-US020327.
 XX 29-SEP-1997; 97US-00940095.
 XX (DASS//) DASSEUX J.
 XX (SEKU//) SEKUL R.
 XX (BUTT//) BUTTNER K.
 XX (CORN//) CORNUT I.
 XX (METZ//) METZ G.
 XX (DUFO//) DUFOURCQ J.
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-277035/23.
 XX Peptide agonists of apolipoprotein A-I.
 XX Example; Page 117; 280pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 XX AAY19223 Length: 22 May 22, 2007 14:41 Type: P Check: 8866 ..
 1 PLELLKELL QELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY19202 standard; peptide; 22 AA.
 XX AC AAY19202;
 XX 14-JUL-1999 (first entry)
 XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #15.
 DE Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 DE lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 DE cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 DE high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 DE septic shock.
 XX Synthetic.
 OS Homo sapiens.
 XX WO9916459-Al.
 XX 08-APR-1999.
 XX 28-SEP-1998; 98WO-US020327.
 XX 29-SEP-1997; 97US-00940095.
 XX (DASS//) DASSEUX J.
 XX (SEKU//) SEKUL R.
 XX (BUTT//) BUTTNER K.
 XX (CORN//) CORNUT I.
 XX (METZ//) METZ G.
 XX (DUFO//) DUFOURCQ J.
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-277035/23.
 XX Peptide agonists of apolipoprotein A-I.
 XX Example; Page 117; 280pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 XX AAY19223 Length: 22 May 22, 2007 14:41 Type: P Check: 8866 ..
 1 PLELLKELL QELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY19202 standard; peptide; 22 AA.
 XX AC AAY19202;
 XX 14-JUL-1999 (first entry)
 XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #15.
 DE Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 DE lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 DE cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 DE high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 DE septic shock.
 XX Synthetic.
 OS Homo sapiens.
 XX WO9916459-Al.
 XX 08-APR-1999.
 XX 28-SEP-1998; 98WO-US020327.
 XX 29-SEP-1997; 97US-00940095.
 XX (DASS//) DASSEUX J.
 XX (SEKU//) SEKUL R.
 XX (BUTT//) BUTTNER K.
 XX (CORN//) CORNUT I.
 XX (METZ//) METZ G.
 XX (DUFO//) DUFOURCQ J.

PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-277035/23.
 XX Peptide agonists of apolipoprotein A-I.
 XX Claim 19; Page 156; 280pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 XX AAY19202 Length: 22 May 22, 2007 14:41 Type: P Check: 8972 ..
 1 PVLIDLFRELW NELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY19207 standard; peptide; 22 AA.
 XX AC AAY19207;
 XX 14-JUL-1999 (first entry)
 XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #20.
 DE Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 DE lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 DE cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 DE high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 DE septic shock.
 XX Synthetic.
 OS Homo sapiens.
 XX WO9916459-Al.
 XX 08-APR-1999.
 XX 28-SEP-1998; 98WO-US020327.
 XX 29-SEP-1997; 97US-00940095.
 XX (DASS//) DASSEUX J.
 XX (SEKU//) SEKUL R.
 XX (BUTT//) BUTTNER K.
 XX (CORN//) CORNUT I.
 XX (METZ//) METZ G.
 XX (DUFO//) DUFOURCQ J.
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-277035/23.
 XX Peptide agonists of apolipoprotein A-I.
 XX Claim 19; Page 156; 280pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with

CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ

AAY19207 Length: 22 May 22, 2007 14:41 Type: P Check: 8817 ..
 1 PVLDLFREGL NELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY19243 standard; peptide; 22 AA.
 XX AC AAY19243;
 XX XX
 DT 14-JUL-1999 (first entry)
 XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #56.
 XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX OS Synthetic.
 OS OS Homo sapiens.
 XX PN WO9916459-A1.
 XX PD 08-APR-1999.
 XX XX
 XX PF 28-SEP-1998; 98WO-US020327.
 XX PR 29-SEP-1997; 97US-00940095.
 XX XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-277035/23.
 XX DR
 XX PT Peptide agonists of apolipoprotein A-I.
 XX PS Example; Page 119; 280pp; English.
 XX CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ

AAY19243 Length: 22 May 22, 2007 14:41 Type: P Check: 8841 ..
 1 PVLDLFRELL NELLEALKQK KK
 !!AA SEQUENCE 1.0
 ID AAY19191 standard; peptide; 22 AA.
 XX AC AAY19191;
 XX XX
 DT 14-JUL-1999 (first entry)
 XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #4.
 XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX OS Synthetic.
 OS OS Homo sapiens.
 XX PN WO9916459-A1.
 XX PD 08-APR-1999.
 XX XX
 XX PF 28-SEP-1998; 98WO-US020327.
 XX PR 29-SEP-1997; 97US-00940095.
 XX XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-277035/23.
 XX DR
 XX PT Peptide agonists of apolipoprotein A-I.
 XX PS Claim 19; Page 155; 280pp; English.
 XX CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ

AAY19191 Length: 22 May 22, 2007 14:41 Type: P Check: 8862 ..
 1 PVLDLFRELL NELLEALKQK LX
 !!AA SEQUENCE 1.0
 ID AAY19198 standard; peptide; 22 AA.
 XX AC AAY19198;
 XX XX
 DT 14-JUL-1999 (first entry)
 XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #11.

XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX Synthetic.
 OS Homo sapiens.
 XX WO9916459-A1.
 PN 08-APR-1999.
 XX 28-SEP-1998; 98WO-US020327.
 PF 29-SEP-1997; 97US-00940095.
 XX (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 PI WPI; 1999-277035/23.
 XX Peptide agonists of apolipoprotein A-I.
 PT Example; Page 120; 280pp; English.
 PS The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ AAY19198 Length: 22 May 22, 2007 14:41 Type: P Check: 8846 ..
 1 FVLDLFKELL QELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY19274 standard; peptide; 22 AA.
 XX AAY19274;
 AC 14-JUL-1999 (first entry)
 DT Lecithin:cholesterol acyltransferase activation exhibiting peptide #87.
 XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX Synthetic.
 OS Homo sapiens.
 XX WO9916459-A1.
 PN 08-APR-1999.
 XX 28-SEP-1998; 98WO-US020327.
 PF 29-SEP-1997; 97US-00940095.
 XX (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.

PD 08-APR-1999.
 XX 28-SEP-1998; 98WO-US020327.
 PF 29-SEP-1997; 97US-00940095.
 XX (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 PI WPI; 1999-277035/23.
 XX Peptide agonists of apolipoprotein A-I.
 PT Example; Page 120; 280pp; English.
 PS The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ AAY19274 Length: 22 May 22, 2007 14:41 Type: P Check: 8866 ..
 1 PULLELKELL QELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY19313 standard; peptide; 22 AA.
 XX AAY19313;
 AC 14-JUL-1999 (first entry)
 DT Lecithin:cholesterol acyltransferase activation exhibiting peptide #126.
 XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX Synthetic.
 OS Homo sapiens.
 XX WO9916459-A1.
 PN 08-APR-1999.
 XX 28-SEP-1998; 98WO-US020327.
 PF 29-SEP-1997; 97US-00940095.
 XX (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.

XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 PI WPI; 1999-277035/23.
 XX Peptide agonists of apolipoprotein A-I.
 PT Claim 19; Page 156; 280pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ

AAY19133 Length: 22 May 22, 2007 14:41 Type: P Check: 8792 ..
 1 PVLDLFPRELL NELGEALKQK LK

!1AA_SEQUENCE 1.0
 ID AAY191318 standard; peptide; 22 AA.
 AC AAY191318;
 XX
 DT 14-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #131.

XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916459-A1.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020327.
 XX
 PR 29-SEP-1997; 97US-00940095.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-277035/23.
 XX Peptide agonists of apolipoprotein A-I.
 XX Claim 19; Page 156; 280pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid

CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ

AAY191318 Length: 22 May 22, 2007 14:41 Type: P Check: 8928 ..
 1 PVLELFPRELL NELLDALRQK LK

!1AA_SEQUENCE 1.0
 ID AAY19189 standard; peptide; 23 AA.
 AC AAY19189;
 XX
 DT 14-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #2.

XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916459-A1.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020327.
 XX
 PR 29-SEP-1997; 97US-00940095.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-277035/23.
 XX Peptide agonists of apolipoprotein A-I.
 XX Claim 19; Page 155; 280pp; English.
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 23 AA;
 SQ

AAV19189 Length: 23 May 22, 2007 14:41 Type: P Check: 578 ..

1 GVLDLFRELL NELLEALKQK LKK

!!AA_SEQUENCE 1.0
ID AAY19227 standard; peptide; 22 AA.

XX AAY19227;

XX AC AAY19227;

XX DT 14-JUL-1999 (first entry)

XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #40.

XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.

XX OS Synthetic.

XX OS Homo sapiens.

XX XX WO9916459-A1.

XX PN 08-APR-1999.

XX PD 28-SEP-1998; 98WO-US020327.

XX PF 29-SEP-1997; 97US-00940095.

XX PR (DASS/) DASSEUX J.

XX PA (SEKU/) SEKUL R.

XX PA (BUTT/) BUTTNER K.

XX PA (CORN/) CORNUT I.

XX PA (METZ/) METZ G.

XX PA (DUFO/) DUFOURCQ J.

XX XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;

XX XX WPI; 1999-277035/23.

XX DR Peptide agonists of apolipoprotein A-I.

XX PT Example; Page 117; 280pp; English.

XX PS The present invention describes an agonist (A) of apolipoprotein A-I

XX CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an

XX CC amphipathic alpha-helix in presence of lipids. (A), and their lipid

XX CC complexes, are used to treat or prevent diseases associated with

XX CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,

XX CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I

XX CC deficiency; hypertriglyceridemia and metabolic syndrome, also for

XX CC treating septic shock. When labeled, (A) can also be used diagnostically

XX CC to measure serum levels of HDL, in particular the HDL subpopulation that

XX CC is involved in retrograde cholesterol transport, also to image HDL at

XX CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to

XX CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity

XX CC exhibiting core peptides, which are apoA-I agonists

XX XX Sequence 22 AA;

XX SQ AAY19227 Length: 22 May 22, 2007 14:41 Type: P Check: 8872 ..

XX 1 PVLDFRELL NELLEALKQK LK

XX !!AA_SEQUENCE 1.0

XX ID AAY19217 standard; peptide; 22 AA.

XX XX AAY19217;

XX XX 14-JUL-1999 (first entry)

XX DT Lecithin:cholesterol acyltransferase activation exhibiting peptide #39.

XX DE Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;

XX KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;

XX KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;

XX KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;

XX KW septic shock.

XX XX Synthetic.

XX OS Homo sapiens.

XX XX WO9916459-A1.

XX PN 08-APR-1999.

XX PD 28-SEP-1998; 98WO-US020327.

XX PF 29-SEP-1997; 97US-00940095.

XX PR (DASS/) DASSEUX J.

XX PA (SEKU/) SEKUL R.

XX PA (BUTT/) BUTTNER K.

XX PA (CORN/) CORNUT I.

XX PA (METZ/) METZ G.

XX PA (DUFO/) DUFOURCQ J.

XX XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;

XX XX WPI; 1999-277035/23.

XX DR Peptide agonists of apolipoprotein A-I.

XX PT Example; Page 117; 280pp; English.

XX PS The present invention describes an agonist (A) of apolipoprotein A-I

XX CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an

XX CC amphipathic alpha-helix in presence of lipids. (A), and their lipid

XX CC complexes, are used to treat or prevent diseases associated with

XX CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,

XX CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I

XX CC deficiency; hypertriglyceridemia and metabolic syndrome, also for

XX CC treating septic shock. When labeled, (A) can also be used diagnostically

XX CC to measure serum levels of HDL, in particular the HDL subpopulation that

XX CC is involved in retrograde cholesterol transport, also to image HDL at

XX CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to

XX CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity

XX CC exhibiting core peptides, which are apoA-I agonists

XX XX Sequence 22 AA;

XX SQ AAY19217 Length: 22 May 22, 2007 14:41 Type: P Check: 8862 ..

XX 1 PVLDFRELL NELLEALKQK LK

XX !!AA_SEQUENCE 1.0

XX ID AAY19226 standard; peptide; 22 AA.

XX XX AAY19226;

XX XX 14-JUL-1999 (first entry)

XX DT Lecithin:cholesterol acyltransferase activation exhibiting peptide #39.

XX DE Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;

XX KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;

XX KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;

XX KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;

XX KW septic shock.

XX XX Synthetic.

XX OS Homo sapiens.

XX XX WO9916459-A1.

XX PN 08-APR-1999.

XX PD 28-SEP-1998; 98WO-US020327.

XX PF 29-SEP-1997; 97US-00940095.

XX PR (DASS/) DASSEUX J.

XX PA (SEKU/) SEKUL R.

XX PA (BUTT/) BUTTNER K.

XX PA (CORN/) CORNUT I.

XX PA (METZ/) METZ G.

XX PA (DUFO/) DUFOURCQ J.

XX XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;

XX XX WPI; 1999-277035/23.

XX DR Peptide agonists of apolipoprotein A-I.

XX PT Example; Page 117; 280pp; English.

XX PS The present invention describes an agonist (A) of apolipoprotein A-I

XX CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an

XX CC amphipathic alpha-helix in presence of lipids. (A), and their lipid

XX CC complexes, are used to treat or prevent diseases associated with

XX CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,

XX CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I

XX CC deficiency; hypertriglyceridemia and metabolic syndrome, also for

XX CC treating septic shock. When labeled, (A) can also be used diagnostically

XX CC to measure serum levels of HDL, in particular the HDL subpopulation that

XX CC is involved in retrograde cholesterol transport, also to image HDL at

XX CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to

XX CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity

XX CC exhibiting core peptides, which are apoA-I agonists

XX XX Sequence 22 AA;

XX SQ AAY19217 Length: 22 May 22, 2007 14:41 Type: P Check: 8862 ..

XX 1 PVLDFRELL NELLEALKQK LK

XX !!AA_SEQUENCE 1.0

XX ID AAY19226 standard; peptide; 22 AA.

XX XX AAY19226;

XX XX 14-JUL-1999 (first entry)

XX DT Lecithin:cholesterol acyltransferase activation exhibiting peptide #39.

XX DE Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;

XX KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;

XX KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;

XX KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;

XX KW septic shock.

XX XX Synthetic.

XX OS Homo sapiens.

XX XX WO9916459-A1.

XX PN 08-APR-1999.

XX PD 28-SEP-1998; 98WO-US020327.

XX PF 29-SEP-1997; 97US-00940095.

XX PR (DASS/) DASSEUX J.

XX PA (SEKU/) SEKUL R.

XX PA (BUTT/) BUTTNER K.

XX PA (CORN/) CORNUT I.

XX PA (METZ/) METZ G.

XX PA (DUFO/) DUFOURCQ J.

XX XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;

XX XX WPI; 1999-277035/23.

XX DR Peptide agonists of apolipoprotein A-I.

XX PT Example; Page 117; 280pp; English.

XX PS The present invention describes an agonist (A) of apolipoprotein A-I

XX CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an

XX CC amphipathic alpha-helix in presence of lipids. (A), and their lipid

XX CC complexes, are used to treat or prevent diseases associated with

XX CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,

XX CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I

XX CC deficiency; hypertriglyceridemia and metabolic syndrome, also for

XX CC treating septic shock. When labeled, (A) can also be used diagnostically

XX CC to measure serum levels of HDL, in particular the HDL subpopulation that

XX CC is involved in retrograde cholesterol transport, also to image HDL at

XX CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to

XX CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity

XX CC exhibiting core peptides, which are apoA-I agonists

XX XX Sequence 22 AA;

XX SQ AAY19217 Length: 22 May 22, 2007 14:41 Type: P Check: 8862 ..

XX 1 PVLDFRELL NELLEALKQK LK

XX !!AA_SEQUENCE 1.0

XX ID AAY19226 standard; peptide; 22 AA.

XX XX AAY19226;

XX XX 14-JUL-1999 (first entry)

XX DT Lecithin:cholesterol acyltransferase activation exhibiting peptide #39.

XX DE Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;

XX KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;

XX KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;

XX KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;

XX KW septic shock.

XX XX Synthetic.

XX OS Homo sapiens.

XX XX WO9916459-A1.

XX PN 08-APR-1999.

XX PD 28-SEP-1998; 98WO-US020327.

XX PF 29-SEP-1997; 97US-00940095.

XX PR (DASS/) DASSEUX J.

XX PA (SEKU/) SEKUL R.

XX PA (BUTT/) BUTTNER K.

XX PA (CORN/) CORNUT I.

XX PA (METZ/) METZ G.

XX PA (DUFO/) DUFOURCQ J.

XX XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;

XX XX WPI; 1999-277035/23.

XX DR Peptide agonists of apolipoprotein A-I.

XX PT Example; Page 117; 280pp; English.

XX PS The present invention describes an agonist (A) of apolipoprotein A-I

XX CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an

XX CC amphipathic alpha-helix in presence of lipids. (A), and their lipid

XX CC complexes, are used to treat or prevent diseases associated with

XX CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,

XX CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I

XX CC deficiency; hypertriglyceridemia and metabolic syndrome, also for

XX CC treating septic shock. When labeled, (A) can also be used diagnostically

XX CC to measure serum levels of HDL, in particular the HDL subpopulation that

XX CC is involved in retrograde cholesterol transport, also to image HDL at

XX CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to

XX CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity

XX CC exhibiting core peptides, which are apoA-I agonists

XX XX Sequence 22 AA;

XX SQ AAY19217 Length: 22 May 22, 2007 14:41 Type: P Check: 8862 ..

XX 1 PVLDFRELL NELLEALKQK LK

XX !!AA_SEQUENCE 1.0

XX ID AAY19226 standard; peptide; 22 AA.

XX XX AAY19226;

XX XX 14-JUL-1999 (first entry)

XX DT Lecithin:cholesterol acyltransferase activation exhibiting peptide #39.

XX DE Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;

XX KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;

XX KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;

XX KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;

XX KW septic shock.

XX XX Synthetic.

XX OS Homo sapiens.

XX XX WO9916459-A1.

XX PN 08-APR-1999.

XX PD 28-SEP-1998; 98WO-US020327.

XX PF 29-SEP-1997; 97US-00940095.

XX PR (DASS/) DASSEUX J.

XX PD 08-APR-1999.
 XX PF 28-SEP-1998; 98WO-US020327.
 XX PR 29-SEP-1997; 97US-00940095.
 XX PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX (DUFO/) DUFOURCQ J.
 XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX DR WPI; 1999-277035/23.
 XX PT Peptide agonists of apolipoprotein A-I.
 XX PS Example; Page 118; 280pp; English.
 XX CC The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 15-29 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 XX SQ
 AAY19226 Length: 22 May 22, 2007 14:41 Type: P Check: 8739 ..
 1 PVLDLFPRELL BELLKALKKK LK
 !!AA SEQUENCE 1.0
 ID AAY19273 standard; peptide; 22 AA.
 XX AC AAY19273;
 XX DT 14-JUL-1999 (first entry)
 XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #86.
 XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX OS Synthetic.
 OS Homo sapiens.
 XX PN WO9916459-A1.
 XX PD 08-APR-1999.
 XX PF 28-SEP-1998; 98WO-US020327.
 XX PR 29-SEP-1997; 97US-00940095.
 XX PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX (DUFO/) DUFOURCQ J.
 XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX DR WPI; 1999-277035/23.
 XX PT Peptide agonists of apolipoprotein A-I.
 XX PS Claim 19; Page 155; 280pp; English.
 XX CC The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 15-29 residue peptide, or analog, that forms an

PA (DUFO/) DUFOURCQ J.
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX DR WPI; 1999-277035/23.
 XX PT Peptide agonists of apolipoprotein A-I.
 XX PS Example; Page 120; 280pp; English.
 XX CC The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 15-29 residue peptide, or analog, that forms an amphipathic alpha-helix in presence of lipids. (A), and their lipid complexes, are used to treat or prevent diseases associated with dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease, atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I deficiency; hypertriglyceridemia and metabolic syndrome, also for treating septic shock. When labeled, (A) can also be used diagnostically to measure serum levels of HDL, in particular the HDL subpopulation that is involved in retrograde cholesterol transport, also to image HDL at e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 XX SQ
 AAY19273 Length: 22 May 22, 2007 14:41 Type: P Check: 8898 ..
 1 PVLELPERLL DELLNALQKK LK
 !!AA SEQUENCE 1.0
 ID AAY19190 standard; peptide; 22 AA.
 XX AC AAY19190;
 XX DT 14-JUL-1999 (first entry)
 XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #3.
 XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX OS Synthetic.
 OS Homo sapiens.
 XX PN WO9916459-A1.
 XX PD 08-APR-1999.
 XX PF 28-SEP-1998; 98WO-US020327.
 XX PR 29-SEP-1997; 97US-00940095.
 XX PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 XX (DUFO/) DUFOURCQ J.
 XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX DR WPI; 1999-277035/23.
 XX PT Peptide agonists of apolipoprotein A-I.
 XX PS Claim 19; Page 155; 280pp; English.
 XX CC The present invention describes an agonist (A) of apolipoprotein A-I (apoA-I) which is a 15-29 residue peptide, or analog, that forms an

CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 SQ
 AAY19190 Length: 22 May 22, 2007 14:41 Type: P Check: 9214 ..
 1 PVLDLFPRELL NELLEWLKQK LK
 !!AA_SEQUENCE 1.0
 ID AAY19285 standard; peptide; 22 AA.
 XX AAY19285;
 AC AAY19285;
 XX
 DT 14-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #98.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916459-A1.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020327.
 XX
 PR 29-SEP-1997; 97US-00940095.
 XX
 PA (DASS//) DASSEUX J.
 PA (SEKU//) SEKUL R.
 PA (BUTT//) BUTTNER K.
 PA (CORN//) CORNUT I.
 PA (METZ//) METZ G.
 PA (DUFO//) DUFOURCQ J.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX
 XX WPI; 1999-277035/23.
 PF
 XX
 PR
 XX
 XX
 XX (DASS//) DASSEUX J.
 PA (SEKU//) SEKUL R.
 PA (BUTT//) BUTTNER K.
 PA (CORN//) CORNUT I.
 PA (METZ//) METZ G.
 PA (DUFO//) DUFOURCQ J.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX
 XX WPI; 1999-277035/23.
 DR
 XX
 PT Peptide agonists of apolipoprotein A-I.
 XX
 PS Example; Page 121; 280pp; English.
 XX
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX

SQ Sequence 22 AA;
 AAY19285 Length: 22 May 22, 2007 14:41 Type: P Check: 8771 ..
 1 PVLDLFPRELL NEELEALKQK LK
 !!AA_SEQUENCE 1.0
 ID AAY19310 standard; peptide; 22 AA.
 XX AAY19310;
 AC AAY19310;
 XX
 DT 14-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #123.
 XX
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916459-A1.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020327.
 XX
 PR 29-SEP-1997; 97US-00940095.
 XX
 PA (DASS//) DASSEUX J.
 PA (SEKU//) SEKUL R.
 PA (BUTT//) BUTTNER K.
 PA (CORN//) CORNUT I.
 PA (METZ//) METZ G.
 PA (DUFO//) DUFOURCQ J.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX
 XX WPI; 1999-277035/23.
 DR
 XX
 PT Peptide agonists of apolipoprotein A-I.
 XX
 PS Claim 19; Page 156; 280pp; English.
 XX
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX
 XX Sequence 22 AA;
 AAY19310 Length: 22 May 22, 2007 14:41 Type: P Check: 8863 ..
 1 QVLDLFPRELL NELLEALKQK LK
 !!AA_SEQUENCE 1.0
 ID AAY19329 standard; peptide; 22 AA.
 XX AAY19329;
 AC AAY19329;
 XX
 DT 14-JUL-1999 (first entry)
 XX

XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #142.
 XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW KW septic shock.
 XX OS Synthetic.
 OS OS Homo sapiens.
 XX OS (SEKU//) SEKUL R.
 XX PN (BUTT//) BUTTNER K.
 XX PN (CORN//) CORNUT I.
 XX PN (METZ//) METZ G.
 XX PN (DUFO//) DUFOURCQ J.
 XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX DR WPI; 1999-277035/23.
 XX PT Peptide agonists of apolipoprotein A-I.
 XX PS Claim 19; Page 157; 280pp; English.
 XX CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX SQ Sequence 22 AA;
 AAY19329 Length: 22 May 22, 2007 14:41 Type: P Check: 8801 ..
 1 PVLELFRELL NEGLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY19316 standard; peptide; 22 AA.
 AC AAY19316;
 XX 14-JUL-1999 (first entry)
 DT DT
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #129.
 XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW KW septic shock.
 XX OS Synthetic.
 OS OS Homo sapiens.
 XX PN (SEKU//) SEKUL R.
 XX PN (BUTT//) BUTTNER K.
 XX PN (CORN//) CORNUT I.

PN WO9916459-A1.
 XX 08-APR-1999.
 XX 28-SEP-1998; 98WO-US020327.
 XX 29-SEP-1997; 97US-00940095.
 XX (DASS//) DASSEUX J.
 PA (SEKU//) SEKUL R.
 PA (BUTT//) BUTTNER K.
 PA (CORN//) CORNUT I.
 PA (METZ//) METZ G.
 PA (DUFO//) DUFOURCQ J.
 XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX DR WPI; 1999-277035/23.
 XX PT Peptide agonists of apolipoprotein A-I.
 XX PS Claim 19; Page 156; 280pp; English.
 XX CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX SQ Sequence 22 AA;
 AAY19316 Length: 22 May 22, 2007 14:41 Type: P Check: 8868 ..
 1 PVLELFNDLL RELLEALQKK LK
 !!AA SEQUENCE 1.0
 ID AAY19319 standard; peptide; 22 AA.
 AC AAY19319;
 XX 14-JUL-1999 (first entry)
 DT DT
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #132.
 XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW KW septic shock.
 XX OS Synthetic.
 OS OS Homo sapiens.
 XX PN (SEKU//) SEKUL R.
 XX PN (BUTT//) BUTTNER K.
 XX PN (CORN//) CORNUT I.
 XX 08-APR-1999.
 XX 28-SEP-1998; 98WO-US020327.
 XX 29-SEP-1997; 97US-00940095.
 XX (DASS//) DASSEUX J.
 PA (SEKU//) SEKUL R.
 PA (BUTT//) BUTTNER K.
 PA (CORN//) CORNUT I.

PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX
 XX
 XX WPI; 1999-277035/23.
 DR
 XX
 XX Peptide agonists of apolipoprotein A-I.
 PT
 XX
 XX Claim 19; Page 156; 280pp; English.
 PS
 XX
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 XX
 XX AAY19215 Length: 22 May 22, 2007 14:41 Type: P Check: 8865 ..
 SQ
 1 PVLDFRELL ENLEALQKK LK
 !!AA SEQUENCE 1.0
 ID _AAY19215 standard; peptide; 22 AA.
 XX
 AC AAY19215;
 XX
 XX 14-JUL-1999 (first entry)
 DT
 XX
 XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #28.
 DE
 XX
 XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 XX Synthetic.
 OS
 OS Homo sapiens.
 OS
 XX WO9916459-A1.
 PN
 XX
 XX 08-APR-1999.
 PD
 XX
 XX 28-SEP-1998; 98WO-US020327.
 PF
 XX
 XX 29-SEP-1997; 97US-00940095.
 PR
 XX
 XX (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 PI WPI; 1999-277035/23.
 XX
 XX Peptide agonists of apolipoprotein A-I.
 PT
 XX
 XX Claim 19; Page 156; 280pp; English.
 PS
 XX
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 XX Sequence 22 AA;
 XX
 XX AAY19319 Length: 22 May 22, 2007 14:41 Type: P Check: 8865 ..
 SQ
 1 PVLDFRELL NELWEALQKK LK
 !!AA SEQUENCE 1.0
 ID _AAY19317 standard; peptide; 22 AA.
 XX
 AC AAY19317;
 XX
 XX 14-JUL-1999 (first entry)
 DT
 XX
 XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #130.
 DE
 XX
 XX Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 XX Synthetic.
 OS
 OS Homo sapiens.
 OS
 XX WO9916459-A1.
 PN
 XX
 XX 08-APR-1999.
 PD
 XX
 XX 28-SEP-1998; 98WO-US020327.
 PF
 XX
 XX 29-SEP-1997; 97US-00940095.
 PR
 XX
 XX (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 PI WPI; 1999-277035/23.
 XX
 XX Peptide agonists of apolipoprotein A-I.
 PT
 XX
 XX Claim 19; Page 156; 280pp; English.
 PS
 XX
 XX The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists

```

XX SQ Sequence 22 AA;
AAV19317 Length: 22 May 22, 2007 14:41 Type: P Check: 8874 ..
1 PVLELFNDLL RELLEALKQK LK
!!AA SEQUENCE 1.0
ID AAY19326 standard; peptide; 22 AA.
XX AC AAY19326;
XX DT 14-JUL-1999 (first entry)
XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #139.
XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX OS Synthetic.
XX OS Homo sapiens.
XX PN WO9916459-A1.
XX PD 08-APR-1999.
XX PF 28-SEP-1998; 98WO-US020327.
XX PR 29-SEP-1997; 97US-00940095.
XX PA (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
PA (DUFO/) DUFOURCQ J.
XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
XX WPI; 1999-277035/23.
XX PT Peptide agonists of apolipoprotein A-I.
XX PS Claim 19; Page 156; 280pp; English.
XX CC The present invention describes an agonist (A) of apolipoprotein A-I
CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
CC complexes, are used to treat or prevent diseases associated with
CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
CC treating septic shock. When labeled, (A) can also be used diagnostically
CC to measure serum levels of HDL, in particular the HDL subpopulation that
CC is involved in retrograde cholesterol transport, also to image HDL at
CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
CC exhibiting core peptides, which are apoA-I agonists
XX SQ Sequence 22 AA;
AAV19195 Length: 22 May 22, 2007 14:41 Type: P Check: 8797 ..
1 PVLDLFRELL NEGLEALKQK LK
!!AA SEQUENCE 1.0
ID AAY19196 standard; peptide; 22 AA.
XX AC AAY19196;
XX DT 14-JUL-1999 (first entry)
XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #9.
XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
KW septic shock.
XX OS Synthetic.
XX OS Homo sapiens.

```

XX WO9916459-A1.
 XX PA (METZ/) METZ G.
 XX PA (DUFO/) DUFOURCQ J.
 XX
 XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX XX WPI; 1999-277035/23.
 XX DR Peptide agonists of apolipoprotein A-I.
 XX PT Claim 19; Page 156; 280pp; English.
 XX PS The present invention describes an agonist (A) of apolipoprotein A-I
 XX CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 XX CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 XX CC complexes, are used to treat or prevent diseases associated with
 XX CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 XX CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 XX CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 XX CC treating septic shock. When labeled, (A) can also be used diagnostically
 XX CC to measure serum levels of HDL, in particular the HDL subpopulation that
 XX CC is involved in retrograde cholesterol transport, also to image HDL at
 XX CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 XX CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 XX CC exhibiting core peptides, which are apoA-I agonists
 XX SQ Sequence 22 AA;
 AAY19196 Length: 22 May 22, 2007 14:41 Type: P Check: 8812 ..
 1 PVLDLFLREL NELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY19203 standard; peptide; 22 AA.
 XX AC AAY19203;
 XX DT 14-JUL-1999 (first entry)
 XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #16.
 XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 XX KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 XX KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 XX KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 XX KW septic shock.
 XX OS Synthetic.
 XX OS Homo sapiens.
 XX PN WO9916459-A1.
 XX PD 08-APR-1999.
 XX PF 28-SEP-1998; 98WO-US020327.
 XX PR 29-SEP-1997; 97US-00940095.
 XX PS (DASS/) DASSEUX J.
 XX PA (SEKU/) SEKUL R.
 XX PA (BUTT/) BUTTNER K.
 XX PA (CORN/) CORNUT I.
 XX PA (METZ/) METZ G.
 XX PA (DUFO/) DUFOURCQ J.
 XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX XX WPI; 1999-277035/23.
 XX DR Peptide agonists of apolipoprotein A-I.
 XX PT Claim 19; Page 156; 280pp; English.
 XX PS The present invention describes an agonist (A) of apolipoprotein A-I
 XX CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 XX CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 XX CC complexes, are used to treat or prevent diseases associated with
 XX CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 XX CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 XX CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 XX CC treating septic shock. When labeled, (A) can also be used diagnostically
 XX CC to measure serum levels of HDL, in particular the HDL subpopulation that
 XX CC is involved in retrograde cholesterol transport, also to image HDL at
 XX CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 XX CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 XX CC exhibiting core peptides, which are apoA-I agonists
 XX SQ Sequence 22 AA;
 AAY19196 Length: 22 May 22, 2007 14:41 Type: P Check: 8812 ..
 1 PVLDLFLREL NELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY19203 standard; peptide; 22 AA.
 XX AC AAY19203;
 XX DT 14-JUL-1999 (first entry)
 XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #16.
 XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 XX KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 XX KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 XX KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 XX KW septic shock.
 XX OS Synthetic.
 XX OS Homo sapiens.
 XX PN WO9916459-A1.
 XX PD 08-APR-1999.
 XX PF 28-SEP-1998; 98WO-US020327.
 XX PR 29-SEP-1997; 97US-00940095.
 XX PS (DASS/) DASSEUX J.
 XX PA (SEKU/) SEKUL R.
 XX PA (BUTT/) BUTTNER K.

PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX
 XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX XX WPI; 1999-277035/23.
 XX DR Peptide agonists of apolipoprotein A-I.
 XX PT Claim 19; Page 156; 280pp; English.
 XX PS The present invention describes an agonist (A) of apolipoprotein A-I
 XX CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 XX CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 XX CC complexes, are used to treat or prevent diseases associated with
 XX CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 XX CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 XX CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 XX CC treating septic shock. When labeled, (A) can also be used diagnostically
 XX CC to measure serum levels of HDL, in particular the HDL subpopulation that
 XX CC is involved in retrograde cholesterol transport, also to image HDL at
 XX CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 XX CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 XX CC exhibiting core peptides, which are apoA-I agonists
 XX SQ Sequence 22 AA;
 AAY19203 Length: 22 May 22, 2007 14:41 Type: P Check: 8898 ..
 1 PVLDLFLREL NELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY19287 standard; peptide; 22 AA.
 XX AC AAY19287;
 XX DT 14-JUL-1999 (first entry)
 XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #100.
 XX KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 XX KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 XX KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 XX KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 XX KW septic shock.
 XX OS Synthetic.
 XX OS Homo sapiens.
 XX PN WO9916459-A1.
 XX PD 08-APR-1999.
 XX PF 28-SEP-1998; 98WO-US020327.
 XX PR 29-SEP-1997; 97US-00940095.
 XX PS (DASS/) DASSEUX J.
 XX PA (SEKU/) SEKUL R.
 XX PA (BUTT/) BUTTNER K.
 XX PA (CORN/) CORNUT I.
 XX PA (METZ/) METZ G.
 XX PA (DUFO/) DUFOURCQ J.
 XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX XX WPI; 1999-277035/23.
 XX DR Peptide agonists of apolipoprotein A-I.
 XX PT Example; Page 121; 280pp; English.
 XX PS

CC The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 CC Sequence 22 AA;
 XX
 SQ AAY19287 Length: 22 May 22, 2007 14:41 Type: P Check: 8862 ...
 1 DVLDLFRELL NELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY19312 standard; peptide; 22 AA.
 XX
 AC AAY19312;
 XX
 DT 14-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #125.
 DE
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916459-A1.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020327.
 XX
 PR 29-SEP-1997; 97US-00940095.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 PI WPI; 1999-277035/23.
 DR
 DR Peptide agonists of apolipoprotein A-I.
 XX
 PT Claim 19; Page 156; 280pp; English.
 XX
 PS The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 CC Sequence 22 AA;
 XX
 SQ AAY19322 Length: 22 May 22, 2007 14:41 Type: P Check: 8850 ...
 1 DVLDLFRELL NELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY19429 standard; peptide; 22 AA.
 XX
 AC AAY19429;

CC exhibiting core peptides, which are apoA-I agonists
 XX
 SQ Sequence 22 AA;
 AAY19312 Length: 22 May 22, 2007 14:41 Type: P Check: 8860 ...
 1 NVLDLFRELL NELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY19322 standard; peptide; 22 AA.
 XX
 AC AAY19322;
 XX
 DT 14-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #135.
 DE
 KW Apolipoprotein A-I; agonist; dyslipidemic disorder; dyslipidemia; human;
 KW lecithin:cholesterol acyltransferase; LCAT; hypercholesterolaemia;
 KW cardiovascular disease; atherosclerosis; restenosis; HDL; apoA-I;
 KW high density lipoprotein; hypertriglyceridemia; metabolic syndrome;
 KW septic shock.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916459-A1.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020327.
 XX
 PR 29-SEP-1997; 97US-00940095.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 PI WPI; 1999-277035/23.
 DR
 DR Peptide agonists of apolipoprotein A-I.
 XX
 PT Claim 19; Page 157; 280pp; English.
 XX
 PS The present invention describes an agonist (A) of apolipoprotein A-I
 CC (apoA-I) which is a 15-29 residue peptide, or analog, that forms an
 CC amphipathic alpha-helix in presence of lipids. (A), and their lipid
 CC complexes, are used to treat or prevent diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) or apoA-I
 CC deficiency; hypertriglyceridemia and metabolic syndrome, also for
 CC treating septic shock. When labeled, (A) can also be used diagnostically
 CC to measure serum levels of HDL, in particular the HDL subpopulation that
 CC is involved in retrograde cholesterol transport, also to image HDL at
 CC e.g. atherosclerotic streaks, and to raise antibodies. AAY19188 to
 CC AAY19441 represent lecithin:cholesterol acyltransferase (LCAT) activity
 CC exhibiting core peptides, which are apoA-I agonists
 CC Sequence 22 AA;
 XX
 SQ Sequence 22 AA;
 AAY19322 Length: 22 May 22, 2007 14:41 Type: P Check: 8850 ...
 1 DVLDLFRELL NELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY19429 standard; peptide; 22 AA.
 XX
 AC AAY19429;

XX DT 09-JUL-1999 (first entry)
 XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #13.
 XX KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
 KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
 XX OS Synthetic.
 OS Homo sapiens.
 FN WO9916409-A2.
 XX PD 08-APR-1999.
 XX PF 28-SEP-1998; 98WO-US020329.
 XX PR 29-SEP-1997; 97US-00940136.
 XX PA (DASS//) DASSEUX J.
 PA (SEKU//) SEKUL R.
 PA (BUTT//) BUTTNER K.
 PA (CORN//) CORNUT I.
 PA (METZ//) METZ G.
 PA (DUFO//) DUFOURCQ J.
 XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-254921/21.
 XX PT Nucleic acid encoding apoproteinA-I agonist peptides.
 XX PS Claim 18; Page 130; 232pp; English.
 XX CC The present invention describes a nucleic acid (A) encoding an
 CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipids, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used to
 CC study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX SQ Sequence 22 AA;
 AAY18429 Length: 22 May 22, 2007 14:41 Type: P Check: 8788 ..
 1 GVLDLFRELL NEGLEALKQK LK
 !!AA_SEQUENCE 1.0
 ID _AAV18446 standard; peptide; 22 AA.
 AC AAY18446;
 XX DT 09-JUL-1999 (first entry)
 XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #30.
 XX KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
 KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
 XX OS Synthetic.
 OS Homo sapiens.
 FN WO9916409-A2.

XX PD 08-APR-1999.
 XX PF 28-SEP-1998; 98WO-US020329.
 XX PR 29-SEP-1997; 97US-00940136.
 XX PA (DASS//) DASSEUX J.
 PA (SEKU//) SEKUL R.
 PA (BUTT//) BUTTNER K.
 PA (CORN//) CORNUT I.
 PA (METZ//) METZ G.
 PA (DUFO//) DUFOURCQ J.
 XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-254921/21.
 XX PT Nucleic acid encoding apoproteinA-I agonist peptides.
 XX PS Example; Page 135; 232pp; English.
 XX CC The present invention describes a nucleic acid (A) encoding an
 CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipids, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used to
 CC study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX SQ Sequence 22 AA;
 AAY18446 Length: 22 May 22, 2007 14:41 Type: P Check: 8862 ..
 1 PVLDLFRELL NELLEALKQK LK
 !!AA_SEQUENCE 1.0
 ID _AAV18546 standard; peptide; 22 AA.
 AC AAY18546;
 XX DT 09-JUL-1999 (first entry)
 XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #130.
 XX KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
 KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
 XX OS Synthetic.
 OS Homo sapiens.
 FN WO9916409-A2.
 XX PD 08-APR-1999.
 XX PF 28-SEP-1998; 98WO-US020329.
 XX PR 29-SEP-1997; 97US-00940136.
 XX PA (DASS//) DASSEUX J.
 PA (SEKU//) SEKUL R.
 PA (BUTT//) BUTTNER K.
 PA (CORN//) CORNUT I.
 PA (METZ//) METZ G.
 PA (DUFO//) DUFOURCQ J.

XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-254921/21.
 XX Nucleic acid encoding apoproteinA-I agonist peptides.
 XX Claim 18; Page 166; 232pp; English.
 XX The present invention describes a nucleic acid (A) encoding an
 CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipids, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used to
 CC study the role of apoA-I in lipid metabolism. (B) can also be used to
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX Sequence 22 AA;
 SQ
 AAY18546 Length: 22 May 22, 2007 14:41 Type: P Check: 8874 ..
 1 PVLEFNDLL RELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID _AAY18545 standard; peptide; 22 AA.
 AC AAY18545;
 XX
 XX 09-JUL-1999 (first entry)
 DT
 XX
 XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #129.
 DE
 XX Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
 KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
 XX
 XX Synthetic.
 OS Homo sapiens.
 OS
 XX WO9916409-A2.
 PN
 XX 08-APR-1999.
 PD
 XX
 XX 28-SEP-1998; 98WO-US020329.
 PF
 XX 29-SEP-1997; 97US-00940136.
 PR
 XX (DASS//) DASSEUX J.
 PA (SEKU//) SEKUL R.
 PA (BUTT//) BUTTNER K.
 PA (CORN//) CORNUT I.
 PA (METZ//) METZ G.
 PA (DUFO//) DUFOURCQ J.
 XX
 XX 08-APR-1999.
 PD
 XX
 XX 28-SEP-1998; 98WO-US020329.
 PF
 XX 29-SEP-1997; 97US-00940136.
 PR
 XX (DASS//) DASSEUX J.
 PA (SEKU//) SEKUL R.
 PA (BUTT//) BUTTNER K.
 PA (CORN//) CORNUT I.
 PA (METZ//) METZ G.
 PA (DUFO//) DUFOURCQ J.
 XX
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-254921/21.
 XX Nucleic acid encoding apoproteinA-I agonist peptides.
 XX Claim 18; Page 165; 232pp; English.
 XX The present invention describes a nucleic acid (A) encoding an
 CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipids, and host cells that contain (A), are

CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used to
 CC study the role of apoA-I in lipid metabolism. (B) can be used to
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX Sequence 22 AA;
 SQ
 AAY18545 Length: 22 May 22, 2007 14:41 Type: P Check: 8868 ..
 1 PVLEFNDLL RELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID _AAY18436 standard; peptide; 22 AA.
 AC AAY18436;
 XX
 XX 09-JUL-1999 (first entry)
 DT
 XX
 XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #20.
 DE
 XX Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
 KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
 XX
 XX Synthetic.
 OS Homo sapiens.
 OS
 XX WO9916409-A2.
 PN
 XX 08-APR-1999.
 PD
 XX
 XX 28-SEP-1998; 98WO-US020329.
 PF
 XX 29-SEP-1997; 97US-00940136.
 PR
 XX (DASS//) DASSEUX J.
 PA (SEKU//) SEKUL R.
 PA (BUTT//) BUTTNER K.
 PA (CORN//) CORNUT I.
 PA (METZ//) METZ G.
 PA (DUFO//) DUFOURCQ J.
 XX
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-254921/21.
 XX Nucleic acid encoding apoproteinA-I agonist peptides.
 XX Claim 18; Page 132; 232pp; English.
 XX The present invention describes a nucleic acid (A) encoding an
 CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipids, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used to
 CC study the role of apoA-I in lipid metabolism. (B) can be used to
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX Sequence 22 AA;
 SQ


```

PR 29-SEP-1997; 97US-00940136.
XX (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
PA (DUFO/) DUFOURCQ J.
XX
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
XX WPI; 1999-254921/21.
XX
XX Nucleic acid encoding apoproteinA-I agonist peptides.
XX
XX Example; Page 169; 232pp; English.
XX
XX The present invention describes a nucleic acid (A) encoding an
XX apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
XX which forms an amphipathic alpha-helix in presence of lipids. (A),
XX optionally as a complex with lipids, and host cells that contain (A), are
XX useful for gene therapy, or prevention, of diseases associated with
XX dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
XX atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
XX deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
XX endotoxemia (septic shock). Host cells containing (A) can also be used to
XX study the role of apoA-I in lipid metabolism. (B) can be used
XX diagnostically, e.g. to measure serum HDL (particularly its subpopulation
XX involved in retrograde cholesterol transport) and for imaging the
XX circulatory system or HDL accumulations at fatty streaks. The present
XX sequence represents a peptide from the present invention
XX
XX Sequence 22 AA;
XX
AAV18559 Length: 22 May 22, 2007 14:41 Type: P Check: 8797
1 PVLDFRELL NEGLEALKQK LK
!!AA SEQUENCE 1.0
ID AAV18455 standard; peptide; 22 AA.
XX
XX AAY18455;
XX
XX 09-JUL-1999 (first entry)
XX
XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #39.
XX
XX Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
XX cardiovascular disease; atherosclerosis; restenosis; LCAT;
XX hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
XX
XX Synthetic.
XX Homo sapiens.
XX
XX WO9916409-A2.
XX
XX 08-APR-1999.
XX
XX 28-SEP-1998; 98WO-US020329.
XX
XX 29-SEP-1997; 97US-00940136.
XX
XX (DASS/) DASSEUX J.
XX (SEKU/) SEKUL R.
XX (BUTT/) BUTTNER K.
XX (CORN/) CORNUT I.
XX (METZ/) METZ G.
XX (DUFO/) DUFOURCQ J.
XX
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
XX WPI; 1999-254921/21.
XX
XX
XX Nucleic acid encoding apoproteinA-I agonist peptides.
XX
XX Example; Page 150; 232pp; English.
XX
XX The present invention describes a nucleic acid (A) encoding an
XX apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
XX which forms an amphipathic alpha-helix in presence of lipids. (A),
XX optionally as a complex with lipids, and host cells that contain (A), are
XX useful for gene therapy, or prevention, of diseases associated with
XX dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
XX atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
XX deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
XX endotoxemia (septic shock). Host cells containing (A) can also be used to
XX study the role of apoA-I in lipid metabolism. (B) can be used
XX diagnostically, e.g. to measure serum HDL (particularly its subpopulation
XX involved in retrograde cholesterol transport) and for imaging the
XX circulatory system or HDL accumulations at fatty streaks. The present
XX sequence represents a peptide from the present invention
XX
XX Sequence 22 AA;
XX
AAV18455 Length: 22 May 22, 2007 14:41 Type: P Check: 8739
1 PVLDFRELL EELLKALKKK LK
!!AA SEQUENCE 1.0
ID AAV18496 standard; peptide; 22 AA.
XX
XX AAY18496;
XX
XX 09-JUL-1999 (first entry)
XX
XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #80.
XX
XX Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
XX cardiovascular disease; atherosclerosis; restenosis; LCAT;
XX hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
XX
XX Synthetic.
XX Homo sapiens.
XX
XX WO9916409-A2.
XX
XX 08-APR-1999.
XX
XX 28-SEP-1998; 98WO-US020329.
XX
XX 29-SEP-1997; 97US-00940136.
XX
XX (DASS/) DASSEUX J.
XX (SEKU/) SEKUL R.
XX (BUTT/) BUTTNER K.
XX (CORN/) CORNUT I.
XX (METZ/) METZ G.
XX (DUFO/) DUFOURCQ J.
XX
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
XX WPI; 1999-254921/21.
XX
XX
XX Nucleic acid encoding apoproteinA-I agonist peptides.
XX
XX Example; Page 150; 232pp; English.
XX
XX The present invention describes a nucleic acid (A) encoding an
XX apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
XX which forms an amphipathic alpha-helix in presence of lipids. (A),
XX optionally as a complex with lipids, and host cells that contain (A), are
XX useful for gene therapy, or prevention, of diseases associated with
XX dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
XX atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
XX deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
XX endotoxemia (septic shock). Host cells containing (A) can also be used to
XX study the role of apoA-I in lipid metabolism. (B) can be used
XX diagnostically, e.g. to measure serum HDL (particularly its subpopulation
XX involved in retrograde cholesterol transport) and for imaging the
XX circulatory system or HDL accumulations at fatty streaks. The present
XX sequence represents a peptide from the present invention
XX
XX Sequence 22 AA;
XX

```

```

PT Nucleic acid encoding apoproteinA-I agonist peptides.
XX
XX Example; Page 138; 232pp; English.
XX
XX The present invention describes a nucleic acid (A) encoding an
XX apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
XX which forms an amphipathic alpha-helix in presence of lipids. (A),
XX optionally as a complex with lipids, and host cells that contain (A), are
XX useful for gene therapy, or prevention, of diseases associated with
XX dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
XX atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
XX deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
XX endotoxemia (septic shock). Host cells containing (A) can also be used to
XX study the role of apoA-I in lipid metabolism. (B) can be used
XX diagnostically, e.g. to measure serum HDL (particularly its subpopulation
XX involved in retrograde cholesterol transport) and for imaging the
XX circulatory system or HDL accumulations at fatty streaks. The present
XX sequence represents a peptide from the present invention
XX
XX Sequence 22 AA;
XX
AAV18455 Length: 22 May 22, 2007 14:41 Type: P Check: 8739
1 PVLDFRELL EELLKALKKK LK
!!AA SEQUENCE 1.0
ID AAV18496 standard; peptide; 22 AA.
XX
XX AAY18496;
XX
XX 09-JUL-1999 (first entry)
XX
XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #80.
XX
XX Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
XX cardiovascular disease; atherosclerosis; restenosis; LCAT;
XX hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
XX
XX Synthetic.
XX Homo sapiens.
XX
XX WO9916409-A2.
XX
XX 08-APR-1999.
XX
XX 28-SEP-1998; 98WO-US020329.
XX
XX 29-SEP-1997; 97US-00940136.
XX
XX (DASS/) DASSEUX J.
XX (SEKU/) SEKUL R.
XX (BUTT/) BUTTNER K.
XX (CORN/) CORNUT I.
XX (METZ/) METZ G.
XX (DUFO/) DUFOURCQ J.
XX
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
XX WPI; 1999-254921/21.
XX
XX
XX Nucleic acid encoding apoproteinA-I agonist peptides.
XX
XX Example; Page 150; 232pp; English.
XX
XX The present invention describes a nucleic acid (A) encoding an
XX apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
XX which forms an amphipathic alpha-helix in presence of lipids. (A),
XX optionally as a complex with lipids, and host cells that contain (A), are
XX useful for gene therapy, or prevention, of diseases associated with
XX dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
XX atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
XX deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
XX endotoxemia (septic shock). Host cells containing (A) can also be used to
XX study the role of apoA-I in lipid metabolism. (B) can be used
XX diagnostically, e.g. to measure serum HDL (particularly its subpopulation
XX involved in retrograde cholesterol transport) and for imaging the
XX circulatory system or HDL accumulations at fatty streaks. The present
XX sequence represents a peptide from the present invention
XX
XX Sequence 22 AA;
XX

```



```
CC study the role of apoA-I in lipid metabolism. (B) can be used
CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
CC involved in retrograde cholesterol transport) and for imaging the
CC circulatory system or HDL accumulations at fatty streaks. The present
CC sequence represents a peptide from the present invention
XX
SQ Sequence 22 AA;

AAV18496 Length: 22 May 22, 2007 14:41 Type: P Check: 8869 ..
1 PVLDLFFRELL NELLEALKQK LK

!!AA_SEQUENCE 1.0
ID AAV18541 standard; peptide; 22 AA.
XX
AC AAV18541;
XX
DT 09-JUL-1999 (first entry)
XX
DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #125.
XX
KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9916409-A2.
XX
DT 08-APR-1999.
XX
PF 28-SEP-1998; 98WO-US020329.
XX
PR 29-SEP-1997; 97US-00940136.
XX
PA (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
PA (DUFO/) DUFOURCQ J.
XX
PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
XX WPI; 1999-254921/21.
XX
PR Nucleic acid encoding apoproteinA-I agonist peptides.
XX
PS Claim 18; Page 164; 232pp; English.
XX
CC The present invention describes a nucleic acid (A) encoding an
CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
CC which forms an amphipathic alpha-helix in presence of lipids. (A),
CC optionally as a complex with lipids, and host cells that contain (A), are
CC useful for gene therapy, or prevention, of diseases associated with
CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
CC endotoxemia (septic shock). Host cells containing (A) can also be used
CC to study the role of apoA-I in lipid metabolism. (B) can be used
CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
CC involved in retrograde cholesterol transport) and for imaging the
CC circulatory system or HDL accumulations at fatty streaks. The present
CC sequence represents a peptide from the present invention
XX
SQ Sequence 22 AA;

AAV18541 Length: 22 May 22, 2007 14:41 Type: P Check: 8860 ..
1 NVLDLFFRELL NELLEALKQK LK

!!AA_SEQUENCE 1.0
ID AAV18541 standard; peptide; 22 AA.
XX
AC AAV18541;
XX
DT 09-JUL-1999 (first entry)
XX
DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #131.
XX
KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
XX
OS Synthetic.
```

```
ID AAV18434 standard; peptide; 22 AA.
XX
AC AAV18434;
XX
DT 09-JUL-1999 (first entry)
XX
DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #18.
XX
KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9916409-A2.
XX
DT 08-APR-1999.
XX
PF 28-SEP-1998; 98WO-US020329.
XX
PR 29-SEP-1997; 97US-00940136.
XX
PA (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
PA (DUFO/) DUFOURCQ J.
XX
PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
XX WPI; 1999-254921/21.
XX
PR Nucleic acid encoding apoproteinA-I agonist peptides.
XX
PS Claim 18; Page 131; 232pp; English.
XX
CC The present invention describes a nucleic acid (A) encoding an
CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
CC which forms an amphipathic alpha-helix in presence of lipids. (A),
CC optionally as a complex with lipids, and host cells that contain (A), are
CC useful for gene therapy, or prevention, of diseases associated with
CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
CC endotoxemia (septic shock). Host cells containing (A) can also be used
CC to study the role of apoA-I in lipid metabolism. (B) can be used
CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
CC involved in retrograde cholesterol transport) and for imaging the
CC circulatory system or HDL accumulations at fatty streaks. The present
CC sequence represents a peptide from the present invention
XX
SQ Sequence 22 AA;

AAV18434 Length: 22 May 22, 2007 14:41 Type: P Check: 8853 ..
1 GVLDLFFRELL NELLEALKQK LK

!!AA_SEQUENCE 1.0
ID AAV18547 standard; peptide; 22 AA.
XX
AC AAV18547;
XX
DT 09-JUL-1999 (first entry)
XX
DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #131.
XX
KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
XX
OS Synthetic.
```

OS Homo sapiens.
 PN WO9916409-A2.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020329.
 XX
 PR 29-SEP-1997; 97US-00940136.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-254921/21.
 XX
 PT Nucleic acid encoding apoproteinA-I agonist peptides.
 XX
 PS Claim 18; Page 166; 232pp; English.
 XX
 CC The present invention describes a nucleic acid (A) encoding an
 CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipids, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used
 CC to study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX
 SQ Sequence 22 AA;
 AAY18547 Length: 22 May 22, 2007 14:41 Type: P Check: 8928 ..
 1 PVLELFKELL NELLDALRQK LK
 !!AA_SEQUENCE 1.0
 ID AAY18418 standard; peptide; 23 AA.
 AC AAY18418;
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #2.
 XX
 KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
 KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916409-A2.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020329.
 XX
 PR 29-SEP-1997; 97US-00940136.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-254921/21.
 XX
 PT Nucleic acid encoding apoproteinA-I agonist peptides.
 XX
 PS Claim 18; Page 128; 232pp; English.
 XX
 CC The present invention describes a nucleic acid (A) encoding an

PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-254921/21.
 XX
 PT Nucleic acid encoding apoproteinA-I agonist peptides.
 XX
 PS Claim 18; Page 127; 232pp; English.
 XX
 CC The present invention describes a nucleic acid (A) encoding an
 CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipids, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used
 CC to study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX
 SQ Sequence 23 AA;
 AAY18418 Length: 23 May 22, 2007 14:41 Type: P Check: 578 ..
 1 GVLDLFRELL NELLEALKQK LKK
 !!AA_SEQUENCE 1.0
 ID AAY18423 standard; peptide; 22 AA.
 AC AAY18423;
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #7.
 XX
 KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
 KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916409-A2.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020329.
 XX
 PR 29-SEP-1997; 97US-00940136.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-254921/21.
 XX
 PT Nucleic acid encoding apoproteinA-I agonist peptides.
 XX
 PS Claim 18; Page 128; 232pp; English.
 XX
 CC The present invention describes a nucleic acid (A) encoding an

CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipids, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used to
 CC study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX Sequence 22 AA;

AAV18423 Length: 22 May 22, 2007 14:41 Type: P Check: 8813 ..

1 PVLDLRELL NELLEALKQK LK

!!AA SEQUENCE 1.0

ID AAV18432 standard; peptide; 22 AA.

AC AAV18432;

09-JUL-1999 (first entry)

Lecithin:cholesterol acyltransferase activation exhibiting peptide #16.

Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 cardiovascular disease; atherosclerosis; restenosis; LCAT;
 hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.

Synthetic.

OS Homo sapiens.

XX WO9916409-A2.

PN 08-APR-1999.

28-SEP-1998; 98WO-US020329.

29-SEP-1997; 97US-00940136.

(DASS/) DASSEUX J.

(SEKU/) SEKUL R.

(BUTT/) BUTTNER K.

(CORN/) CORNUT I.

(METZ/) METZ G.

(DUFO/) DUFOURCQ J.

Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;

WPI; 1999-254921/21.

Nucleic acid encoding apoproteinA-I agonist peptides.

Claim 18; Page 131; 232pp; English.

The present invention describes a nucleic acid (A) encoding an
 CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipids, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used to
 CC study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention

XX Sequence 22 AA;

AAV18432 Length: 22 May 22, 2007 14:41 Type: P Check: 8898 ..

1 PVLDLRELL NELLEALKQK LK

!!AA SEQUENCE 1.0

ID AAV18542 standard; peptide; 22 AA.

AC AAV18542;

09-JUL-1999 (first entry)

Lecithin:cholesterol acyltransferase activation exhibiting peptide #126.

Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 cardiovascular disease; atherosclerosis; restenosis; LCAT;
 hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.

Synthetic.

OS Homo sapiens.

XX WO9916409-A2.

08-APR-1999.

28-SEP-1998; 98WO-US020329.

29-SEP-1997; 97US-00940136.

(DASS/) DASSEUX J.

(SEKU/) SEKUL R.

(BUTT/) BUTTNER K.

(CORN/) CORNUT I.

(METZ/) METZ G.

(DUFO/) DUFOURCQ J.

Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;

WPI; 1999-254921/21.

Nucleic acid encoding apoproteinA-I agonist peptides.

Claim 18; Page 165; 232pp; English.

The present invention describes a nucleic acid (A) encoding an
 CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipids, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used to
 CC study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention

XX Sequence 22 AA;

AAV18542 Length: 22 May 22, 2007 14:41 Type: P Check: 8792 ..

1 PVLDLRELL NELLEALKQK LK

!!AA SEQUENCE 1.0

ID AAV18554 standard; peptide; 22 AA.

AC AAV18554;

09-JUL-1999 (first entry)

XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #138.
 XX KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 KW KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
 KW KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
 XX OS Synthetic.
 OS OS Homo sapiens.
 XX PN WO9916409-A2.
 XX PD 08-APR-1999.
 XX PF 28-SEP-1998; 98WO-US020329.
 XX PR 29-SEP-1997; 97US-00940136.
 XX PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-254921/21.
 XX PT Nucleic acid encoding apoproteinA-I agonist peptides.
 XX PS Claim 18; Page 168; 232pp; English.
 XX CC The present invention describes a nucleic acid (A) encoding an
 CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipide, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can be used to
 CC study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX SQ Sequence 22 AA;
 XX AAY18554 Length: 22 May 22, 2007 14:41 Type: P Check: 9149 ..
 1 PVLDLPRELL NEGLEWLKQK LK
 !!AA SEQUENCE 1.0
 ID AAY18428 standard; peptide; 22 AA.
 XX AC AAY18428;
 XX DT 09-JUL-1999 (first entry)
 XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #12.
 XX KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 KW KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
 KW KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
 XX OS Synthetic.
 OS OS Homo sapiens.
 XX PN WO9916409-A2.
 XX PD 08-APR-1999.
 XX PF 28-SEP-1998; 98WO-US020329.
 XX PR 29-SEP-1997; 97US-00940136.
 XX PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-254921/21.
 XX PT Nucleic acid encoding apoproteinA-I agonist peptides.
 XX PS Claim 18; Page 168; 232pp; English.
 XX CC The present invention describes a nucleic acid (A) encoding an
 CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipide, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can be used to
 CC study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX SQ Sequence 22 AA;
 XX AAY18554 Length: 22 May 22, 2007 14:41 Type: P Check: 9149 ..
 1 PVLDLPRELL NEGLEWLKQK LK
 !!AA SEQUENCE 1.0
 ID AAY18428 standard; peptide; 22 AA.
 XX AC AAY18428;
 XX DT 09-JUL-1999 (first entry)
 XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #12.
 XX KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 KW KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
 KW KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
 XX OS Synthetic.
 OS OS Homo sapiens.
 XX PN WO9916409-A2.
 XX PD 08-APR-1999.
 XX PF 28-SEP-1998; 98WO-US020329.
 XX PR 29-SEP-1997; 97US-00940136.
 XX PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-254921/21.
 XX PT Nucleic acid encoding apoproteinA-I agonist peptides.
 XX PS Claim 18; Page 130; 232pp; English.
 XX CC The present invention describes a nucleic acid (A) encoding an
 CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipids, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can be used to
 CC study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX SQ Sequence 22 AA;
 XX AAY18428 Length: 22 May 22, 2007 14:41 Type: P Check: 8777 ..
 1 PVLDLPRELL NELLEAGKQK LK
 !!AA SEQUENCE 1.0
 ID AAY18558 standard; peptide; 22 AA.
 XX AC AAY18558;
 XX DT 09-JUL-1999 (first entry)
 XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #142.
 XX KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 KW KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
 KW KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
 XX OS Synthetic.
 OS OS Homo sapiens.
 XX PN WO9916409-A2.
 XX PD 08-APR-1999.
 XX PF 28-SEP-1998; 98WO-US020329.
 XX PR 29-SEP-1997; 97US-00940136.
 XX PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;

XX WPI; 1999-254921/21.
 XX Nucleic acid encoding apoproteinA-I agonist peptides.
 XX Claim 18; Page 169; 232pp; English.
 XX The present invention describes a nucleic acid (A) encoding an
 CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipids, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used to
 CC study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX Sequence 22 AA;
 SQ

AA18558 Length: 22 May 22, 2007 14:41 Type: P Check: 8801 ..
 1 PVLELFPRELL NEGLEALKQK LK
 !!AA_SEQUENCE 1.0
 ID AAY18424 standard; peptide; 22 AA.
 AC AAY18424;
 XX
 XX 09-JUL-1999 (first entry)
 XX
 XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #8.
 XX Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
 KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
 XX Synthetic.
 OS Homo sapiens.
 OS WO9916409-A2.
 PN
 XX 08-APR-1999.
 PD
 XX 28-SEP-1998; 98WO-US020329.
 PF
 XX 29-SEP-1997; 97US-00940136.
 PR
 XX (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 PI WPI; 1999-254921/21.
 DR
 XX Nucleic acid encoding apoproteinA-I agonist peptides.
 XX Claim 18; Page 129; 232pp; English.
 XX The present invention describes a nucleic acid (A) encoding an
 CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipids, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used to
 CC study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX Sequence 22 AA;
 SQ

AA18424 Length: 22 May 22, 2007 14:41 Type: P Check: 8797 ..
 1 PVLDLFPRELL NEGLEALKQK LK
 !!AA_SEQUENCE 1.0
 ID AAY18425 standard; peptide; 22 AA.
 XX AAY18425;
 AC
 XX 09-JUL-1999 (first entry)
 XX
 XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #9.
 XX Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
 KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
 XX Synthetic.
 OS Homo sapiens.
 OS WO9916409-A2.
 PN
 XX 08-APR-1999.
 PD
 XX 28-SEP-1998; 98WO-US020329.
 PF
 XX 29-SEP-1997; 97US-00940136.
 PR
 XX (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX
 XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 PI WPI; 1999-254921/21.
 DR
 XX Nucleic acid encoding apoproteinA-I agonist peptides.
 XX Claim 18; Page 129; 232pp; English.
 XX The present invention describes a nucleic acid (A) encoding an
 CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipids, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used to
 CC study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX Sequence 22 AA;
 SQ

```

1 PVLDLRELQ NELLEALKQK LK
!!AA SEQUENCE 1.0
ID AAY18433 standard; peptide; 22 AA.
XX
AC AAY18433;
XX
DT 09-JUL-1999 (first entry)
XX
DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #17.
XX
KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9916409-A2.
XX
PD 08-APR-1999.
XX
PF 28-SEP-1998; 98WO-US020329.
XX
PR 29-SEP-1997; 97US-00940136.
XX
PA (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
PA (DUFO/) DUFOURCQ J.
XX
PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
XX
PD WPI; 1999-254921/21.
XX
PF Nucleic acid encoding apoproteinA-I agonist peptides.
XX
PR Claim 18; Page 131; 232pp; English.
XX
PS The present invention describes a nucleic acid (A) encoding an
CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
CC which forms an amphipathic alpha-helix in presence of lipids. (A),
CC optionally as a complex with lipids, and host cells that contain (A), are
CC useful for gene therapy, or prevention, of diseases associated with
CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
CC endotoxemia (septic shock). Host cells containing (A) can also be used
CC to study the role of apoA-I in lipid metabolism. (B) can be used
CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
CC involved in retrograde cholesterol transport) and for imaging the
CC circulatory system or HDL accumulations at fatty streaks. The present
CC sequence represents a peptide from the present invention
XX
SQ Sequence 22 AA;
XX
AAY18433 Length: 22 May 22, 2007 14:41 Type: P Check: 8850 ..
1 PVLELPELL QELLEALKQK LK
!!AA SEQUENCE 1.0
ID AAY18550 standard; peptide; 22 AA.
XX
AC AAY18550;
XX
DT 09-JUL-1999 (first entry)
XX
DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #134.
XX
KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
KW cardiovascular disease; atherosclerosis; restenosis; LCAT;

```

```

KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9916409-A2.
XX
PD 08-APR-1999.
XX
PF 28-SEP-1998; 98WO-US020329.
XX
PR 29-SEP-1997; 97US-00940136.
XX
PA (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
PA (DUFO/) DUFOURCQ J.
XX
PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
XX
PD WPI; 1999-254921/21.
XX
PF Nucleic acid encoding apoproteinA-I agonist peptides.
XX
PR Claim 18; Page 167; 232pp; English.
XX
PS The present invention describes a nucleic acid (A) encoding an
CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
CC which forms an amphipathic alpha-helix in presence of lipids. (A),
CC optionally as a complex with lipids, and host cells that contain (A), are
CC useful for gene therapy, or prevention, of diseases associated with
CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
CC endotoxemia (septic shock). Host cells containing (A) can also be used
CC to study the role of apoA-I in lipid metabolism. (B) can be used
CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
CC involved in retrograde cholesterol transport) and for imaging the
CC circulatory system or HDL accumulations at fatty streaks. The present
CC sequence represents a peptide from the present invention
XX
SQ Sequence 22 AA;
XX
AAY18550 Length: 22 May 22, 2007 14:41 Type: P Check: 8912 ..
1 PVLELPERLL EDLLKALNOK LK
!!AA SEQUENCE 1.0
ID AAY18551 standard; peptide; 22 AA.
XX
AC AAY18551;
XX
DT 09-JUL-1999 (first entry)
XX
DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #135.
XX
KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9916409-A2.
XX
PD 08-APR-1999.
XX
PF 28-SEP-1998; 98WO-US020329.
XX
PR 29-SEP-1997; 97US-00940136.
XX

```

PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 DR WPI; 1999-254921/21.
 DR Nucleic acid encoding apoproteinA-I agonist peptides.
 PT Claim 18; Page 167; 232pp; English.
 XX The present invention describes a nucleic acid (A) encoding an
 CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipids, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used
 CC to study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX Sequence 22 AA;
 SQ AAY18551 Length: 22 May 22, 2007 14:41 Type: P Check: 8850 ..
 1 DVLDLPRELL NELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY18438 standard; peptide; 22 AA.
 AC AAY18438;
 XX 09-JUL-1999 (first entry)
 DT Lecithin:cholesterol acyltransferase activation exhibiting peptide #22.
 DE Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 XX cardiovascular disease; atherosclerosis; restenosis; LCAT;
 XX hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
 OS Synthetic.
 OS Homo sapiens.
 XX WO9916409-A2.
 XX 08-APR-1999.
 XX 28-SEP-1998; 98WO-US020329.
 XX 29-SEP-1997; 97US-00940136.
 XX (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 DR WPI; 1999-254921/21.
 DR Nucleic acid encoding apoproteinA-I agonist peptides.

PS Claim 18; Page 133; 232pp; English.
 XX The present invention describes a nucleic acid (A) encoding an
 CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipids, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used
 CC to study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX Sequence 22 AA;
 SQ AAY18438 Length: 22 May 22, 2007 14:41 Type: P Check: 8958 ..
 1 PVLDLPRELL NELLEGLKQK LK
 !!AA SEQUENCE 1.0
 ID AAY18552 standard; peptide; 22 AA.
 AC AAY18552;
 XX 09-JUL-1999 (first entry)
 DT Lecithin:cholesterol acyltransferase activation exhibiting peptide #136.
 DE Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 XX cardiovascular disease; atherosclerosis; restenosis; LCAT;
 XX hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
 OS Synthetic.
 OS Homo sapiens.
 XX WO9916409-A2.
 XX 08-APR-1999.
 XX 28-SEP-1998; 98WO-US020329.
 XX 29-SEP-1997; 97US-00940136.
 XX (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 DR WPI; 1999-254921/21.
 DR Nucleic acid encoding apoproteinA-I agonist peptides.
 PT Claim 18; Page 167; 232pp; English.
 XX The present invention describes a nucleic acid (A) encoding an
 CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipids, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used
 CC to study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation

CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX
 SQ Sequence 22 AA;
 AAY18552 Length: 22 May 22, 2007 14:41 Type: P Check: 8800 ..
 1 PALELFKDLL QELLEALKQK LK
 !:AA_SEQUENCE 1.0
 ID AAY18557 standard; peptide; 22 AA.
 XX
 AC AAY18557;
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #141.
 XX
 KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
 KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916409-A2.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020329.
 XX
 PR 29-SEP-1997; 97US-00940136.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX
 DR WPI; 1999-254921/21.
 XX
 PT Nucleic acid encoding apoproteinA-I agonist peptides.
 XX
 PS Claim 18; Page 169; 232pp; English.
 XX
 CC The present invention describes a nucleic acid (A) encoding an
 CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipids, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used to
 CC study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX
 SQ Sequence 22 AA;
 AAY18557 Length: 22 May 22, 2007 14:41 Type: P Check: 8767 ..
 1 PVLDFRELL NEGLEALKQK LK
 !:AA_SEQUENCE 1.0
 ID AAY18427 standard; peptide; 22 AA.
 XX
 AC AAY18427;
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #15.
 XX
 KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
 KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916409-A2.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020329.
 XX
 PR 29-SEP-1997; 97US-00940136.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX
 DR WPI; 1999-254921/21.
 XX
 PT Nucleic acid encoding apoproteinA-I agonist peptides.
 XX
 PS Claim 18; Page 169; 232pp; English.
 XX
 CC The present invention describes a nucleic acid (A) encoding an
 CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipids, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used to
 CC study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX
 SQ Sequence 22 AA;

AC AAY18427;
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #11.
 XX
 KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
 KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916409-A2.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020329.
 XX
 PR 29-SEP-1997; 97US-00940136.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX
 DR WPI; 1999-254921/21.
 XX
 PT Nucleic acid encoding apoproteinA-I agonist peptides.
 XX
 PS Claim 18; Page 129; 232pp; English.
 XX
 CC The present invention describes a nucleic acid (A) encoding an
 CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipids, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used to
 CC study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX
 SQ Sequence 22 AA;
 AAY18427 Length: 22 May 22, 2007 14:41 Type: P Check: 8846 ..
 1 PVLDFRELL QELLEALKQK LK
 !:AA_SEQUENCE 1.0
 ID AAY18431 standard; peptide; 22 AA.
 XX
 AC AAY18431;
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #15.
 XX
 KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
 KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX

PN WO9916409-A2.
XX
PD 08-APR-1999.
XX
PF 28-SEP-1998; 98WO-US020329.
XX
PR 29-SEP-1997; 97US-00940136.
XX
PA (DASS//) DASSEUX J.
PA (SEKU//) SEKUL R.
PA (BUTT//) BUTTNER K.
PA (CORN//) CORNUT I.
PA (METZ//) METZ G.
XX (DUFO//) DUFOURCQ J.
XX
PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
XX WPI; 1999-254921/21.
XX
DR Nucleic acid encoding apoproteinA-I agonist peptides.
XX
PT Claim 18; Page 131; 232pp; English.
XX
PS The present invention describes a nucleic acid (A) encoding an
CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
CC which forms an amphipathic alpha-helix in presence of lipids. (A),
CC optionally as a complex with lipids, and host cells that contain (A), are
CC useful for gene therapy, or prevention, of diseases associated with
CC dyslipidemia, specifically hypercholesterolemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
CC endotoxemia (septic shock). Host cells containing (A) can also be used
CC to study the role of apoA-I in lipid metabolism. (B) can be used
CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
CC involved in retrograde cholesterol transport) and for imaging the
CC circulatory system or HDL accumulations at fatty streaks. The present
CC sequence represents a peptide from the present invention
XX Sequence 22 AA;
SQ
AA18431 Length: 22 May 22, 2007 14:41 Type: P Check: 8972 ..
1 PVLDLFRELW NELLEALKQK LK
!!AA SEQUENCE 1.0
ID -AA18456 standard; peptide; 22 AA.
XX
AC AA18456;
XX
DT 09-JUL-1999 (first entry)
XX
DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #40.
XX
KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9916409-A2.
XX
PD 08-APR-1999.
XX
PF 28-SEP-1998; 98WO-US020329.
XX
PR 29-SEP-1997; 97US-00940136.
XX
PA (DASS//) DASSEUX J.
PA (SEKU//) SEKUL R.
PA (BUTT//) BUTTNER K.
PA (CORN//) CORNUT I.
PA (METZ//) METZ G.
XX (DUFO//) DUFOURCQ J.
XX
PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
XX WPI; 1999-254921/21.
XX
DR Nucleic acid encoding apoproteinA-I agonist peptides.
XX
PT Example; Page 152; 232pp; English.
XX
PS The present invention describes a nucleic acid (A) encoding an
CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
CC which forms an amphipathic alpha-helix in presence of lipids. (A),
CC optionally as a complex with lipids, and host cells that contain (A), are
CC useful for gene therapy, or prevention, of diseases associated with
CC dyslipidemia, specifically hypercholesterolemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
CC endotoxemia (septic shock). Host cells containing (A) can also be used
CC to study the role of apoA-I in lipid metabolism. (B) can be used
CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
CC involved in retrograde cholesterol transport) and for imaging the
CC circulatory system or HDL accumulations at fatty streaks. The present
CC sequence represents a peptide from the present invention
XX Sequence 22 AA;
SQ
AA18456 Length: 22 May 22, 2007 14:41 Type: P Check: 8872 ..
1 PVLDLFNELL RELLEALQKK LK
!!AA SEQUENCE 1.0
ID -AA18503 standard; peptide; 22 AA.
XX
AC AA18503;
XX
DT 09-JUL-1999 (first entry)
XX
DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #87.
XX
KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9916409-A2.
XX
PD 08-APR-1999.
XX
PF 28-SEP-1998; 98WO-US020329.
XX
PR 29-SEP-1997; 97US-00940136.
XX
PA (DASS//) DASSEUX J.
PA (SEKU//) SEKUL R.
PA (BUTT//) BUTTNER K.
PA (CORN//) CORNUT I.
PA (METZ//) METZ G.
XX (DUFO//) DUFOURCQ J.
XX
PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
XX WPI; 1999-254921/21.
XX
DR Nucleic acid encoding apoproteinA-I agonist peptides.
XX
PT Example; Page 152; 232pp; English.
XX
PS The present invention describes a nucleic acid (A) encoding an
CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
CC which forms an amphipathic alpha-helix in presence of lipids. (A),
CC optionally as a complex with lipids, and host cells that contain (A), are
CC useful for gene therapy, or prevention, of diseases associated with
CC dyslipidemia, specifically hypercholesterolemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
CC endotoxemia (septic shock). Host cells containing (A) can also be used
CC to study the role of apoA-I in lipid metabolism. (B) can be used
CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
CC involved in retrograde cholesterol transport) and for imaging the
CC circulatory system or HDL accumulations at fatty streaks. The present
CC sequence represents a peptide from the present invention
XX Sequence 22 AA;
SQ

CC optionally as a complex with lipids, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used to
 CC study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX
 SQ Sequence 22 AA;

AAV18503 Length: 22 May 22, 2007 14:41 Type: P Check: 8866 ..

1 PLELLKELL QELLEALKQK LK

!!AA SEQUENCE 1.0
 ID _AAV18543 standard; peptide; 22 AA.

AC AAV18543;

DT 09-JUL-1999 (first entry)

DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #127.
 KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
 KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.

XX Synthetic.

OS Homo sapiens.

PN WO9916409-A2.

XX 08-APR-1999.

PF 28-SEP-1998; 98WO-US020329.

PR 29-SEP-1997; 97US-00940136.

XX (DASS/) DASSEUX J.

PA (SEKU/) SEKUL R.

PA (BUTT/) BUTTNER K.

PA (CORN/) CORNUT I.

PA (METZ/) METZ G.

PA (DUFO/) DUFOURCQ J.

XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-254921/21.

XX Nucleic acid encoding apoproteinA-I agonist peptides.
 PT Claim 18; Page 165; 232pp; English.

PS The present invention describes a nucleic acid (A) encoding an
 XX apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipids, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used to
 CC study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX
 SQ Sequence 22 AA;

AAV18543 Length: 22 May 22, 2007 14:41 Type: P Check: 9038 ..

1 PVLDFRELL NELLELKQK LK

!!AA SEQUENCE 1.0

ID _AAV18548 standard; peptide; 22 AA.

AC AAV18548;

DT 09-JUL-1999 (first entry)

DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #132.
 KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
 KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.

XX Synthetic.

OS Homo sapiens.

PN WO9916409-A2.

XX 08-APR-1999.

PF 28-SEP-1998; 98WO-US020329.

PR 29-SEP-1997; 97US-00940136.

XX (DASS/) DASSEUX J.

PA (SEKU/) SEKUL R.

PA (BUTT/) BUTTNER K.

PA (CORN/) CORNUT I.

PA (METZ/) METZ G.

PA (DUFO/) DUFOURCQ J.

XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-254921/21.

XX Nucleic acid encoding apoproteinA-I agonist peptides.
 PT Claim 18; Page 166; 232pp; English.

PS The present invention describes a nucleic acid (A) encoding an
 XX apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipids, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used to
 CC study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX
 SQ Sequence 22 AA;

AAV18548 Length: 22 May 22, 2007 14:41 Type: P Check: 8865 ..

1 PVLDFRELL ENLEALQK LK

!!AA SEQUENCE 1.0

ID _AAV18472 standard; peptide; 22 AA.

AC AAV18472;

DT 09-JUL-1999 (first entry)

DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #56.

XX KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
XX OS Synthetic.
OS Homo sapiens.
XX WO9916409-A2.
XX PD 08-APR-1999.
XX 28-SEP-1998; 98WO-US020329.
XX 29-SEP-1997; 97US-00940136.
XX (DASS//) DASSEUX J.
PA (SEKU//) SEKUL R.
PA (BUTT//) BUTTNER K.
PA (CORN//) CORNUT I.
PA (METZ//) METZ G.
PA (DUFO//) DUFOURCQ J.
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
XX WPI; 1999-254921/21.
XX Nucleic acid encoding apoproteinA-I agonist peptides.
XX Example; Page 143; 232pp; English.
XX The present invention describes a nucleic acid (A) encoding an
CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
CC which forms an amphipathic alpha-helix in presence of lipids. (A),
CC optionally as a complex with lipids, and host cells that contain (A), are
CC useful for gene therapy, or prevention, of diseases associated with
CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
CC endotoxemia (septic shock). Host cells containing (A) and apoA-I
CC study the role of apoA-I in lipid metabolism. (B) can also be used to
CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
CC involved in retrograde cholesterol transport) and for imaging the
CC circulatory system or HDL accumulations at fatty streaks. The present
CC sequence represents a peptide from the present invention
XX Sequence 22 AA;
XX AAY18472 Length: 22 May 22, 2007 14:41 Type: P Check: 8841 ..
1 PVLDLFRELL NELLEALKQK KK
!!AA_SEQUENCE 1.0
ID AAY18514 standard; peptide; 22 AA.
XX AC AAY18514;
XX 09-JUL-1999 (first entry)
XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #98.
XX Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
XX OS Synthetic.
OS Homo sapiens.
XX WO9916409-A2.
XX PD 08-APR-1999.
XX 28-SEP-1998; 98WO-US020329.

XX PR 29-SEP-1997; 97US-00940136.
XX (DASS//) DASSEUX J.
PA (SEKU//) SEKUL R.
PA (BUTT//) BUTTNER K.
PA (CORN//) CORNUT I.
PA (METZ//) METZ G.
PA (DUFO//) DUFOURCQ J.
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
XX WPI; 1999-254921/21.
XX Nucleic acid encoding apoproteinA-I agonist peptides.
XX Example; Page 156; 232pp; English.
XX The present invention describes a nucleic acid (A) encoding an
CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
CC which forms an amphipathic alpha-helix in presence of lipids. (A),
CC optionally as a complex with lipids, and host cells that contain (A), are
CC useful for gene therapy, or prevention, of diseases associated with
CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
CC endotoxemia (septic shock). Host cells containing (A) can also be used to
CC study the role of apoA-I in lipid metabolism. (B) can be used
CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
CC involved in retrograde cholesterol transport) and for imaging the
CC circulatory system or HDL accumulations at fatty streaks. The present
CC sequence represents a peptide from the present invention
XX Sequence 22 AA;
XX AAY18514 Length: 22 May 22, 2007 14:41 Type: P Check: 8771 ..
1 PVLDLFRELL NELLEALKQK LK
!!AA_SEQUENCE 1.0
ID AAY18539 standard; peptide; 22 AA.
XX AC AAY18539;
XX 09-JUL-1999 (first entry)
XX Lecithin:cholesterol acyltransferase activation exhibiting peptide #123.
XX Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
XX OS Synthetic.
OS Homo sapiens.
XX WO9916409-A2.
XX PD 08-APR-1999.
XX 28-SEP-1998; 98WO-US020329.
XX 29-SEP-1997; 97US-00940136.
XX (DASS//) DASSEUX J.
PA (SEKU//) SEKUL R.
PA (BUTT//) BUTTNER K.
PA (CORN//) CORNUT I.
PA (METZ//) METZ G.
PA (DUFO//) DUFOURCQ J.
XX Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
XX WPI; 1999-254921/21.

XX PT Nucleic acid encoding apoproteinA-I agonist peptides.
 XX PS Claim 18; Page 164; 232pp; English.
 XX CC The present invention describes a nucleic acid (A) encoding an
 CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipids, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used to
 CC study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX SQ Sequence 22 AA;
 AAY18539 Length: 22 May 22, 2007 14:41 Type: P Check: 8863 ..
 1 QVLDLFFRELL NELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY18439 standard; peptide; 22 AA.
 AC AAY18439;
 XX 09-JUL-1999 (first entry)
 XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #23.
 XX KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
 KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
 XX OS Synthetic.
 XX OS Homo sapiens.
 XX PN WO9916409-A2.
 XX 08-APR-1999.
 XX 28-SEP-1998; 98WO-US020329.
 XX 29-SEP-1997; 97US-00940136.
 (DASS/) DASSEUX J.
 (SEKU/) SEKUL R.
 (BUTT/) BUTTNER K.
 (CORN/) CORNUT I.
 (METZ/) METZ G.
 (DUFO/) DUFOURCQ J.
 Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 WPI; 1999-254921/21.
 Nucleic acid encoding apoproteinA-I agonist peptides.
 Claim 18; Page 133; 232pp; English.
 The present invention describes a nucleic acid (A) encoding an
 apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 which forms an amphipathic alpha-helix in presence of lipids. (A),
 optionally as a complex with lipids, and host cells that contain (A), are
 useful for gene therapy, or prevention, of diseases associated with
 dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 deficiency, hypertriglyceridemia and metabolic syndrome, also to treat

CC endotoxemia (septic shock). Host cells containing (A) can also be used to
 CC study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX SQ Sequence 22 AA;
 AAY18439 Length: 22 May 22, 2007 14:41 Type: P Check: 8830 ..
 1 PLLELFFKELL QELLEALKQK LK
 !!AA SEQUENCE 1.0
 ID AAY18502 standard; peptide; 22 AA.
 AC AAY18502;
 XX 09-JUL-1999 (first entry)
 XX DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #86.
 XX KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
 KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
 XX OS Synthetic.
 XX OS Homo sapiens.
 XX PN WO9916409-A2.
 XX 08-APR-1999.
 XX 28-SEP-1998; 98WO-US020329.
 XX 29-SEP-1997; 97US-00940136.
 (DASS/) DASSEUX J.
 (SEKU/) SEKUL R.
 (BUTT/) BUTTNER K.
 (CORN/) CORNUT I.
 (METZ/) METZ G.
 (DUFO/) DUFOURCQ J.
 Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 WPI; 1999-254921/21.
 Nucleic acid encoding apoproteinA-I agonist peptides.
 Example; Page 152; 232pp; English.
 The present invention describes a nucleic acid (A) encoding an
 apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 which forms an amphipathic alpha-helix in presence of lipids. (A),
 optionally as a complex with lipids, and host cells that contain (A), are
 useful for gene therapy, or prevention, of diseases associated with
 dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used
 CC study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX SQ Sequence 22 AA;
 AAY18502 Length: 22 May 22, 2007 14:41 Type: P Check: 8898 ..
 1 PVLELFFRELL DELLNALQKK LK

```

!!AA SEQUENCE 1.0
ID AAY18442 standard; peptide; 22 AA.
XX
AC AAY18442;
XX
DT 09-JUL-1999 (first entry)
XX
DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #26.
XX
KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9916409-A2.
XX
PD 08-APR-1999.
XX
PF 28-SEP-1998; 98WO-US020329.
XX
PR 29-SEP-1997; 97US-00940136.
XX
PA (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
PA (DUFO/) DUFOURCQ J.
XX
PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
XX
WPI; 1999-254921/21.
XX
PT Nucleic acid encoding apoproteinA-I agonist peptides.
XX
PS Claim 18; Page 134; 232pp; English.
XX
CC The present invention describes a nucleic acid (A) encoding an
CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
CC which forms an amphipathic alpha-helix in presence of lipids. (A),
CC optionally as a complex with lipids, and host cells that contain (A), are
CC useful for gene therapy, or prevention, of diseases associated with
CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
CC endotoxemia (septic shock). Host cells containing (A) can also be used
CC to study the role of apoA-I in lipid metabolism. (B) can be used
CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
CC involved in retrograde cholesterol transport) and for imaging the
CC circulatory system or HDL accumulations at fatty streaks. The present
CC sequence represents a peptide from the present invention
XX
SQ Sequence 22 AA;
XX
AAY18442 Length: 22 May 22, 2007 14:41 Type: P Check: 9038 ..
1 PVLDLFPRELL NELLEALKQK LK
!!AA SEQUENCE 1.0
ID AAY18445 standard; peptide; 22 AA.
XX
AC AAY18445;
XX
DT 09-JUL-1999 (first entry)
XX
DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #29.
XX
KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
XX

```

```

OS Synthetic.
OS Homo sapiens.
XX
PN WO9916409-A2.
XX
PD 08-APR-1999.
XX
PF 28-SEP-1998; 98WO-US020329.
XX
PR 29-SEP-1997; 97US-00940136.
XX
PA (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
PA (DUFO/) DUFOURCQ J.
XX
PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
XX
WPI; 1999-254921/21.
XX
PT Nucleic acid encoding apoproteinA-I agonist peptides.
XX
PS Claim 18; Page 135; 232pp; English.
XX
CC The present invention describes a nucleic acid (A) encoding an
CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
CC which forms an amphipathic alpha-helix in presence of lipids. (A),
CC optionally as a complex with lipids, and host cells that contain (A), are
CC useful for gene therapy, or prevention, of diseases associated with
CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
CC endotoxemia (septic shock). Host cells containing (A) can also be used
CC to study the role of apoA-I in lipid metabolism. (B) can be used
CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
CC involved in retrograde cholesterol transport) and for imaging the
CC circulatory system or HDL accumulations at fatty streaks. The present
CC sequence represents a peptide from the present invention
XX
SQ Sequence 22 AA;
XX
AAY18445 Length: 22 May 22, 2007 14:41 Type: P Check: 8847 ..
1 AVLDLFPRELL NELLEALKQK LK
!!AA SEQUENCE 1.0
ID AAY18516 standard; peptide; 22 AA.
XX
AC AAY18516;
XX
DT 09-JUL-1999 (first entry)
XX
DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #100.
XX
KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9916409-A2.
XX
PD 08-APR-1999.
XX
PF 28-SEP-1998; 98WO-US020329.
XX
PR 29-SEP-1997; 97US-00940136.
XX
PA (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
XX

```

PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 XX WPI; 1999-254921/21.
 DR
 XX
 PT Nucleic acid encoding apoproteinA-I agonist peptides.
 XX
 PS Example; Page 157; 232pp; English.
 XX
 CC The present invention describes a nucleic acid (A) encoding an
 CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipids, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used
 CC to study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX
 SQ Sequence 22 AA;

AA18516 Length: 22 May 22, 2007 14:41 Type: P Check: 8862 ..

1 PVLDLFRELL NELLEALKQK LK

!!AA SEQUENCE 1.0
 ID _AA18555 standard; peptide; 22 AA.
 AC
 XX
 AC AAY18555;
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #139.
 XX
 KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
 KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916409-A2.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020329.
 XX
 PR 29-SEP-1997; 97US-00940136.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 PI WPI; 1999-254921/21.
 DR
 XX
 PT Nucleic acid encoding apoproteinA-I agonist peptides.
 XX
 PS Claim 18; Page 168; 232pp; English.

CC The present invention describes a nucleic acid (A) encoding an
 CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipids, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used
 CC to study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present
 CC sequence represents a peptide from the present invention
 XX
 SQ Sequence 22 AA;

AA18555 Length: 22 May 22, 2007 14:41 Type: P Check: 8907 ..

1 PVLDLFRELM NEGLEALKQK LK

!!AA SEQUENCE 1.0
 ID _AA18440 standard; peptide; 22 AA.
 XX
 AC AAY18440;
 XX
 DT 09-JUL-1999 (first entry)
 XX
 DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #24.
 XX
 KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
 KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
 KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9916409-A2.
 XX
 PD 08-APR-1999.
 XX
 PF 28-SEP-1998; 98WO-US020329.
 XX
 PR 29-SEP-1997; 97US-00940136.
 XX
 PA (DASS/) DASSEUX J.
 PA (SEKU/) SEKUL R.
 PA (BUTT/) BUTTNER K.
 PA (CORN/) CORNUT I.
 PA (METZ/) METZ G.
 PA (DUFO/) DUFOURCQ J.
 XX
 PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
 PI WPI; 1999-254921/21.
 DR
 XX
 PT Nucleic acid encoding apoproteinA-I agonist peptides.
 XX
 PS Claim 18; Page 133; 232pp; English.
 XX
 CC The present invention describes a nucleic acid (A) encoding an
 CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
 CC which forms an amphipathic alpha-helix in presence of lipids. (A),
 CC optionally as a complex with lipids, and host cells that contain (A), are
 CC useful for gene therapy, or prevention, of diseases associated with
 CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
 CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
 CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
 CC endotoxemia (septic shock). Host cells containing (A) can also be used
 CC to study the role of apoA-I in lipid metabolism. (B) can be used
 CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
 CC involved in retrograde cholesterol transport) and for imaging the
 CC circulatory system or HDL accumulations at fatty streaks. The present

```

CC sequence represents a peptide from the present invention
XX
SQ Sequence 22 AA;

AAV18440 Length: 22 May 22, 2007 14:41 Type: P Check: 8856
1 PVLDFRELL NELLEALKK LK

!!AA SEQUENCE 1.0
ID AAY18444 standard; peptide; 22 AA.
XX
AC AAY18444;
XX
DT 09-JUL-1999 (first entry)
XX
DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #28.
XX
KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9916409-A2.
XX
PD 08-APR-1999.
XX
PF 28-SEP-1998; 98WO-US020329.
XX
PR 29-SEP-1997; 97US-00940136.
XX
PA (DASS/) DASSEUX J.
PA (SEKU/) SEKUL R.
PA (BUTT/) BUTTNER K.
PA (CORN/) CORNUT I.
PA (METZ/) METZ G.
PA (DUFO/) DUFOURCQ J.
XX
PI Dasseux J, Sekul R, Buttner K, Cornut I, Metz G, Dufourcq J;
XX
WPI; 1999-254921/21.
XX
PR Nucleic acid encoding apoproteinA-I agonist peptides.
XX
PS Example; Page 137; 232pp; English.
XX
CC The present invention describes a nucleic acid (A) encoding an
CC apolipoprotein A-I (apoA-I) agonist (B) that is a peptide, or analog,
CC which forms an amphipathic alpha-helix in presence of lipids. (A),
CC optionally as a complex with lipids, and host cells that contain (A), are
CC useful for gene therapy, or prevention, of diseases associated with
CC dyslipidemia, specifically hypercholesterolaemia, cardiovascular disease,
CC atherosclerosis, restenosis, HDL (high density lipoprotein) and apoA-I
CC deficiency, hypertriglyceridemia and metabolic syndrome, also to treat
CC endotoxemia (septic shock). Host cells containing (A) can also be used
CC to study the role of apoA-I in lipid metabolism. (B) can be used
CC diagnostically, e.g. to measure serum HDL (particularly its subpopulation
CC involved in retrograde cholesterol transport) and for imaging the
CC circulatory system or HDL accumulations at fatty streaks. The present
CC sequence represents a peptide from the present invention
XX
SQ Sequence 22 AA;

AAV18452 Length: 22 May 22, 2007 14:41 Type: P Check: 8866
1 PLLELLKELL QELLEALKK LK

!!AA SEQUENCE 1.0
ID AAY18419 standard; peptide; 22 AA.
XX
AC AAY18419;
XX
DT 09-JUL-1999 (first entry)
XX
DE Lecithin:cholesterol acyltransferase activation exhibiting peptide #3.
XX
KW Gene therapy; apolipoprotein A-I; agonist; dyslipidemic disorder; ApoA-I;
KW cardiovascular disease; atherosclerosis; restenosis; LCAT;
KW hyperlipidemia; septic shock; lecithin:cholesterol acyltransferase.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9916409-A2.
XX

```

